<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>CA2266341A1 - Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/CA2266341A1/en">
    <meta name="description" content="
     The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministering an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin 
       ">
    <meta name="DC.date" content="1997-09-19" scheme="dateSubmitted">
    <meta name="DC.description" content="
     The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministering an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent. 
   
   ">
    <meta name="citation_patent_application_number" content="CA:002266341A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/3e/42/d5/8bec34d596e35d/CA2266341A1.pdf">
    <meta name="citation_patent_publication_number" content="CA:2266341:A1">
    <meta name="DC.date" content="1998-03-26">
    <meta name="DC.contributor" content="Guy L. Reed" scheme="inventor">
    <meta name="DC.contributor" content="Individual" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA909199" lang="EN" source="national office" load-source="docdb" class="style-scope patent-text">
    <div class="abstract style-scope patent-text">The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministering an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.</div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="G01N33/86"><a id="link" href="#" class="style-scope state-modifier">G01N33/86</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/395"><a id="link" href="#" class="style-scope state-modifier">A61K39/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/395"><a id="link" href="#" class="style-scope state-modifier">A61K39/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/39533"><a id="link" href="#" class="style-scope state-modifier">A61K39/39533</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/3955"><a id="link" href="#" class="style-scope state-modifier">A61K39/3955</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P7/00"><a id="link" href="#" class="style-scope state-modifier">A61P7/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the blood or the extracellular fluid</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P7/02"><a id="link" href="#" class="style-scope state-modifier">A61P7/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P9/00"><a id="link" href="#" class="style-scope state-modifier">A61P9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the cardiovascular system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P9/10"><a id="link" href="#" class="style-scope state-modifier">A61P9/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/38"><a id="link" href="#" class="style-scope state-modifier">C07K16/38</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2039/505"><a id="link" href="#" class="style-scope state-modifier">A61K2039/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies comprising antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K38/00"><a id="link" href="#" class="style-scope state-modifier">A61K38/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing peptides</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/20"><a id="link" href="#" class="style-scope state-modifier">C07K2317/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/24"><a id="link" href="#" class="style-scope state-modifier">C07K2317/24</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2319/00"><a id="link" href="#" class="style-scope state-modifier">C07K2319/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Fusion polypeptide</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 10 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">CA2266341A1</h2>
                  <p class="tagline style-scope patent-result">Canada</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Laid-open patent application</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/3e/42/d5/8bec34d596e35d/CA2266341A1.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;seq&quot;,&quot;molecule&quot;,&quot;immunologic&quot;,&quot;amino acids&quot;,&quot;immunologic molecule&quot;]" data-before="19960920"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/CA2266341A1"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2266341A1/fr"><a id="link" href="#" class="style-scope state-modifier">French</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Guy L. Reed"><a id="link" href="#" class="style-scope state-modifier">Guy L. Reed</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    Harvard College
  
                  </dd><dd class="style-scope patent-result">
                    
    General Hospital Corp
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">1997</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP0937146A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP97942435A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US6114506A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US08/933,983</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO1998012334A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US1997/016123</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2266341A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA002266341A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2001502895A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP10514756A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Ceased</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2001515345A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP51475598A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Ceased</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO1998012329A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US1997/016122</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU734997B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU44134/97A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Ceased</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2266339A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA002266339A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU741338B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU44135/97A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Ceased</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20030017147A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US08/934,000</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP0941345A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP97942436A</div>
                <div class="style-scope application-timeline">Filing date: 1997-09-19</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2001</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20030031664A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US09/977,283</div>
                <div class="style-scope application-timeline">Filing date: 2001-10-16</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application CA002266341A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">1997-09-19</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Individual"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Individual</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">1998-03-26</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2266341A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of CA2266341A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Abandoned</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (42)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (14)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=CA&amp;NR=2266341A1&amp;KC=A1&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/CA/2266341/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2266341/summary.html">CIPO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/CA2266341A1">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES62773923" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    <disclosure class="style-scope patent-text">
      <div class="description-paragraph style-scope patent-text"> Background of the Invention Statement as to Rights to Inventions Made Under Federally-Sponsored Research and Development This invention was made in part with Government support under Contract #HL-02348 awarded by the National Institutes of Health. The Government has certain rights in this invention.<br class="style-scope patent-text">     Field of the Invention The present invention relates to a composition and method of treatment for pulmonary embolism, myocardial infarction, thrombosis, and stroke in a patient, and more specifically to a therapy which enhances fibrinolysis comprising administering an alpha-2-antiplasmin-binding molecule. The invention also relates to a treatment for enhancing fibrinolysis comprising administering an alpha-2-antiplasmin-binding molecule together with a thrombolytic agent.<br class="style-scope patent-text">     Description ojBackground Art Venous thrombosis and pulmonary embolism are major causes of morbidity and mortality in the United States, accounting for about 270,000 hospitalizations a year (Anderson, F.A, Jr. et al., Arch. Intern. Med. 151:933-(1991)). In addition, it is estimated that about 50,000-200,000 patients a year die from pulmonary embolism (Lilienfeld, D.E. et al. , Chest 98:1067-1072 ( 1990)).<br class="style-scope patent-text"> In surprising contrast with the mortality rate for myocardial infarction, the mortality rate for pulmonary embolism (estimated at 9.2% in treated patients) has not improved in the last 30 years (Lilienfeld, D.E. et al., Chest 98:1067-1072 ( 1990); Giuntini, C. et al., Chest l07:3 S-9S ( 1995)). Moreover, survivors of venous thromboembolism are known to be at risk for recurrent thrombosis, WO 98/I2329 PCTlUS97/16122 postphlebitic syndrome, and pulmonary hypertension (Sutton, G.C. et al., Br.<br class="style-scope patent-text">Heart J. 39:1 I35-1 I92 (l977); Salzman, E.W. and Hirsch, J., "The Epidemiology, Pathogenesis and Natural History of Venous Thrombosis," in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Coleman, R.W. et al., eds., 3rd ed. Philadelphia, PA (1994), pp. 127S-1296).<br class="style-scope patent-text">    A. Mechanism of Clot Formation and Lysis Clots (or thrombi in a patient) are composed of fibrin and blood platelets in various ratios. The fundamental reaction in blood clotting involves the conversion of a soluble plasma protein (fibrinogen) into insoluble fibrin. The conversion of fibrinogen into fibrin is catalyzed by the enzyme, thrombin, which is a serine protease.<br class="style-scope patent-text">     Clot lysis is mediated by plasmin. Under natural conditions, plasminogen is converted to plasmin by plasminogen activators. Natural plasmin inhibitors include a2-antipiasmin, a2-macroglobulin and a-1-antitrypsin, a11 glycoproteins.<br class="style-scope patent-text">Alpha-2-antiplasmin has a much higher affinity for plasmin than a2-macroglobulin and binds specifically to plasmin in a 1:1 ratio. The larger pool of a-macroglobulin acts as a reservoir inhibitor (Kane, K.K., Ann. Clin. Lab. Sci.<br class="style-scope patent-text">l4:443-449 (1984)). Thus, clot lysis by the administration of t-PA is limited by the rapid and irreversible inactivation of plasmin by plasmin inhibitors.<br class="style-scope patent-text">     B. Treatment for Venous Thrombosis and Pulmonary Embolism Standard therapy for venous thromboembolism is heparin, which potentiates thrombin and factor Xa inhibition by antithrombin III (Goldhaber, S., Chest l07:45 S-51 S ( 1995)). Although heparin decreases new thrombus (clot) formation, clinical studies suggest that there is little early endogenous lysis of the large thrombi that often exist at the time of diagnosis in patients with venous WO 98/12329 PCT/US9'7/16122 thromboembolism (Goldhaber, S.Z. et al., Lancet 2:886-889 (1986); "The Urokinase Pulmonary Embolism Trial," Circulation 47:1-l08 (1973); Goldhaber, S.Z. et al., Am. J. Med 88:235-240 (1990); GoIdhaber, S.Z. et al., Lancet 34l:507-511 (1993)). Since large thrombi are associated with an increase in morbidity and mortality, several studies have examined the effects of plasminogen activators in patients with venous thromboembolism (Goldhaber, S.Z. et al., Lancet 2:886-889 (1986); "The Urokinase Pulmonary Embolism Trial,"<br class="style-scope patent-text"> Circulation 47:l-108 (1973); Goldhaber, S.Z. et al., Am. J. Med. 88:235-240 (l990); Goldhaber, S.Z. et al., Lancet 34l:507-5l1 (l993)).<br class="style-scope patent-text">     Compared with heparin alone, plasminogen activators cause significant increases in the lysis of venous thromboemboli, but patients are frequently left with large amounts of residual thrombi in the lungs or deep veins immediately after therapy (Goldhaber, S.Z. et al., Lancet 2:886-889 (l986); "The Urokinase Pulmonary Embolism Trial," Circulation 47:1-108 (1973); Goldhaber, S.Z. et al., Am. J. Med. 88:235-240 (1990); Goldhaber, 5.Z. et al., Lancet 34l:507-511 {l993)). None of the randomized, controlled trials of patients with pulmonary embolism have demonstrated a mortality benefit from plasminogen activators, although this may well be due to the small numbers of patients enrolled in these studies. Use of plasminogen activators for myocardial infarctions has shown that 45-70% of patients with coronary thrombosis have failed to achieve fuIt 90 minutes reperfusion with these agents.<br class="style-scope patent-text">     Why venous thromboemboli resist fibrinolysis is unknown. Physical characteristics such as size, retraction, exposure to blood flow, and age may affect the lysis of these large fibrin-rich thrombi (Prewitt, R.M., Chest 99:157S-(l991)). However, it is also likely that the fibrinolytic resistance of these thrombi is regulated by specific molecular factors such as factor XIII, plasminogen activator inhibitor 1 (PAI-1 ), and alpha-2-antiplasmin (a2AP) (Collen, D., Eur.<br class="style-scope patent-text">     J. Biochem. 69:209-216 (1976); Moroi, M. and Aoki, N., J. Biol. Chem.<br class="style-scope patent-text">25l:5956-S965 (1976); Mullertz, S. and Clemmensen, L, Biochem. J. 159:545-553 (1976}; Sakata, Y. and Aoki, N., J. Clin. Invest. 69:536-542 (1982); <br class="style-scope patent-text">Robbie, L.A. etal., Thromb. Haemostas. 70:301-306 (1993); Francis, C.W. and Marder, V.J., J. Clin. Invest. 80:1459-1465 (l987); Jansen, J.W.C.M. et al., Thromb.<br class="style-scope patent-text">     Haemostas) 57:171-175 (1987); Reed, G.L. et al., Trans. Assoc. Am. Phys.<br class="style-scope patent-text">l04:21-28 (1991); Stringer, H.A, and Pannekoek, H., J. Biol. Chem. 270:11205-S 11208 (1995); Carmeliet, P. et al., J. Clin. Invest. 92:2756-2760 (1993); <br class="style-scope patent-text">Lang, LM. et al., Circulation 89:271 S-272l ( 1994); Marsh, J.J. et al. , Circulation 90:3091-3097 (l994)).<br class="style-scope patent-text">     Because a2AP is an ultrafast covalent inhibitor of plasmin (the enzyme that degrades thrombi), a2AP is a particularly likely cause of thrombus resistance (Collen, D., Eur. J. Biochem. 69:209-216 ( 1976); Moroi, M. and Aoki, N., J. Biol. Chem. 25l:5956-5965 (l976); Mullertz, S. and Clemmensen, L, Biochem.<br class="style-scope patent-text">J. l59:545-553 (1976)). Moreover, a2AP is the only fibrinolytic inhibitor that is covalently crosslinked to the fibrin surface (Sakata, Y. and Aoki, N., J. <br class="style-scope patent-text">Clin.<br class="style-scope patent-text">     Invest. 69:S36-S42 (1982)). This crosslinking (by activated factor XIII) concentrates a2AP on the fibrin surface, where it inhibits the initiation of fibrinolysis (Sakata, Y. and Aoki, N., J. Clifz Invest. 69:S36-542 (1982)).<br class="style-scope patent-text">Previous in vitro studies have Shown that clots from a2AP-deficient patients lyse spontaneously, suggesting that a2AP plays a critical role in thrombus resistance to endogenous plasminogen activators (Aoki, N. et al.) Blood 62:1118-1122 (1983); Miles, L.A. et al., Blood S9:1246-1251 (l982)). These observations led to the hypothesis that a2AP is a molecular mediator of the thrombus resistance seen in patients with pulmonary embolism. .To test this hypothesis, we generated a specific inhibitor of a2AP and used it to determine the role played by a2AP <br class="style-scope patent-text">in the regulation of lysis of experimental pulmonary emboli.<br class="style-scope patent-text">If an individual has formed a fibrin clot (thrombus) prior to the availability of medical assistance, the clot may be dissolved through the use of agents capable of lysing the fibrin thrombus, and thereby permitting blood to again flow through the affected blood vessel. Such agents include plasmin, anti-coagulants (such as, for example, heparin, hirudin and activated protein C), plasminogen activators (such as, for example, streptokinase, prourokinase, urokinase, tissue-type -S-plasminogen activator, staphylokinase, and vampire bat plasminogen activator), and other such agents (Ganz, W. et al., J. Amer. Coll. Cardiol. I:1247-1253 (1983); Rentrop, K.P. et al., Amer. J. Cardiol. 54:29E-31E (1984); Gold, H.K.<br class="style-scope patent-text">et al., Amer. J. Cardiol. 53:122C-125C (1984)).<br class="style-scope patent-text">     At present, treatment of pulmonary embolism, myocardial infarction, thrombosis, and stroke is partially achieved through the administration of thrombolytic agents. Use of such agents in therapy often results in incomplete lysis, and promotes the reformation of thrombi and reocclusion of the affected blood vessels. Hence, a need exists for an improvement in thrombolytic therapy which enhances fibrinolysis, while minimizing fibrinogen breakdown and preventing reformation of thrombi.<br class="style-scope patent-text">     C. Alpha-Z anh'plasmin Antibodies Alpha-2-antiplasmin (a2AP) has three functional domains: the reactive site for plasmin, the plasmin(ogen) or LBS-binding site [complementary to the LB S (lysine-binding site) of plasmin(ogen)), and the crosslinking site for fibrin.<br class="style-scope patent-text">Mimuro, J. et al., Blood 69:446-4S3 (1987). Mimuro et al. discloses antibodies to a2AP, one of which (JPTI-1 ) was specific to the reactive site of a2AP and prevented formation of a2AP complexes, thereby inhibiting antiplasmin activity.<br class="style-scope patent-text">However, Mimuro et al. does not teach administration of the JPTI-1 antibody to enhance clot lysis. Other antibodies specific for a2AP are taught by Plow, E.F.<br class="style-scope patent-text">et al., J. Biol. Chem. 25S:2902-2906 (1980); Wimen, B. et al., Scan. J. Clin. <br class="style-scope patent-text">Lab.<br class="style-scope patent-text">   Invest. 43:27-33 (1983); Hattey, E. et al., Thromb. Res. 45:485-495 (l987);<br class="style-scope patent-text">Collen, U.S. Patent No. 4,34b,029 (1980); and Collen, U.S. Patent No. <br class="style-scope patent-text">4,198,335 (1980). <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98/12329 PCT/US9?/16122 Summary of the Invention The present invention relates to an improved thrombolytic therapy for the treatment of pulmonary embolism, myocardial infarction, thrombosis and stroke in patients. The invention is directed to an immunologic molecule capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins. In preferred embodiments, the immunologic molecule is a chimeric antibody, a humanized antibody, or a single chain antibody. The invention is also directed to a method for treating pulmonary embolism, myocardial infarction, thrombosis and stroke in a patient comprising administering an a2-antiplasmin-binding molecule capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins. The invention further provides a method of treatment for pulmonary embolism, myocardial infarction, thrombosis and stroke in a patient which comprises co-administrating to a patient in need of such treatment:<br class="style-scope patent-text">(a) a therapeutically effective amount of an immunologic molecule capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crossiinked a2-antiplasmins; and (b) a therapeutically effective amount of a thrombolytic agent, wherein the immunologic molecule (a) is different from the thrombolytic agent (b), thereby treating the patient.<br class="style-scope patent-text">     The invention provides a monoclonal antibody or fragment thereof wherein the monoclonal antibody is capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins arid (2) human and nonhuman fibrin crosslinked a2-antiplasmins. In one embodiment, the invention is monoclonal antibody 77A3.<br class="style-scope patent-text"> In another embodiment, the invention is monoclonal antibody 49C9. In another embodiment, the monoclonal antibody is 70B 11.<br class="style-scope patent-text">     The invention also provides a method of making the monoclonal antibody comprising: <br class="style-scope patent-text"> <br class="style-scope patent-text"> _'j_ (a) immunizing an animal with a2-antiplasmin or fragment thereof;<br class="style-scope patent-text">(b) fusing cells from the animal with tumor cells to make a hybridoma cell line;<br class="style-scope patent-text">(c) cloning the hybridoma cell line;<br class="style-scope patent-text">(d) selecting for the monoclonal antibody capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins; and (e) obtaining the monoclonal antibody.<br class="style-scope patent-text">     The invention provides a hybridoma cell line which produces the monoclonal antibody capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2 antiplasmins. In one embodiment, the invention is hybridoma cell line 77A3 (ATCC Accession No. HB-12192; Deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20862 on September 20, 1996).<br class="style-scope patent-text">     The invention is directed to a method of making the hybridoma cell line compnsmg:<br class="style-scope patent-text">(a) immunizing an animal with a2-antiplasmin or fragment thereof;<br class="style-scope patent-text">(b) fusing the cells from the animal with tumor cells to make the hybridoma cell line; and (c) obtaining the hybridoma cell line which produces the monoclonal antibody capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins.<br class="style-scope patent-text">    The invention also provides a method for treating a number of diseases and conditions, including pulmonary embolism, myocardial infarction, thrombosis and stroke in a patient comprising administering a therapeutically effective amount of an immunologic molecule which is capable of binding to both (1) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crossiinked a2-antiplasmins, thereby treating the patient. <br class="style-scope patent-text"> <br class="style-scope patent-text"> _g_ The invention fi~rther provides a method of treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises co-administering to a patient in need of such treatment:<br class="style-scope patent-text">(a) a therapeutically effective amount of an immunologic molecule which is capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins; <br class="style-scope patent-text">and (b) a therapeutically effective amount of a thrombolytic agent, wherein the immunologic molecule (a) is different from the thrombolytic agent (b), thereby treating the patient.<br class="style-scope patent-text">     In preferred embodiments, the thrombolytic agent is plasmin, anti-coagulant, or plasminogen activator. In one embodiment, the anti-coagulant is selected from the group consisting of heparin, hirudin and activated protein C. In another embodiment, the plasminogen activator is selected from the group consisting of staphylokinase, streptokinase, prourokinase, urokinase, tissue-type plasminogen activator, and vampire bat plasminogen activator.<br class="style-scope patent-text">   Other embodiments of the invention include, the immunologic molecule provided to the patient by an intravenous infusion, by an intravenously injected bolus, or with a first bolus containing the immunologic molecule (a) and a subsequently administered second bolus containing the thrombolytic agent (b).<br class="style-scope patent-text">     Further embodiments include, the immunologic molecule (a) provided to the patient at a dose of between 3 to 300 nmole per kg of patient weight; and the thrombolytic agent (b) provided to the patient at a dose of between 0.01 to 3.0 mg per kg of patient weight.<br class="style-scope patent-text">     The invention provides a kit usefial for carrying out the method of treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient, being compartmentalized in close confinement to receive two or more container means therein, which comprises:<br class="style-scope patent-text">( 1 ) a first container containing a therapeutically effective amount of the immunologic molecule (a); and (2) a second container containing a therapeutically effective amount of the thrombolytic agent (b), wherein the immunologic molecule (a) is different from the thrombolytic agent (b).<br class="style-scope patent-text">     The invention also provides nucleic acid molecules encoding immunologic molecules capable of binding to both ( 1 ) human and nonhuman circulating a2 antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins.<br class="style-scope patent-text">  Also provided are molecules comprising an amino acid sequence of the binding region of an immunologic molecule described herein.<br class="style-scope patent-text">     Brief Description of the Figures Figure 1. Comparison of binding to 'xsl-a2-antiplasmin of monoclonal antibodies 49C9, 70B 11, 77A3, RWR and anti-digoxin (control). Wells of a microtiter plate were coated with goat antimouse antibody. The wells were incuhated in duplicate with 49C9, 70B 1 l, 77A3, RWR or a control (antidigoxin) MAb (Mudgett-Hunter, M. et al., Mol. Immunol. 22:477-488 (1985)). After a wash, 1x51-a2AP (60,000 cpm) was added for an hour. The wells were rinsed and the amount of bound 'zsl_a2AP was measured in a gamma counter.<br class="style-scope patent-text">     Figure Z. Competition binding assays of monoclonal antibodies 49C9, 70B 1 i, 77A3, RWR and anti-digoxin with immobilized 70B 11. Competition radioimmunoassays were performed by coating wells of a microtiter plate with pl of purified MAb (70B 11 ) in duplicate ( 10 pg/ml) for 1 hour. The wells were washed and blocked with 1% BSA for 1 hour. After washing, 25 gl of a competitor MAb, same MAb or negative control MAb was added to different wells (50 ug/ml) followed by 25 p l of'zsl_a2-antiplasmin ( 100,000 cpm). <br class="style-scope patent-text">After 1 hour incubation, the wells were washed, cut and the radioactivity was measured in a gamma scintillation counter. <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98/12329 PCTlUS97/16I22 Figure 3. Comparison of amount of lysis by different monoclonal antibodies (or TBS alone) as a function of dose of urokinase. See Example 1, below, for detailed description of the method. The amount of lysis was determined by gamma counting. The percent lysis was defined at 100 x (total supernatant cpm ~- total clot cpm).<br class="style-scope patent-text">     Figure 4. Dose response studies in the absence or presence of MAb 77A3. Lysis by urokinase is increased approximately 100-fold by 77A3.<br class="style-scope patent-text">     Figure S. Reduced SDS-polyacrylamide gel electrophoresis of 77A3 purification. Ascites containing 77A3 were harvested and purified. Lane 1, protein standards with molecular mass in kDa (left); lane 2, supernatant after precipitation with 40% ammonium sulfate; lane 3, purified 77A3. The reduced 77A3 immunoglobulin consists of bands of ~50 kDa, corresponding to the heavy chain, and ~25 kDa, corresponding to the light chain.<br class="style-scope patent-text"> Figure 6. Effect of 77A3 on the rate of lysis of ferret plasma clots in vitro. Ferret plasma clots formed with trace amounts of '2sI-labeled human fibrinogen were incubated with 100 ,ul of TBS (control) or purified MAb (25 ,ug, 77A3 or RWR). Clot lysis was initiated by adding 0.1 unit of rt-PA per tube. <br class="style-scope patent-text">The clots were incubated at 37~C and the amount of lysis was determined by sampling for the release of radiolabeled fibrin degradation products into the supernatant as described (Reed, G.L. III et al., Proc. Natl. Acad. Sci. LISA 87:1114-1118 ( 1990)).<br class="style-scope patent-text">     Figure 7. Effect of in vivo administration of MAb 77A3 on functional a2AP levels in ferrets. In dose finding experiments, two anesthetized ferrets (A, B) were given 77A3 intravenously (22.5 mg/kg) and the amount of functional a2AP was measured in citrated plasma samples drawn before (time 0) and 1 and 4 hours after infusion. The data represent the meantSD inhibition of a2AP in plasma samples.<br class="style-scope patent-text">     Figure 8. EfFect of rt-PA and a2AP inhibition on the lysis of pulmonary emboli in vivo. Anesthetized ferrets were given a heparin bolus ( 100 U/kg) and S 'ZSl_labeled fibrin clots were embolized into the lungs. After embolization, three groups of ferrets were given rt-PA (0, l, or 2 mg/kg} over 2 hours intravenously (plain bars). Two other groups of ferrets also received rt-PA ( 1 mg/kg) and a control MAb (antidigoxin, black bar, 22.5 mg/kg} or a MAb that inhibits a2AP<br class="style-scope patent-text">(77A3, striped bar, same dose). The graph shows the amount of lysis (mean~SD) for each treatment group. The number of ferrets in each treatment group is shown, and the P values for differences between groups are indicated.<br class="style-scope patent-text">     Figure 9. Residua( fibrinogen levels in animals treated with heparin, rt-PA, and an a2AP inhibitor. Blood samples were collected (on EDTA with aprotinin) from ferrets before pulmonary embolization and at the end of the experiment. Residual fibrinogen levels were measured as described (Rampling, M. W. and Gaffiley, P.J., Clin. Chim. Acta. 67:43-52 ( 1976)). The graph shows the mean~SD percentage residual fibrinogen level for animals receiving rt-PA<br class="style-scope patent-text">alone (0, 1, or 2 mg/kg; plain bars) and those receiving rt-PA and the a2AP<br class="style-scope patent-text">inhibitor (striped bar).<br class="style-scope patent-text">     Figure 10. The peptide sequences of the amino terminus of purified light chains from 49C9 (SEQ I!D NO:1) , 70B11 (SEQ lD N0:2) and 77A3 (SEQ m N0:3} are shown.<br class="style-scope patent-text"> Figure 11. The cDNA sequence (SEQ m N0:4) and corresponding deduced amino acid sequence of the signal peptide (amino acids -20 to -1 of SEQ<br class="style-scope patent-text">ID NO:S) and light chain variable regions (amino acids 1 to 107 of SEQ B7 NO:S) of 49C9 are shown. <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98I12329 PCT/US97l16122 Figure 12. The cDNA sequence (SEQ m N0:6) and corresponding deduced amino acid sequence of the signal peptide (amino acids -20 to -1 of SEQ<br class="style-scope patent-text">117 N0:7) and light chain variable regions (amino acids 1 to 107 of SEQ ID <br class="style-scope patent-text">N0:7) of 70B 11 are shown.<br class="style-scope patent-text">     S Figure 13. The cDNA sequence (SEQ )D N0:8) and corresponding deduced amino acid sequence ofthe signal peptide (amino acids -20 to -1 of SEQ<br class="style-scope patent-text">ID N0:9) and light chain variable regions (amino acids 1 to 107 of SEQ ID <br class="style-scope patent-text">N0:9) of 77A3 are shown.<br class="style-scope patent-text">     Figure 14. The cDNA sequence (SEQ m NO:10) and corresponding deduced amino acid sequence of the signal peptide (amino acids -19 to -1 of SEQ<br class="style-scope patent-text">    ID NO:11} and heavy chain variable regions (amino acids 1-1l9 of SEQ ID<br class="style-scope patent-text"> NO:11) of 49C9 are shown.<br class="style-scope patent-text">     Figure IS. The cDNA sequence (SEQ m N0:12) and corresponding deduced amino acid sequence of the signal peptide (amino acids -19 to -1 of SEQ<br class="style-scope patent-text">m N0:13) and heavy chain variable regions (amino acids 1-119 of SEQ B7 N0:13 ) of 70B 11 are shown.<br class="style-scope patent-text">     Figure 16. The cDNA sequence (SEQ lZ7 N0:14) and corresponding deduced amino acid sequence ofthe signal peptide (amino acids -19 to -1 of SEQ<br class="style-scope patent-text">&gt;D NO:15) and heavy chain variable regions (amino acids 1-1l9 of SEQ ID<br class="style-scope patent-text">     NO:15) of 77A3 are shown.<br class="style-scope patent-text">     Figure 17. The cDNA sequence (SEQ 1D N0:16) and corresponding amino acid sequence (SEQ U~ N0.17) of humanized77A3-1 and humanized 77A3-2 light chain. Positions falling within the CDR loops are shown enclosed within the boxes with solid borders. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Figure 18 The cDNA sequence (SEQ m N0:18) and corresponding amino acid sequence (SEQ ID N0:19) of humanized 77A3-1 heavy chain.<br class="style-scope patent-text">Positions falling within the CDR loops are shown enclosed within the boxes with solid borders.<br class="style-scope patent-text">     Figure 19. The cDNA sequence (SEQ ID N0:20) and corresponding amino acid sequence (SEQ m N0:21) of humanized 77A3-2 heavy chain.<br class="style-scope patent-text">Positions falling within the CDR loops are shown enclosed within the boxes with solid borders.<br class="style-scope patent-text">     Figure 20. Results of murine 77A3 (X), chimeric 77A3 (~) and humanized 77A3-1 (~) in the plasmin assay with chromogenic substrate are shown.<br class="style-scope patent-text">     Figure 21. The amino acid sequences of the light chains are shown:<br class="style-scope patent-text">h77A3-1 and h77A3-2 (SEQ m N0:17); m77A3 (SEQ ll~ N0:9); m49C9 (SEQ<br class="style-scope patent-text">   ID NO:S); m708 11 (SEQ &gt;D N0:7); murine consensus (SEQ &gt;D N0:75), which I5 shows the consensus between m77A3, m49C9, and m70811; 77A3/49C9 consensus (SEQ ID N0:76), which shows the consensus between 77A3 and 49C9; and all (SEQ ID N0:77), which shows the consensus between h77A3-l, h77A3-2, m77A3, m49C9, and m708 11. Positions falling withing the CDR loops are shown enclosed within the boxes.<br class="style-scope patent-text">     Figure 22. The amino acid sequences of the heavy chains are shown.<br class="style-scope patent-text">h77A3-1 (SEQ m N0:19); h77A3-2 (SEQ lD N0:21); m77A3 (SEQ m NO:15);<br class="style-scope patent-text">m49C9 (SEQ m NO:11); m?OBI I (SEQ &gt;D N0:13); humanized consensus (SEQ<br class="style-scope patent-text">     ID NO:78), which is the consensus between h7?A3-1 and h77A3-2; murine consensus (SEQ ID N0:79), which is the consensus between m77A3, m49C9, and m70B11; 77A3/49C9 consensus {SEQ DJ N0:80), which is the consensus between 77A3 and 49C9; and all (SEQ ID N0:81), which is the consensus WO 98l12329 PCT/US97/16122 between h77A3-1, h77A3-2, m77A3, m49C9, and m70B 11, Positions falling withing the CDR loops are shown enclosed within the boxes.<br class="style-scope patent-text">     Detailed Description of the Preferred Embodiments Alpha-2-antiplasmin (a2AP) is a molecular mediator of the thrombus resistance in patients with pulmonary embolism. A specific inhibitor of a2AP <br class="style-scope patent-text">is described which is used to determine the role played by a2AP in the regulation of fibrinolysis.<br class="style-scope patent-text">     A. Immunologic Molecules In the following description, reference will be made to various methodologies well-known to those skilled in the art of immunology. Standard reference works setting forth the general principles of immunology include Klein, J., Immunology. The Science of Cell Noncell Discrimination, John Wiley &amp;<br class="style-scope patent-text">  Sons, New York (1982); Kennett, R. et al., Monoclonal Antibodies, Hybridoma:<br class="style-scope patent-text">     A New Dimension in Biological Analyses, Plenum Press, New York (1980);<br class="style-scope patent-text">   Campbell, A., "Monoclonal Antibody Technology," in Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 13, Burdon, R., et al., eds., Elsevier, Amsterdam ( 1984); and Eisen, H.N., Microbiology) 3rd ed., Davis, B.D., et al. <br class="style-scope patent-text">, Harper &amp; Row, Philadelphia ( 1980).<br class="style-scope patent-text">     As used herein, a2AP-binding molecule includes antibodies (polyclonal or monoclonal), as well as ligands. As used herein, an "immunologic molecule"<br class="style-scope patent-text">refers to polypeptides comprising the binding region of a monoclonal antibody.<br class="style-scope patent-text">Thus, monoclonal antibodies, antibody fragments, chimeric antibodies, humanized antibodies, and fusion proteins comprising antibody binding regions are "immunologic molecules". The term "antibody" (Ab) or "monoclonal antibody"<br class="style-scope patent-text">(MAb) is meant to include intact molecules as well as antibody fragments (such as, for example, Fv, Fab and F(ab')2 fragments), single chain antigen-binding proteins, "humanized" antibodies, and chimeric antibodies which are capable of specifically binding to a2AP. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., J. Nucl. Med. <br class="style-scope patent-text">24:316-325 (l983)). Thus, these fragments are preferred.<br class="style-scope patent-text"> An antibody is said to be "capable of binding" a molecule if it is capable of specifically reacting with the molecule to thereby hind the molecule to the antibody. As used herein, the term "hapten" is intended to refer to any molecule capable of being bound by an antibody. The term "epitope" is meant to refer to that portion of a hapten which can be recognized and bound by an antibody. A<br class="style-scope patent-text">hapten or antigen may have one, or more than one epitope. An "antigen" or "immunogen" is a hapten which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. The specific reaction referred to above is meant to indicate that the hapten will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.<br class="style-scope patent-text">     The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing a2AP (or fractions, lysates, etc.<br class="style-scope patent-text">thereof) can be administered to an animal in order to induce the production of sera containing polyclonal antibodies that are capable of binding a2AP. In a preferred method, a preparation of a2AP of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.<br class="style-scope patent-text">     The antibodies of the present invention may also be prepared using phage display technology. Methods of preparing antibodies using phage display are known in the art. See, for example, U.S. Patent No. 5,565,332; Clarkson et al., Nature 3S2:624-628 ( 1991 ); Huse, Science 246:127S-1281 ( 1989); Kang, Proc.<br class="style-scope patent-text">  Natl. Acac~ Sci. USA 88:11120-11123 (1993}; Marks, J. Mol. Biol. 222:58l-597 (1991); and McCafferty et al., Nature 348:552-554 (l990). <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98/12329 PCTlUS97/16122 In one preferred method, the immunogenic molecules of the present invention are monoclonal antibodies (or a2AP binding molecules). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al., Nature 2S6:495 ( 1975); Kohler et al., Eur. J. Immunol. 6: 5 I 1 ( 1976); <br class="style-scope patent-text">Kohler et al.) Eur. J. Immunol. 6:292 (1976); Hammerling et al., in Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., pp. S63-68l (1981)). In general, such procedures involve immunizing an animal (preferably a mouse) with the antigen or with a cell which expresses the antigen. A preferred antigen is purified a2AP.<br class="style-scope patent-text">The most preferred antigen is a2AP fragment (fibrin binding region) obtained by trypsin digest of a plasma clot, then afi~nity purified with a SEPHAROSE-coupled monoclonal antibody, RWR (Reed, G.L. III et al., Trans. Assoc. Am. Phys.<br class="style-scope patent-text">101:250-256 (1988); U.S. Patent No. 5,372,8l2, issued December 13, 1994).<br class="style-scope patent-text">Suitable cells can be recognized by their capacity to secrete anti-a2AP <br class="style-scope patent-text">antibody.<br class="style-scope patent-text">Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 ~ C), and supplemented with about 10 ~g/I of nonessential amino acids, about 1,000 U/ml of penicillin, and about pglml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. The method of somatic cell fusion is described in Galfre, G. and Milstein, C., Meth. Enrymol. 73:3-46 ( 1981 ). After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al., Gasiroenterology 80:225-232 (198l). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding a2AP.<br class="style-scope patent-text">   Alternatively, additional antibodies capable of binding to the a2AP antigen may be produced in a two-step procedure through the use of anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and that, therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, a2AP-specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the a2AP-specific antibody can be blocked by the a2AP antigen. Such antibodies comprise anti-idiotypic antibodies to the a2AP-specific antibody and can be used S to immunize an animal to induce formation of further a2AP-specific antibodies.<br class="style-scope patent-text">     It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, a2AP-binding fragments can be produced through the application of recombinant DNA technology, through synthetic chemistry, or biotinylation.<br class="style-scope patent-text">     Also intended within the scope of the present invention are humanized or chimeric antibodies, produced using genetic constructs derived from hybridoma 1S cells producing the MAbs described above. Humanized antibodies are antibodies in which the framework or other regions of the murine Ab is replaced with the homologous regions of a nonmurine antibody. Chimeric antibodies are antibodies in which the murine constant region has been replaced with a non-murine constant region. Methods for production of chimeric antibodies are known in the art. <br class="style-scope patent-text">See, for review: Mornson, Science, 229:1202-1207 (1985); Oi et al., BioTechniques 4:214 ( 1986); see also) Cabilly et al. , U. S. Patent 4, 816, S 67 (3 /28/89); Taniguchi et al., EP171496 (2/19/86); Mornson et al., EP173494 (3/S/86); Neuberger et al., W08601533 (3/13l86); Robinson et al., WO 870267l (S/7/87); Boulianne et al., Nature 312:643-646 ( 1984); and Neuberger et al.) Nature 314:268-270 ( 1985 ).<br class="style-scope patent-text">2S Methods for production of humanized antibodies are known in the art. See, for example, U.S. Patent 5,58S,089; Jones et al., Nature 321:S22-SZS (1986); and Kettleborough et al., Protein Engineering 4:773-783 (199I).<br class="style-scope patent-text">    Also provided in the present invention are single-chain antibodies capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a2-antiplasmins. Methods of making -IS-single chain antibodies are well known in the art. .S~~c.~. for e~cample, C.'. <br class="style-scope patent-text">S. Patent No. =1,916,778; U.S. Patent No. a260,203; U.S. Patent No. ~,091,~ 13; and U.S.<br class="style-scope patent-text">     Patent No ~,-1&gt;j,030, all of which are herein incorporated by reference.<br class="style-scope patent-text">also intended within the scope of the present invention are variants of the monoclonal antibodies described above.<br class="style-scope patent-text">     The present inventors have determined the nucleotide and amino acid sequence of several immunologic molecules capable of binding to both ( 1 ) human and nonhuman circulating a2-antiplasmins and (2) human and nonhuman fibrin crosslinked a~-antiplasmins. Accordingly, the present invention provides for nucleic acid molecules comprising a nucleotide sequence. encoding for an immunologic molecule of the present invention or fragment thereof.<br class="style-scope patent-text">   Due to the degeneracy of the genetic code. and to the fact that the genetic code is known, all other nucleotide sequences which encode the same amino acid sequence as the nucleotides of the present invention can be determined and used 1~ in the practice of the present invention.<br class="style-scope patent-text">     DNA clones containing nucleotide sequences encoding the following antibody chains were deposited at the American Type Culture Collection, l2301 Parklawn Drive, Rockville, Maryland, 20862 on September 19, 1997: light chain of 77A3 (77:i LC), ATCC Accession No. 209290; light chain of 49C9 (49C9 LC), ATCC Accession No. 209291; light chain of 70B 1 1 (70B 1 I LC), ATCC<br class="style-scope patent-text">     Accession No. 209292; heave chain of 77A3 (77A3 HC), ATCC Accession No.<br class="style-scope patent-text">209287; heave chain of 19C9 (19C9 HC), ATCC Accession No. 209289; and heavy chain of 70B 1 I (70B I 1 HC), ATCC Accession No. 209288.<br class="style-scope patent-text">   The nucleic acid molecules of the present invention include: nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 77A3 as shown in SEQ ID N0:9 or as encoded by the clone contained in the ATCC Accession No. 209290; nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 49C9 as shown in SEQ ID ~10:~ or as encoded by the clone contained in ATCC Accession No. 209291; and nucleic acid molecules containing a nucleotide sequence encoding the mature light chain AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> of 70B l I as shown in SEQ ID N0:7 or as encoded by the clone contained in -~TCC accession No. ~09?92.<br class="style-scope patent-text">:also included in the present invention are nucleic acid molecules containing a nucleotide sequence encoding an antibody heave chain, including:<br class="style-scope patent-text">nucleic acid molecules containing a nucleotide sequence encoding the mature heave chain of 77A3 as shown in SEQ ID NO: l ~ or as encoded by the clone contained in :~T'CC :accession No. 209287; nucleic acid molecules containing a nucleotide sequence encoding the mature heave chain of 49C9 as shown in SEQ<br class="style-scope patent-text">ID NO: I 1 or as encoded by the clone contained in :~TCC :accession No. <br class="style-scope patent-text">209289;<br class="style-scope patent-text">and nucleic acid molecules containing a nucleotide sequence encoding the mature heave chain of 70B 1 1 as shown in SEQ 1D NO: 13 or as encoded by the clone contained in _-~TCC accession No. 209288.<br class="style-scope patent-text">.-also included are nucleic acid molecules encoding humanized antibodies including: nucleic acid molecules comprising a nucleotide sequence encoding for 1~ amino acid residues 1 to l07 of SEQ ID N0:17; nucleic acid molecules comprising a nucleotide sequence encodin, for amino acid residues 1 to 1 19 of SEQ ID NO: 19; and nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues 1 to 1 19 of SEQ ID N0:21.<br class="style-scope patent-text">.-also intended within the scope of the invention are nucleic acid molecules ?0 encoding ''consensus" amino acid sequences of heave and light chain ofantibodies, including: nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues 1 to l07 of SEQ ID N0:75; nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues 1 to 107 to of SEQ ID N0:76; nucleic acid molecules comprising a nucleotide sequence 25 encoding for amino acid residues 1 to I07 of SEQ ID N0:77; nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues 1 to I l9 of SEQ ID N0:78; nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues 1 to I 19 of SEQ ID N0:79; nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1 to 119 of SEQ ID N0:80; and nucleic acid molecules comprising a nucleotide sequence encoding for amino acid residues 1 to 119 of SEQ ID N0:81.<br class="style-scope patent-text">     Nucleic acid molecules encoding an immunologic molecule of the present invention can be used to express recombinant proteins. A nucleic acid molecule encoding an immunologic molecule of the present invention can be inserted into a vector in accordance with conventional techniques. A "vector" should be understood as a nucleic acid vehicle used for cloning or expressing a desired sequence in a host.<br class="style-scope patent-text">     In one embodiment, the recombinant vector is capable of expressing the immunologic molecule of the present invention. A vector is said to be "capable of expressing" a polypeptide if it contains a nucleotide sequence that encodes for the polypeptide, as well as transcriptional and translational regulator information operably linked to the nucleotide sequence that encodes the polypeptide. Two nucleotide sequences are said to be "operably linked" if the nature of the linkage between the two nucleotide sequences does not: result in the introduction of a frame-shift mutation; interfere with the ability of the promoter region sequence to direct the transcription of the desired sequence; or interfere with the ability of the desired sequence to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a desired nucleotide sequence if the promoter were capable of effecting transcription of that nucleotide sequence.<br class="style-scope patent-text">     Once the recombinant vector is constructed, it can be introduced into a host cell, either prokaryotic or eukaryotic, by a variety of conventional techniques including transfection, transduction, electroporation, calcium-phosphate precipitation, and microinjection. Prokaryotic hosts include bacteria such as E.<br class="style-scope patent-text">coli, Bacillus, Streptomyces, and Salmonella. The most preferred prokaryotic host is E. coli. Eukaryotic hosts include yeast cells, insect cells, and mammalian cells, such as COS cells, CHO cells, and myeloma cells. In one embodiment of the invention, CHO cells are preferred.<br class="style-scope patent-text">     In one embodiment of the invention, a nucleic acid molecule comprising a nucleotide sequence encoding for the light chain of an antibody is introduced WO 98/12329 PCT/~JS97/16122 into a vector, and a nucleic acid molecule comprising a nucleotide sequence encoding for the heavy chain of an antibody is introducing into another vector.<br class="style-scope patent-text">Both vectors are introduced into the same host cell. Alternatively, both chains could be introduced into the same vector.<br class="style-scope patent-text"> S Following expression in an appropriate host, the polypeptide can be readily isolated using standard techniques, including afFlnity chromatography.<br class="style-scope patent-text">     Also intended within the scope of the present invention are molecules comprising an anuno acid sequence of the binding region of an immunologic molecule described herein. Molecules comprising an amino acid sequence of the binding region of an immunologic molecule described herein include, but are not limited to, monoclonal antibodies, humanized antibodies, chimeric antibodies, fragments of any such antibodies, single chain antibodies, fusion proteins, and the Iike. Such molecules can be used in the assays and methods of treatment of the present invention described below.<br class="style-scope patent-text">     The amino acid sequence of the binding region of the immunologic molecules of the present invention are shown in Figure 21 for the light chains and Figure 22 for the heavy chains. In Figure 21, the amino acid sequence of the binding regions ofthe light chains of h77A3-1 and h77A3-2 (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID N0:17), m77A3 (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID N0:9), m44C9 (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID NO: S), m70B 11 (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID N0:7), the murine consensus (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ 117 N0:75), the 7?A3l49C9 consensus (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ 1D<br class="style-scope patent-text">N0:76) and the consensus of all light chains (amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID N0:77) are shown in the larger boxes.<br class="style-scope patent-text">     In Figure 22, the amino acid sequence of the binding regions of the heavy chains of h77A3-I (amino acid residues 26 to 3 5, 50 to 66 and 99 to l08 of SEQ<br class="style-scope patent-text">   ID N0:19), h77A3-2 (amino acid residues 26 to 35, 50 to 66 and 99 to 108 of SEQ 117 N0:21 ), m77A3 (amino acid residues 26 to 3 5, 50 to 66 and 99 to l O8 WO 98112329 PCT/US9~/16122 of SEQ ID NO:15), m49C9 (amino acid residues 26 to 35, 50 to 66 and 99 to 108 of SEQ ID NO:11), m70B11 (amino acid residues 26 to 35, 50 to 66 and 99 to l08 of SEQ ID N0:13), the humanized consensus (amino acid residues 26 to 35, 50 to 66 and 99 to 108 of SEQ ID N0:78), the murine consensus (amino acid residues 26 to 3 5, 50 to 66 and 99 to 108 of SEQ ID N0:79), the 77A3/49C9 consensus {amino acid residues 26 to 35, 50 to 66 and 99 to l08 of SEQ ID<br class="style-scope patent-text">N0:80), and the consensus of all the heavy chains (amino acid residues 26 to 35, 50 to 66 and 99 to 108 of SEQ ID N0:81 ) are shown in the overlapping boxes.<br class="style-scope patent-text">     B. Assays Methods for immunoblotting are known in the art (see, for example, Reed, G.L. et al., J. Immunol. 150:4407-4415 (1993)). In a preferred method, the a2AP is electrophoresed on a slab minigel under reducing and non-reducing conditions. The gel is electroblotted to polyvinylidene difluoride membrane. <br class="style-scope patent-text">The blot is exposed to different hybridoma supernatants in the channels of a miniblotter apparatus. After washing, the bound antibody is detected by incubation with'25I-goat antimouse antibody. After additional washing, the membrane is exposed in a phosphorimager (Molecular Devices, Sunnyvale, CA).<br class="style-scope patent-text">     Methods for radioimmunoassays are also known. For example, the wells of a microtiter plate are coated with goat antimouse antibody. The wells are washed and blocked with BSA. The hybridoma supernatants are added to the empty wells. After incubation, the wells are washed and '25I-a2AP is added.<br class="style-scope patent-text">  After washing, the wells are cut and the bound antibody is measured by gamma scintillation counting. For competition assays, the wells of a microtiter plate are coated with a competing MAb. In a preferred embodiment, the binding of MAbs to'ZSI-a2AP (preferably, the fibrin binding region fragment of a2AP, obtained by binding to RWR) is assayed by reverse solid-phase radioimmunoassay.<br class="style-scope patent-text">Methods for clot assays are also known (see, for example, Reed, G.L. III<br class="style-scope patent-text">et al., Proc. Natl. Acad. Sci. USA 87:11l4-1118 (1990). In a preferred embodiment, plasma is mixed with '25I-fibrinogen, then clotted by mixing with CaCl2 and thrombin. Clots are compressed and washed with Tris-buffered saline to remove unbound proteins. The supernatant is removed and the clots counted in a gamma counter. To each set of duplicate clots is added, various amounts of plasminogen activator, anti-coagulant, and Tris-buffered saline containing the MAb or no MAb. The clots are incubated and at various intervals, a portion of the solution is temporarily removed and gamma-counted to determine the amount of lysis. The percent lysis may be defined at 100X (total supernatant cpm/total clot cpm).<br class="style-scope patent-text">     Fibrinogen assays are known. Blood samples and platelet-poor plasma are assayed for fibrinogen by, for example, the sodium sulfite method (Rampling, M.W. and Gaffney, P.J., Clin. Chim. Acta. 67:43-52 (1976)).<br class="style-scope patent-text">     Alpha-2-antiplasmin levels in plasma are assayed, for example, with a chromogenic substrate assay for plasmin inhibition (Stachrom kit) as described in Reed, G.L., III et al., Proc. Natl. Acad. Sci. USA 87:1114-1118 (I990).<br class="style-scope patent-text">     Statistical tests may be analyzed by, for example, a one way analysis of variance followed by a Bonferroni-Dunn procedure for multiple comparison testing.<br class="style-scope patent-text">     In vivo pulmonary embolism experiments are described in Example 2, below.<br class="style-scope patent-text">     G Methods of Treatment By "patient" is intended, human or nonhuman. Nonhumans include, for example, baboon, green monkey, dog, cynamologus, marmoset, ferret, guinea pig, and gerbil.<br class="style-scope patent-text">    By "clot" is intended, an in vitro blood or fibrin clot, or "thrombi" in a patient. Diseases treated according to the methods of his invention include, but are not limited to pulmonary thromboembolism; acute coronary syndrome, including unstable angina pectoris and non-Q-wave myocardial infarction; <br class="style-scope patent-text">various forms of thrombosis, including venous thrombosis (e.g., deep venous thrombosis), and arterial thrombosis (e.g., renal, mesenteric, and limb thrombosis); and cerebral and thrombosis embolism; renal vein and peripheral arterial thrombosis, myocardial infarction, stroke, and other thromboses. This method may also be S used to treat thrombotic conditions secondary or concomitant to surgical procedures, including percutaneous transluminal coronary angioplasty, peripheral arterial angioplasty, bypass graft, and stmt. The "treating" or "treatment" is by, for example, inhibiting the formation of a thrombus, dissolving a thrombus, or by enhancing fibrinolysis.<br class="style-scope patent-text">   By the term "co-administration" is intended that each of the hapten-binding molecule and thrombolytic agent will be administered during a time frame wherein the respective periods of pharmacological activity overlap. The two agents may be administered simultaneously or sequentially.<br class="style-scope patent-text">     The a2AP-binding molecules of the present invention may be monoclonal antibodies or fragments thereof. It is preferable to employ the F(ab')Z <br class="style-scope patent-text">fragment of such an antibody for this purpose, in order to minimize any immunological reaction caused by the Fc portion of the immunoglobulin. Also preferred are single-chain antibodies, such as sFv. Procedures for preparing monoclonal antibodies are disclosed by Kaprowski, H. et al., United States Patent No.<br class="style-scope patent-text">4,172,124, and Kohler et al. , Nature 256:495-497 ( 1975). The preparation of monoclonal antibodies capable of preventing the inhibition of plasmin are taught by Mimuro, 3. et al., Blood 69:446-4S3 ( 1987), and described in the examples section of the present application.<br class="style-scope patent-text">     As used herein, an "antigen" is a molecule capable of being bound by an antibody such as, for example, a2AP. In order to be used in accordance with the present invention, the "antigen-binding molecule" must be capable of binding to a plasmin inhibitor and thereby prevent such an inhibitor from forming inhibitor-plasmin complexes. Any such antigen-binding molecule may be employed in accordance with the present invention. A preferred embodiment is a2AP-binding molecule which is capable of binding to a2AP or fragment thereof. An especially preferred a2AP-binding molecule for this purpose is a monoclonal antibody.<br class="style-scope patent-text">    Preferred embodiments of the monoclonal antibody is 77A3, 70B I 1 or 49C9, described more fully below. The hybridoma producing MAb 77A3 has been deposited under the terms of the Budapest Treaty with the International Depository Authority American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, U.S.A., on September 20, 1996; the ATCC Accession No.<br class="style-scope patent-text">is HB-12192.<br class="style-scope patent-text">     Also preferred are chimeric an humanized antibodies. An especially preferred chimeric antibody for this purpose is c77A3, described more fully below.<br class="style-scope patent-text">    Especially preferred humanized antibodies for this purpose are h77A3-1 and h77A3-2, described more fully below. Also preferred are antibody fragments and single-chain antibodies, including sFv77A3-1 and sFv77A3-2, described below.<br class="style-scope patent-text">     The terms "thrombolytic agent" are meant to refer to any agent capable of either dissolving a fibrin andlor platelet clot (or thrombus), or inhibiting the formation of such a clot. Examples of thrombolytic agents include fibrinolytic molecules, such as plasmin, plasminogen activator (for example, staphylokinase, streptokinase, prourokinase, urokinase, tissue-type plasminogen activator, and vampire bat plasminogen activator); anti-coagulants (for example, inhibitors of fibrin formation, such as heparin, hirudin and activated protein C; and anti-platelet agents, such as ticlopidine, aspirin, and clopidigrel and inhibitors of glycoprotein IIb/IIIa fianction). Use of t-PA for these purposes is especially preferred.<br class="style-scope patent-text"> Although natural t-PA may be employed, it is preferable to employ recombinant t-PA (rt-PA). The invention may additionally employ hybrids, physiologically active fragments or mutant forms of the above thrombolytic agents. For example, the term "tissue-type plasminogen activator" as used herein is intended to include such hybrids, fragments and mutants, as well as both naturally derived and recombinantly derived tissue-type plasminogen activator.<br class="style-scope patent-text">    As stated, the methods of the invention comprise the adnunistration of the a2AP-binding molecule alone or in combination with a thrombolytic agent. When administered alone the molecule enhances endogenous fibrinolysis or thrombolysis _26_ by significantly augmenting clot lysis by endogenous plasminogen activators.<br class="style-scope patent-text">Further, administration of the a2AP-binding molecule does not increase fibrinogen consumption over that obtained with equivalent doses of t-PA alone. Thus, the present method of clot-specific inhibition of a2AP enhances the potency of the plasminogen activator and preserves its fibrin selectivity.<br class="style-scope patent-text">     Alternatively, the a2AP-binding molecule is administered with a thrombolytic agent. In this embodiment, the a2AP-binding molecule and the thrombolytic agent of the present invention are intended to be co-administered to the recipient. It is preferable to provide the a2AP-binding molecule to the patient prior to the administration of the thrombolytic agent.<br class="style-scope patent-text">     The a2AP-binding molecule of the present invention is provided for the purpose of preventing the inhibition of plasmin by a plasmin inhibitor. It has been discovered that coadministration of the a2AP-binding molecule together with a thrombolytic agent causes a synergistic effect, and thereby enhances clot lysis (thrombalysis) to a greater extent than would be expected if the eiTects of a2AP-binding molecule administration and thrombolytic agent administration was merely additive.<br class="style-scope patent-text">     The a2AP-binding molecule of the present invention encompasses clot-specific inhibitors of a2AP. It is demonstrated that the combination of t-PA <br class="style-scope patent-text">and the specific inhibitors, particularly monoclonal antibodies to a2AP, does not increase fibrinogen consumption over that obtained with equipotent doses of plasminogen activator alone. Further, clot-specific inhibition of a2AP <br class="style-scope patent-text">enhances the potency of plasminogen activators and preserves fibrin selectivity. For agents such as urokinase, which is not selective for fibrin, inhibition of clot bound a2AP<br class="style-scope patent-text">would cause a similar, or more pronounced, enhancement in potency and lead to less fibrinogen consumption as well.<br class="style-scope patent-text">     Thus, the inhibition of clot-bound a2AP enhances clot lysis by endogenous plasminogen activators. Further, when administered in combination with a thrombolytic agent, thrombolysis is significantly increased compared with the lysis achieved by equivalent doses of the thromboiytic agent alone. This increased lysis by the combination of the thrombolytic agent and a2AP inhibitor occurs without decreasing circulating fibrinogen or a2AP levels. The net result is a synergistic interaction between the two agents.<br class="style-scope patent-text">     When used alone, an amount of a2AP-binding molecule capable of preventing inhibition of plasmin and thereby enhancing clot lysis when provided to a patient is a "therapeutically effective" amount. In order to enhance clot lysis and prevent clot reformation, it is desirable to provide between 3 to 300 nmole of a2AP-binding molecule per kilogram of patient weight. This dosage may be administered, in one embodiment, over a period of between 60 to 480 minutes, by continual intravenous infusion at a rate of 0.006 to 5 nmoIe/kg/min. <br class="style-scope patent-text">Alternatively, it is possible to provide the a2AP-binding molecule in an intravenously injectable bolus at a dose of between 3 to 600 nmole/kg, and most preferably between 30 to 60 nmole (of a2AP-binding molecule) per kilogram of patient weight. If the a2AP-binding molecule is provided in this manner, a single bolus is sufficient to prevent potential clot reformation. The a2AP-binding molecule of the present invention may be dissolved in any physiologically tolerated liquid in order to prepare an injectable bolus. It is preferable to prepare such a bolus by dissolving the a2AP-binding molecule in normal saline.<br class="style-scope patent-text">     When the a2AP-binding molecule capable of preventing inhibition of plasmin is co-administered with a thrombolytic agent, it is desirable to provide 3 to 300 nmole of a2AP-binding molecule per kilogram~of patient weight. This dosage may be administered, in one embodiment, over a period of 60 to 480 minutes, by continuous intravenous infusion. Alternatively, it is possible to provide the a2AP-binding molecule in an intravenously injectable bolus at a dose of between 3 to 600 nmole/kg, and most preferably between 30 to 60 nmole/kg of patient weight. An amount of thrombolytic agent capable of causing such lysis is a "therapeutically effective" amount. It is desirable to provide between 0.01 to 3.0 mg per kilogram of patient weight. In one embodiment, the thrombolytic agent is provided over a prolonged period (i.e., from about l80 to about l440 minutes). In a preferred embodiment, the thrombolytic agent of the present invention is provided as an intravenously injected bolus containing between 0.5 to 1.0 mg/kg, and most preferably between 0.5 to 0.75 mg/kg. For example, for pulmonary embolism, the dosage of t-PA by continuous infusion is 100 mg for 2 hours (Goldhaber, S.C. et al., Lancet 34l:507 (1993)). The dosage to be used of thrombolytic agent of the present invention is generally known in the art (see, e.g., Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia, PA (1994)).<br class="style-scope patent-text"> The thrombolytic agent of the present invention may be dissolved in any physiologically tolerated liquid in order to prepare an injectable bolus. It is, however, preferable to prepare such a bolus by dissolving the thrombolytic agent in normal saline.<br class="style-scope patent-text">     A patient treated according to the preferred embodiment will, therefore, receive an intravenously injected bolus of the a2AP-binding molecule in combination with an intravenously injected bolus of the thrombolytic agent. <br class="style-scope patent-text">This preferred treatment minimizes the amount of t-PA required for thrombolysis, thus reducing the extent of fibrinogen breakdown and lessening any tendency for general hemorrhage. Importantly, the use of the preferred treatment results in the dissolution of the occluding thrombus at a rate which greatly exceeds the rate of thrombus dissolution when either the a2AP-binding molecule or the thrombolytic agent is provided by infiasion alone. Additionally, the risk of reocclusion is substantially reduced.<br class="style-scope patent-text">  In previous models of fibrinolysis (3 ), the chief role assigned to a2AP has been to inactivate circulating plasmin and prevent a systemic lytic state. <br class="style-scope patent-text">Thus, it may be surprising that an a2AP inhibitor can increase clot lysis without increasing fibrinogenolysis. This marked amplification of thrombolysis by a2AP inhibitor underscores the importance of fibrin bound a2AP in regulating fibrinolysis. <br class="style-scope patent-text">Since the subject antibodies augment clot lysis by a fibrin-selective agent such as t-PA<br class="style-scope patent-text">as well as that by the nonselective activators urokinase and streptokinase, it appears that fibrin-bound a2AP plays a critical role in determining the rate of lysis by any exogenous plasminogen activator. <br class="style-scope patent-text"> <br class="style-scope patent-text"> These unexpected findings are important because it had previously not been possible to accelerate the rate of clot lysis without increasing the tendency to hemorrhage. The preferred embodiment, therefore, provides a method of treatment in which the administration of a bolus of a a2AP-binding molecule in combination with the administration of a bolus of a thrombolytic agent are capable of dissolving an occluding thrombus at a faster rate than can be obtained when either compound is administered alone. Moreover, the preferred embodiment accomplishes this goal while minimizing both fibrinogen breakdown and the risk of reocclusion. Thus, the combination of agents can significantly increase the potency and specificity of thrombolytic therapy.<br class="style-scope patent-text">     As would be apparent to one of ordinary skill in the art, the required dosage of the anti-a2AP binding molecule or thrombotytic agent will depend upon the severity of the condition of the patient, and upon such criteria as the patient's height, weight, sex, age, and medical history.<br class="style-scope patent-text">     The a2AP-binding molecule or thrombolytic agent of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, such as by admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation are described, for example, in Remington's Pharmaceutical Sciences, I 6th Ed., Osol, A., ed., Mack, Easton PA<br class="style-scope patent-text">( I980). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the a2AP-binding molecule or thrombolytic agent, either alone, or with a suitable amount of carrier vehicle.<br class="style-scope patent-text">     Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved by the use of polymers to complex or absorb the a2AP-binding molecule or thrombolytic agents of the present invention. The controlled delivery may be exercised by selecting appropriate macromolecules (for example, polyesters, polyamino acids, polyvinyl pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate). The rate of drug release may also be controlled by altering the concentration of such macromolecules. Another possible method for controlling the duration of action comprises incorporating the therapeutic agents into particles of a polymeric substance such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, it is possible to entrap the therapeutic agents in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly(methylmethacrylate) microcapsules, respectively, or in a colloid drug delivery system, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, nanocapsules, or in macroemulsions. Such teachings are disclosed in Remington's Pharma ceutical Sciences, 16th Ed., Osol, A,, ed., Mack, Easton PA (l980}.<br class="style-scope patent-text">     The thrombolytic agent or a2AP-binding molecule may be provided to a patient by means well known in the art. Such means of introduction include oral means, intranasal means, subcutaneous means, intramuscutar means, intravenous means, intra-arterial means, or parenteral means. In one preferred method of treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke, a patient is provided with a bolus (intravenously injected) containing between 0,5 to 1.0 mg/kg of a thrombolytic agent.<br class="style-scope patent-text">     Generally, the results reported herein demonstrate that an inhibitor, particularly a monoclonal antibody, can be used to augment the catalytic function of an enzyme by neutralizing an inhibitor of that enzyme. This approach can be applied to biological processes which are tightly governed by inhibitors. <br class="style-scope patent-text">Because coagulation is a finely balanced system in which the effects of enzymes (generally serine proteases) are pitted against the effects of inhibitors, frequently serpins (serine protease inhibitors) pathological alterations in clotting can be treated by augmenting enzyme activity or by neutralizing an inhibitor.<br class="style-scope patent-text">     Having now generally described this invention, the same will be better understood by reference to certain specific examples which are included herein for purposes of illustration and are not intended as limiting. <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98l12329 PCT/US97/16122 Example 1 Preparation of an Antibody Directed to Alpha-2-antiplasmin A. Monoclonal Antibody Production, Purification and Characterization Two Balb/C mice were immunized subcutaneousiy with 25 ~g of purified human a2AP fragments derived from the trypsin digest of a human plasma clot.<br class="style-scope patent-text">     The a2AP fragments were aflrnity purified with a SEPHAROSE-coupled monoclonal antibody, RWR (Reed, G.L. III et al., Trans. Assoc. Am. Phys.<br class="style-scope patent-text">10l:250-2S6 (l988); U.S. Patent No. 5,372,812, issued December 13, 1994), against human a2AP. Mice were initially immunized with complete Freund's adjuvant and boosted 90 days later with .50 ~g of a2AP fragment in incomplete Freund's adjuvant. The antisera titer was tested in a solid-phase radioimmunoassay (Reed, G.L. III et al., Proc. Natl. Acad. Sci. USA 87:1114-1118 (1990)) with a2AP immobilized in the wells of a microtiter plate. Four days before fusion, the mouse with the highest titer of a2AP antibody was hyperimmunized with 100 ~cg a2AP intraperitoneally. Somatic cell fusion was performed as described (Galfre, G. and Milstein, C., Meth. Enrymol. 73:3-46 (1981)).<br class="style-scope patent-text">     Hybridomas were tested for the production of antibodies to the a2AP<br class="style-scope patent-text">fiagment and for their ability to inhibit a2AP as described in Reed, G.L. III <br class="style-scope patent-text">et al., Proc. Natl. Acad. Sci. USA 87:1114-1118 ( 1990). The binding of monoclonal antibodies (MAbs) to 'ZSI-a2AP was tested in a solid-phase radioimmunoassay.<br class="style-scope patent-text">Wells of a microtiter plate were coated with goat antimouse antibody (25 ~1, 5 ~g/ml) for 2 hours. The wells were rinsed and nonspecific protein binding sites were blocked with 1 % bovine serum albumin in Tris-buffered saline, pH 7.4, for 1 hour. After a wash, 25 ul of hybridoma supernatant was added to the wells and incubated for 1 hour. The wells were rinsed and 'ZSI-a2AP was added (25 ~1, b0,000 cpm) for I hour. The '25I-a2AP was then removed and the wells were rinsed and gamma-counted.<br class="style-scope patent-text">     Cloned hybridomas (limiting dilution) were expanded into ascites in pristane-primed BalblC mice. Antibodies were purified from filtered ascites by precipitation with 40% ammonium sulfate, dialysis into I O mM KHZPO4, pH 7.2, and ion-exchange chromatography on DEAF-AFFIGEL BLUE SEPHAROSE<br class="style-scope patent-text">(BioRad, Hercules, CA) with a linear gradient from 0 to 100 mM NaCt.<br class="style-scope patent-text">     B. Immunoblotting These were performed largely as described in Reed, G.L. et al.) J.<br class="style-scope patent-text">     Immunol. l50:4407-4415 (1993). Purified human a2AP (5 pg, American Diagnostica, Greenwich, CT) was electrophoresed in a large single sample lane on a 12% slab minigel (BioRad, Hercules, CA) under reducing and non-reducing conditions. The sample was electroblotted (Kyhse-Anderson, 1084) to polyvinylidene difluoride membranes (Millipore, Bedford, MA) and nonspecific protein binding sites were blocked with 5% dry milk. The blots were exposed to different hybridomas supernatants for 1 hour in the channels of a miniblotter apparatus (Immunetics, Cambridge, MA). After washing, the bound antibody was detected by incubation with '25I-goat antimouse antibody ( 1. S million cpm/membrane). After additional washing, the membranes were exposed in a phosphorimager (Molecular Devices, Sunnyvale, CA).<br class="style-scope patent-text">     C. Radiaimmunoassays Wells of a microtiter plate were coated with goat antimouse antibody (25 ~1, 5 ~I/ml) for 2 hours at 21 ~C. They were washed and blocked with 1%<br class="style-scope patent-text">   BSA (bovine albumin serum) for 1 hour. To the empty wells in duplicate were added 25 ltl of hybridoma supernatants. After incubation for I hour the wells were washed and 25 ~l of'2sI_a2AP was added to the wells for another hour. <br class="style-scope patent-text"> <br class="style-scope patent-text"> After washing the wells were cut and the bound antibody measured by gamma scintillation counting.<br class="style-scope patent-text">     Competition radioimmunoassays were performed by coating wells of a microtiter plate with 25 ul of purified MAb (70B 11 ) in duplicate (10 pg/ml) for 1 hour. The wells were washed and blocked with 1% BSA for 1 hour. After washing, 25 pl of a competitor MAb, same MAb or negative control MAb was added to different wells (50 ~g/mI) followed by 25 pl of 'zsl-a2-antiplasmin ( 100,000 cpm). After 1 hour incubation, the wells were washed, cut and the radioactivity was measured in a gamma scintillation counter.<br class="style-scope patent-text">     D. Plasma Clot Lysis Assays These were performed largely as described in Reed, G.L. III et al., Proc.<br class="style-scope patent-text">     Natl. Acad. Sci. USA 87:1l14-1118 (1990). Pooled fresh frozen plasma was obtained from 5 random donors to the Massachusetts General Hospital Blood Bank. The plasma was mixed with'zsI-fibrinogen to achieve 1,000 cpm/pl. The plasma was clotted for 1 hour at 37~C in a 12 x 65 mm test tube by mixing SO <br class="style-scope patent-text">p.l with 50 pl of CaClz (5 mM final) and thrombin (1 U/ml). Clots were compressed and washed in 1 ml Tris-buffered saline (pH 7.4) to remove unbound proteins.<br class="style-scope patent-text">    The supernatant was removed and the clots were counted in a gamma counter.<br class="style-scope patent-text"> To each set of duplicate clots was added 100 pl containing various amounts of urokinase, 100 pl of pooled plasma containing 1 ulml of hirudin and 100 ~tl of Tris-buffered saline containing ? ug (Figure 4) or 21 ug (Figure 5) of MAb or no MAb. The clots were placed in a 37~C water bath and at various intervals 100 pl of solution was temporarily removed and gamma-counted to determine the amount of lysis. The percent lysis was defined at 100 x (total supernatant cpm total clot cpm).<br class="style-scope patent-text">     E. Results Three hybridomas were selected that appeared to inhibit a2AP function in screening assays. The serotypes of these MAbs were: 49C9 (Ig~y2aK), 70B 11 (Igy 1K), and 77A3 (Ig~y2aK). Figure 1 compares the binding of these MAbs to '~sI-a2AP in a reverse solid-phase assay. When compared to the original a2AP<br class="style-scope patent-text">inhibitor RWR, these MAbs bound with greater avidity. To determine if the MAbs bound to the same epitopes, competition assays is shown for 70B 11 in Figure 2. Compared to the negative control, anti-digoxin MAb, RWR had no significant inhibitory effects on the binding of'ZSI-a2AP to immobilized 70B <br class="style-scope patent-text">11.<br class="style-scope patent-text">In contrast, when 70B 11 was used as a competitor, it completely inhibited the binding of'zsI_a2AP to immobilized 70B 11, as expected. However, 49C9 and 77A3 were also excellent competitors as well. The results of these assays are shown in tabular form in Table 1, below. MAbs 49C9, 70B 11, 77A3 also fully inhibited the binding of each other to 'z5I-a2AP, but they had no inhibitory effects on the binding of RWR. The converse was also true, RWR as a competitor had no effect on the binding of '25I-a2AP to the other MAbs. This indicated that MAbs 49C9, 70B 11 and 77A3 competed for binding to the same epitope, while RWR appeared to bind to a separate region of a2AP.<br class="style-scope patent-text">     To determine if the MAbs recognized a continuous or discontinuous epitope in a2AP, immunoblotting experiments were performed with denatured and reduced a2AP. In these studies RWR bound well to denatured and reduced a2AP, indicating that it recognized an epitope which was not affected by boiling with SDS, nor reduction of disulfide bonds. In contrast, MAbs 49C9, 70B 11 and 77A3 did not bind to denatured a2AP, suggesting that they recognize a conformation-dependent epitope. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Clot lysis assays were performed to examine the relative potency of these MAbs in amplifying the fibrinolysis by urokinase. Figure 3 compares the amount of lysis achieved by 7 pg of different purified MAbs (or TB5 alone) as a function of dose of urokinase. Compared to urokinase alone (TB S) or urokinase with the control antidigoxin MAb, RWR, 49C9, 70B 11 and 77A3 all accelerate clot lysis.<br class="style-scope patent-text">   However, 49C9, 70B 1 I and 77A3 appear to be significantly more potent than RWR in these assays. To examine the increase in fibrinolytic potency of urokinase achieved by one of these antibodies, dose response studies were performed in the absence or presence of MAb 77A3. Figure 4 shows that MAb 77A3 markedly increases the potency of lysis of urokinase by roughly I00-fold.<br class="style-scope patent-text">     As a means of further discriminating among the functional and epitope binding specificities of these MAbs, their ability to inhibit the a2AP ftom different animal species in plasma clot lysis assays was examined. The results of these assays are summarized in Table 2, below. In the different species of animal plasmas tested, RWR appeared to inhibit only human a2AP. In contrast, the other MAbs showed a broader species cross-reactivity and ability to inhibit nearly all primate and some non-primate a2APs. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Table 1 Effect of Different MAb Inhibitors on the binding of'TSI-a2AP                   <br class="style-scope patent-text">to Immobilized MAbs.                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> Immobilized MAb Inhibitor          RWR 49C9    70B 11  77A3 RWR                +      _       -       _ S          49C9               -      +       +       + <br class="style-scope patent-text"> <br class="style-scope patent-text"> 70B 11             -   +       +       + <br class="style-scope patent-text"> <br class="style-scope patent-text"> 77A3               -      +       +       + <br class="style-scope patent-text"> <br class="style-scope patent-text"> anti-digoxin       -      -       -       -To wells of a microtiter plate containing an immobilized MAbs was added 'BSI-a2AP                        <br class="style-scope patent-text">and a different competitor MAbs.                          <br class="style-scope patent-text">     A"+" indicates that the competitor inhibited the binding of '25I-a2AP                       <br class="style-scope patent-text">to the plate) whereas a "-" indicates that there was no inhibition.                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> Table 2 The cross reactivity of MAbs with different a2-antiplasmins.                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> Species      RWR      49C9     70B 11    77A3 IRAN         ++-      ++       ++        -i-+-Baboon       -        ++/+     ++/+      ++ <br class="style-scope patent-text"> <br class="style-scope patent-text"> Grn Monkey   -        ++   ++        ++ <br class="style-scope patent-text"> <br class="style-scope patent-text"> Dog          -        +        +/-       + <br class="style-scope patent-text"> <br class="style-scope patent-text"> cynamologus -        ++       ++        ++ <br class="style-scope patent-text"> <br class="style-scope patent-text"> marmoset     -        +        +         + <br class="style-scope patent-text"> <br class="style-scope patent-text"> ferret       -        +/++     +)-       +/++ <br class="style-scope patent-text"> <br class="style-scope patent-text"> guinea pig   -        -        +/-       +/-gerbil       -        -        -         -The crossreaetivity of each MAb was determined by its ability to accelerate the lysis of that species' plasma clots.                            <br class="style-scope patent-text">     A "-" indicated that the MAb did not accelerate plasma clot lysis, a "+"                             <br class="style-scope patent-text">indicated modest effects, and "++"                                 <br class="style-scope patent-text">indicates significant acceleration of plasma clot lysis (i.e., significant functional crossreactivity).                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> Example 2 In Irvo Study of Pulmonary Embolism A. Materials Materials were obtained from the following suppliers: rt-PA with a specific activity of 580,000 IUlmg, Genentech (South San Francisco, California); <br class="style-scope patent-text">ketamine ( l 00 mg/ml), Fort Dodge Laboratories (Fort Dodge, Iowa); acepromazine maleate, Ferments Animal Health Co. (Kansas City, MO); heparin (l000 Ulml), Elkins-Sinn Inc. (Cherry Hill, NJ); sodium iodide, Aldrich Chemical Co.<br class="style-scope patent-text">(Milwaukee, WI); calcium chloride, Ma.llinckrodt (Paris, Kentucky); normal saline for intravenous use, Travenol Laboratories (Deerfield, IL); a2AP assay kit, Stachrom (Asnieres, France); purif ed a2AP and fibrinogen, American Diagnostics (Greenwich, CT); goat antimouse antibody, Cappel Organon Technika (Durham, NC); human plasma pooled from random donors, Massachusetts General Hospital (Boston); bovine thrombin, Parke-Davis (Morris Plains, NJ); Na'25I, Dupont-NEN<br class="style-scope patent-text">(Cambridge, MA); Bard Parker surgical blade, Becton Dickinson (Franklin Lake, NJ); 4.0 silk sutures, American Cyanamid Co. (Danbury, CT); SURFLO IV<br class="style-scope patent-text">catheter and 20 gauge I-1I4-inch VENOJECT tubes with K3EDTA, Terumo Medical Corp. (Elkton, MD); sterile three-way stopcock, Mallinckrodt Critical Care (Glens Falls, NY); auto syringe infusion pump, Baxter Health Care Corp.<br class="style-scope patent-text">(Hooksett, NH); infusion pump tubing and microbore 60-inch extension set, McGaw of Puerto Rico (Sabana Grand, Puerto Rico); surgical instruments, VWR<br class="style-scope patent-text">(Boston); tubing, Namic (Glens Falls, NY); ferrets (~.8- I kg), Marshall Farms (New York, NY); aprotinin, Sigma (St. Louis, MO); and microcentrifuge tubes, National Scientific Supply Co. (San Rafael, CA). <br class="style-scope patent-text"> <br class="style-scope patent-text"> B. In Intro Clot Lysis Assays Pooled, fresh-frozen, citrated ferret plasma ( 1100 ,ul) was mixed with 15 ;ul of'25I_labeled human fibrinogen (40,000 cpm/clot). Ferret plasma (35 ~cl) was mixed with 35 ,ul of Tris-buffered saline (TBS) containing 10 mM CaCl2 and thrombin (1 Ulml) in twelve 65-mm plastic tubes and clotted for 1 hour at 37~C.<br class="style-scope patent-text">The clots were washed in TB S, the supernatant was removed, and then 100 ~cl of TBS or 25 ug of purified MAb (RWR or 77A3) was added to tubes in duplicate.<br class="style-scope patent-text">    Clot lysis was initiated by adding 0.1 U of rt-PA per tube. The clots were incubated at 37~C far 5 hours and the amount of lysis was determined by sampling for the release of radiolabeled fibrin degradation products into the supernatant, as described (Reed, G.L. III et al., Proc. Natl. Acad. Sci. USA 87:1114-1118 ( 1990)).<br class="style-scope patent-text">     G Pulmonary Embolism Experiments Male ferrets were anesthetized by intramuscular injection (0.4 ml) of a mixture of ketamine and acepromazine (two parts acepromazine [ 10 mg/ml] to one part ketamine [ 100 mg/ml]). Intraperitoneal injections were repeated as necessary to keep the animals anesthetized. After an anterior midline incision had been made in the neck, the jugular vein and the carotid artery were exposed by blunt dissection and cannulated with 20G catheters that were secured at the proximal and distal ends with 4-0 silk sutures. The catheters were capped with three-way stopcocks.<br class="style-scope patent-text">     Pooled, citrated human plasma was mixed with '25I-fibrinogen to achieve 1,000,000 cpm/ml. Individual clots were formed by mixing '25I-fibrinogen labeled plasma (45 ,ul) with 2. 5 ,ul of bovine thrombin ( 100 Ulml) and 2. 5 /,cl of calcium chloride (0.4 M). These clots were incubated at 37~C for 90 minutes, compressed, and washed thoroughly with saline three times to remove unbound proteins. The radioactive content of the clots was measured in a gamma counter immediately before clot injection. Blood samples were drawn at base line and at the end ofthe experiment. Sodium iodide (10 mg) was injected to block thyroid uptake. Clots were embolized into the lungs by injection through the internal jugular vein. Ferrets weighing less than I kg received three clots; those weighing I kg or more received four clots. Successful embolization was evidenced by the accumulation of radioactivity in the thorax. After the clots had been injected, the ferrets were turned on their sides to ease breathing.<br class="style-scope patent-text">     All animals received weight-adjusted heparin at l00 U/kg (bolus), a dose sufficient to keep the activated partial thromboplastin time (aPTT) above 150 seconds throughout the procedure. The a2AP inhibitor (sterile-filtered, 14 mg/ml in saline) or a purified control MAb (antidigoxin) was given intravenously as a single dose (22.5 mg/kg). The rt-PA was given as a continuous infusion over 2 hours (I or 2 mg/kg in 5 m1 normal saline). Animals were observed for a total of four hours after pulmonary embolization and then killed by lethal injection of anesthesia or by COZ inhalation. The thorax was dissected and all intrathoracic structures were removed for gamma counting to detect residual thrombi. The percentage of clot lysis was determined for each ferret by dividing the total residual radioactivity in the thorax (cpm) by that in the initial thrombi.<br class="style-scope patent-text">     This experimental protocol was approved by the Harvard Medical Area Standing Committee on Animals. The Harvard Medical School animal management program is accredited by the American Association of Laboratory Animal Care, and the procedures were conducted in accordance with National Institutes of Health standards, as set forth in the Guide for the Care and Use of Laboratory Animals (DHHS Publication No. [Ngi] 85-23, revised 1985), the Pubfic Health Service Policy on the Humane Care and Use of Laboratory Animals by Awardee Institutions, and the NIH Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training. <br class="style-scope patent-text"> <br class="style-scope patent-text"> D. Statistical Tests The data were analyzed by a one way analysis of variance followed by a Bonferroni-Dunn procedure for multiple comparison testing.<br class="style-scope patent-text">     E. Fibrinogen Assays Blood samples were collected on K3EDTA (0.l5% solution final) with aprotinin (50 kallikrein U/ml). Platelet-poor plasma was obtained by centrifugation of whole blood (Mustard, J.F. et al., Meth. Enrymol. l69:3-11 ( 1989)) and assayed for fibrinogen by the sodium sulfite method (Rampling, M. <br class="style-scope patent-text">W.<br class="style-scope patent-text">and Gaffney, P.J., Clin. Chim. Acta.67:43-52 (l976)).<br class="style-scope patent-text">  F. a2 Antiplasmin Assays To measure a2AP levels, we collected ferret blood on sodium citrate (1/10 volume) and centrifuged it to obtain plasma (Mustard, J.F. et al., Meth. <br class="style-scope patent-text">Enrymol.<br class="style-scope patent-text">     I69:3-11 (l989)). The plasma was tested for functional a2AP with a chromogenic substrate assay for plasmin inhibition (Stachrom kit) as described (Reed, G.L. III et al., Proc. Natl. Acad. Sci. USA 87:1114-1118 (1990)).<br class="style-scope patent-text">     G. Results From a panel of hybridomas we selected 77A3, a MAb that bound tightly to human a2AP. MAb 77A3 was purified from mouse ascites by ion exchange chromatography, and its purity was confirmed by SDS-polyacrylamide gel analysis (Figure 5). To study the role of a2AP in experimental pulmonary embolism in vivo, we tested purified 77A3 in several different animal plasma clot lysis assays to determine whether it could bind and inhibit a non-human a2AP. Of various small animal plasmas tested (e.g. hamster, gerbil, guinea pig, rat, etc.), significantly crossreacted with ferret plasma. Figure 6 compares the lytic effects of 77A3 with those of another MAb inhibitor of human a2AP, RWR (Reed, G.L.<br class="style-scope patent-text">     III et al., Trans. Assoc. Am. Phys. 101:250-256 (1988); U.S. Patent No. </div>
      <div class="description-paragraph style-scope patent-text">5, 3 72, 812, issued December 13, 1994), and with buffer alone. Figure 6 shows that in comparison with the control (buffer alone), 77A3 accelerated the lysis of ferret plasma clots induced by a low dose of rt-PA (0.1 unit). In contrast, RWR, which inhibits human a2AP (Reed, G.L. III et al., Trans. Assoc. Am. Phys.<br class="style-scope patent-text">10l:250-2S6 (1988); U.S. Patent No. 5,372,812, issued December 13, 1994) but does not crossreact with nonhuman a2AP, had no detectable effect. This experiment indicated that 77A3 inhibited ferret a2AP and amplified ferret clot lysis in vitro.<br class="style-scope patent-text">     The cross-reactivity of 7?A3 allowed us to investigate the role of a2AP<br class="style-scope patent-text">in a ferret model of pulmonary embolism. In humans, pulmonary embolism is usually treated with heparin (Goldhaber, S., Chest 107:45 S-51 S ( 1995)).<br class="style-scope patent-text">Consequently, ferrets were treated with a weight-adjusted bolus dose of heparin at 100 U/kg. This dose was sufficient to keep the aPTT above 150 seconds throughout the experiment (n=3). To investigate the effects of intravenous MAb 77A3 on the activity of a2AP in the blood, we selected a dose, 22.5 mg/kg, that was in molar excess to the level of ferret a2AP. Our ex vivo measurements of ferret a2AP activity, 1 and 4 hours after intravenous dosing, showed that ---75%<br class="style-scope patent-text">of ferret a2AP activity was inhibited at this dose (Figure 7, n=2).<br class="style-scope patent-text">     Using heparin at 100 U/kg and 77A3 at 22.5 mglkg, we then investigated the effect of these agents and rt-PA on the lysis of pulmonary emboli (Figure 8).<br class="style-scope patent-text"> All animals received heparin. Control animals (n=8), which received no rt-PA, showed 15.6t10.5% (mean~SD) lysis of their pulmonary emboli. Animals receiving rt-PA at 1 mg/kg (n=4) over 2 hours showed 38.5t6.3% lysis, which was significantly greater than lysis obtained in those receiving heparin alone (P&lt;.01 ). Similarly, animals receiving rt-PA at 1 mg/kg and a control (antidigoxin) MAb (n=3) showed 35.24.6% lysis. Ferrets treated with rt-PA at 2 mg/kg (n=4) showed a minimal increase in lysis over those treated at 1 mg/kg (45.06.5% vs 38.5t6.3%, P&lt;.OS). However, animals receiving rt-PA at 1 mg/kg together with the a2AP inhibitor (n=4) showed greater lysis (56.2t4.7%) than those receiving an equivalent dose of rt-PA alone (P&lt;.O1), with or without the control (antidigoxin) MAb (P&lt;.01 ), or those receiving twice the dose of rt-PA alone (P&lt;.OS).<br class="style-scope patent-text">     In addition to inhibiting plasmin on the thrombus surface, a2AP and other inhibitors inactivate plasmin in the blood (Collen, D., Eur. J. Biochem. <br class="style-scope patent-text">69:209-2I6 (l976); Moroi, M. and Aoki, N., J. Biol. Chem. 251:59S6-596S (l976); Mullertz, S. and Clemmensen, L, Biochem J. 159:545-553 (1976)). We measured fibrinogen levels in the blood to determine if inhibition of a2AP led to nonspecific plasminolysis of a circulating clotting factor. Figure 9 shows residual fibrinogen levels expressed as a function of their initial values in four treatment groups. In animals that received no rt-PA, fibrinogen levels varied moderately but did not diminish during the experiment. Ferrets receiving 1 mg/kg and 2 mg/kg of rt-PA<br class="style-scope patent-text">alone showed no significant change in fibrinogen level. Similarly, animals receiving the combination of rt-PA and the a2AP inhibitor showed no detectable change in circulating fibrinogen levels.<br class="style-scope patent-text">     H. Discussion Clinical and experimental studies suggest that pulmonary emboli and venous thrombi resist endogenous fibrinolysis and lysis induced by plasminogen activators (Goldhaber, S., Chest 107:455-51S (1995); Goldhaber, S.Z. et al., Lancet 2:886-889 (1986); The Urokinase Pulmonary Embolism Trial, Circulation 47:1-108 (l973); Goldhaber, S.Z. et al., Am. J. Med 88:235-240 (l990);<br class="style-scope patent-text">Goldhaber, S.Z. et al., Lancet 34I:507-511 (1993)). This resistance to lysis is due in part to specific molecular factors in the thrombus that act to oppose fibrinolysis.<br class="style-scope patent-text">During thrombus formation, a2AP is covalently crosslinked to fibrin by activated factor ~ (Sakata, Y. and Aoki, N., J. Clin. Invest. 69:536-542 ( 1982)). <br class="style-scope patent-text">Studies in vitro indicate that when a2AP in the clot is absent or inhibited by MAbs, clots undergo spontaneous lysis (Aoki, N. et al., Blood 62:1118-1122 (1983); Miles, L.A. et al., Blood 59:1246-12S 1 (1982); Reed, G.L. III et al., Trans. Assoc. <br class="style-scope patent-text">Am.<br class="style-scope patent-text">   Phys. 101:2S0-256 (1988); Reed, G.L. III et al., Proc. Natl. Acad. Sci. USA<br class="style-scope patent-text">87:1114-I 118 (1990)). Conversely, when levels of a2AP in clots are increased by supplementation in vitro, fibrinolysis is inhibited (Sakata, Y. and Aoki, N., J.<br class="style-scope patent-text">    Clin. Invest. 69:536-542 (l982)). In the present study we investigated the hypothesis that a2AP plays a major regulatory role in fibrinolysis and that it contributes to the thrombus resistance obtained in pulmonary embolism.<br class="style-scope patent-text">     We measured the effect of rt-PA, with and without a2AP inhibition, on the net lysis of pulmonary emboli in ferrets. Because heparin is the established therapy for humans with pulmonary embolism, we considered animals treated with heparin alone as the control group. The weight-adjusted bolus dose of heparin given to the ferrets was sufficient to maintain a high level of anticoagulation throughout the experiment. In animals treated with rt-PA, at a dose comparable to that used in humans (1 mg/kg), lysis of pulmonary emboli was enhanced significantly in comparison with lysis in animals treated with heparin alone.<br class="style-scope patent-text">Increasing the dose of rt-PA to 2 mg/kg, a dose higher than is safe in humans, led to a minimal increase in lysis. A similar plateau in the dose response for t-PA-induced lysis has been noted in experimental studies of pulmonary embolism in dogs (Werier, J. et al., Chest. I00:464-469 (1991)). However, specific inhibition of a2AP markedly potentiated the lysis of experimental pulmonary emboli by rt-PA ( I mg/kg), causing significantly more lysis than was seen in ferrets treated with the same dose of rt-PA: alone or with a control MAb, the iysis achieved with a2AP inhibition was also greater than that achieved in ferrets treated with high-dose rt-PA (2 mg/kg). At the same time, despite the higher total lysis obtained in animals treated with the a2AP inhibitor, there was no significant consumption of circulating fibrinogen. In these studies of experimental pulmonary embolism, a2AP played an important role in thrombus resistance to lysis induced by rt-PA. Further studies will be necessary to establish the relative quantitative roles of circulating and thrombus bound a2AP in this process. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Besides a2AP, other molecular factors may regulate the thrombus resistance of pulmonary emboli. A leading candidate is PAI-1, a serine protease inhibitor of t-PA and urinary-type plasminogen activator (u-PA or urokinase) (Stringer, H.A. and Pannekoek, H., J. Biol. Chem. 270:11205-11208 (1995);<br class="style-scope patent-text"> Carmeliet, P. et al., J. Clin. Invest. 92:2756-2760 (1993); Lang, LM. et al., Circulation 89:2715-2721 ( 1994); Marsh, J. J. et al. , Circulation 90:3 09 I -( 1994)). Unlike a2AP, PAI-1 is not specifically crosslinked to fibrin in the thrombus, although it has been shown to bind to fibrin in vitro (Stringer, H.A. and Pannekoek, H., J. Biol. Chem. 270:11205-11208 (1995)). By adding recombinant PAI-1 to developing thrombi, Marsh et al. (Marsh, J.J. et al., Circulation 90:3091-3097 (1994)) have shown that PAI-1-enriched clots can suppress the spontaneous lysis of pulmonary emboli in a canine model; however, the role of PAI-1 in the lysis of autologous thrombi was not investigated. Pathologic studies of pulmonary emboli extracted by thrombectomy have suggested that PAI-1 expression increases in the endothelial cells at the margins of fresh thrombi but is not detectable in the thrombi themselves (Lang, LM. et al., Circulation 89:2715-2721 (1994)). Since PAI-1-deficient mice (by gene deletion) are less likely than regular mice to develop venous thrombosis induced by endotoxin (Carmeliet, P.<br class="style-scope patent-text">et al., J. Clin. Invest. 9Z:2756-2760 ( 1993)), the expression of PAI-1 in endothelial cells at the margin of the developing thrombus may be functionally important. Nonetheless, the role of PAI-1 in thrombus resistance to pharmacologic plasminogen activators is less clear: in patients given t-PA, the inhibitory capacity ofPAI-1 is overwhelmed completely (Lucore, C.L. and Sobel, B.E., Circulation 77:6b0-669 ( 1988)), and thrombus resistance is also observed in patients given streptokinase, against which PAI-1 has no effect.<br class="style-scope patent-text">     Another potential cause of thrombus resistance in pulmonary embolism is activated factor XIII. Several studies in vitro suggest that this coagulation enzyme renders the fibrin in clots more resistant to degradation by plasmin by crosslinking fibrin chains together and by crosslinking a2AP to fibrin. <br class="style-scope patent-text">(Sakata, Y.<br class="style-scope patent-text">and Aoki, N., J. Clin. Invest. 69:536-542 (1982); Robbie, L.A. et al., Thromb. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Haemostas 70:30l-306 (l993); Francis, C.W. and Marder, V.J., J. Clin. Invest.<br class="style-scope patent-text">80: l45 9-l465 ( 1987); Jansen, J. W. C. M. et al. , Thromb. Haemostas. S <br class="style-scope patent-text">7:171- l 75 ( 1987); Reed, G.L. et al., Trans. Assoc. Am. Phys. I04:2 I -28 ( 1991 )) However, little is known about activated factor XIII and thrombus resistance in vivo. <br class="style-scope patent-text">This is probably due to the fact that a potent inhibitor of factor XIII function has only recently become available (Reed, G.L. and Lukacova, D., Thromb. Haemostas.<br class="style-scope patent-text">74:680-685 ( 1995)). One study has suggested that when factor XIII is partially inhibited, coronary thrombi lyse at accelerated rates in response to t-PA<br class="style-scope patent-text">(Shebuski, R.J. et al., Blood 75:1455-1459 (1990)). This observation argues that factor XIII, through its effects on fibrin-fibrin and a2AP-fibrin crosslinking, also contributes to thrombus resistance.<br class="style-scope patent-text">     Improving the lysis of thrombi in patients with pulmonary embolism and deep venous thrombosis remains a challenge. Unfortunately, increasing the dose of plasminogen activators is not a promising approach. High dose t-PA has been associated with an unacceptable increase in the risk of cerebral bleeding (Passamani, E. et al., J. Am. Coll. Cardiol. 10:51B-64B (1987)). In addition, in the present study and others (Werier, J. et al., Chest. l00:464-469 (199l)), high-dose t-PA (&gt;_2 mg/kg) produced only minimal increases in net lysis. The current FDA-approved doses of urokinase and streptokinase cause plasminogen "depletion"; thus, increasing the doses of these agents is also not likely to have an effect on net lysis (Onundarson, P.T. et al., J. Lab. Clin. Med. l20:120-128 (l992)). Several potent inhibitors of thrombin generation and activity are under development. Although these agents may further reduce the formation of new thrombi, they will not directly improve lysis of the large thrombi that typically exist in patients at the time they are diagnosed. These considerations suggest that fundamental insights into the molecular factors that oppose physiologic or pharnlacologic lysis in thrombi will be necessary to spark improved treatments for venous thromboembolism. The results of the present study indicate that a2AP is a major contributor to thrombus resistance in experimental pulmonary embolism, and they suggest that inhibiting a2AP might improve iysis in patients with thrombotic disease.<br class="style-scope patent-text">     Example 3 Cloning and Sequencing of Antibody cDNA<br class="style-scope patent-text">     A. Amino Terminnl Sequences of Antibodies Monoclonal antibodies (49C9, 70B 11 and 77A3) were expanded into ascites and purified by ion exchange chromatography on DEAE Affigel Blue or by protein A agarose as described in Lukacova, D. et al., Biochemistry 30:10164-10170 ( 1991 ). The purified MAbs ( 15 Itg) were subjected to SDS-PAGE on 10% minigels (BioRad, Hercules, CA). The protein samples were electroblotted to PVDF membranes (Millipore, Bedford, MA) using semi-dry technique (Kyhse-Anderson, J., J. Biochem. Biophys. Meth. l0:203-209 (l984)) at 4 ~ C for 2 hrs at 75 milliamps (Millipore electroblotter). The bands were stained with Ponceau Dye (Sigma, St. Louis) and excised. The amino terminal sequences of the light chain of the antibodies are shown in Figure 10 (SEQ m NOS: 1-3).<br class="style-scope patent-text">   B. Molecular Cloning of Antibody cDNA<br class="style-scope patent-text">     Cloned hybridoma cell lines 49C9, 70B 11 and 77A3 were grown in 150 mm tissue culture plates in 20% fetal bovine serum in Dulbecco's modified Eagle's medium with 4.5 g/1 of glucose and penicillin and streptomycin. The cells were harvested and centrifuged at 1200 rpm for 7 min. The cell pellet was resuspended in sterile phosphate buffered saline {pH 7.4) and re-centrifuged. Then 5 m1 of RNAzoI (Teltest, Friendswood, T~ was added and the pellet was homogenized for 2 min. Chloroform (500 pl) was added and the mixture was vortexed and left to incubate on ice for 15 min. The samples were centrifuged at 12, 000 rpm for min. The aqueous layer was mixed with 4.5 ml of isopropanol arid vortexed. The mixture was precipitated at -70 ~ C for 90 min. and recentrifizged at 12, 000 rpm for 15 min. The pellet was washed in 2 ml of 70% ethanol in DEPC-treated water.<br class="style-scope patent-text">After repeat centrifugation, the supernatant was removed and the pellet air-dried.<br class="style-scope patent-text">The pellet was dissolved in 200 pl of diethyl-pyrocarbonate (DEPC)-treated water and 20 Ill of 3 M NaCI and 800 pl of ethanol were added. The mRNA was precipitated overnight at -70 ~ C and the pellet resuspended in DEPC-water.<br class="style-scope patent-text">     The cDNA corresponding to the light and heavy chain sequences were isolated by primer guided reverse transcription followed by polymerase chain reaction as described (Gene Amp Thermostable rTth Reverse Transcriptase RNA<br class="style-scope patent-text">     PCR kit (Perkin-Elmer Cetus, San Francisco, CA). The light chain mRNA was primed for reverse transcription with a 3' primer {5' N6GAATTCACTGGATGG<br class="style-scope patent-text">     TGGGAAGATGGA 3' (SEQ ID N0:22)) corresponding to the constant region of the light chain ( Coloma, M. J., et al. , Biotechniques I1:152-154, 156 ( 1991 )) and the heavy chain was primed with a 3' primer (5' N6GAATTCA(TC) CTCCACACACAGG(AG)(AG)CCAGTGGATAGAC 3' (SEQ ID N0:23)) corresponding to the constant region of the heavy chain (Coloma, M.J., et al., Biotechniques 11:152-154, 156 (1991)). Because the light chain amino terminal sequences were known, a specific primer corresponding to the likely 5' sense sequence was used (5' ACTAGTCGACATGAGTGTGCTCACTCAGGTCCTGG<br class="style-scope patent-text">(GC)GTTG 3' (SEQ ID N0:24); Jones, S.T., and Bendig, M.M., BiolTechnology 9:88-89 (Erratum) (l991)) for cDNA amplification. For cloning of the heavy chain, mouse heavy chain variable primers I -12 were used as described (Jones, S.T., and Bendig, M.M., Bioll'echnolo~ 9:88-89 (Erratum) ( 1991 )). All heavy chains amplified best with primer 9; though lesser amplification was also seen with primers 12, 10 and 6. The PCR products were isolated by low melt agarose fractionation and ligated into a vector. The light chain PCR product was ligated into PCR II vector (Invitrogen, San Diego, CA) The heavy chain PCR product from primer 9 was ligated into PCR IL 1 vector (Invitrogen, San Diego, CA).<br class="style-scope patent-text">After transformation, the plasmid DNA was isolated and subjected to restriction digestion with EcoRl. Two clones from each heavy and light chain were expanded and the DNA harvested. Both strands of the cDNA clones were sequenced using T7 and M 13 primers with an ABI Prism automated sequencing apparatus. The cDNA sequences and deduced amino acid sequences are shown in Figures 11-16 (SEQ m NOS:4-15).<br class="style-scope patent-text">Example 4 Preparation and Characterization of Chimeric and Humanized Antibodies In designing the sequence for a chimeric or humanized antibody, there are many parameters to consider. In the constant regions, a whole antibody may be made, or an antibody fragment (Fab and Fab'2) can be made. The constant regions may be murine or human. It is an accepted practice to replace murine constant regions with human constant regions, thus forming a "chimeric" <br class="style-scope patent-text">antibody.<br class="style-scope patent-text"> Chimeric antibodies are less immunogenic than murine antibodies and are thus more acceptable in the clinic.<br class="style-scope patent-text">     The subclass of the antibody must also be considered. It is most common to express recombinant antibodies as IgGs, but within this class, one must choose amongst recombinant chimeric human IgGI, IgG2, IgG3, and IgG4. These subclasses have different biological properties. The present inventors took a conservative approach of using IgG2 because 1 ) the strong complement activating properties of IgGI and IgG3 were not needed for this antibody and 2) IgG2 may be more straightforward to manufacture than IgG4. Any of the other subclasses could be made with the same specificity following similar strategies.<br class="style-scope patent-text">   There are also parameters to consider in designing the variable region. The antibodies could be constructed to be chimeric or humanized. The chimeric antibody (murine V region, human constant region) is a more conservative approach, and virtually guarantees very similar antigen-binding activity to the murine antibody. With humanization, there is the risk of reducing the affinity WO 98l12329 PCT/US97/16122 and/or biological activity of the antibody, but it can be presumed that the antibody will be less immunogenic. The present inventors have produced chimeric antibody as well as three forms of the humanized antibody.<br class="style-scope patent-text">     Depending upon the strategy taken, humanization of any particular antibody can result in many different variable regions. At the simplest level, humanization consists of choosing a human variable region to serve as a template, and then deciding which residues should be "human" and which "murine". Thus, the choice of both the human template and which residues to maintain as human will affect the final sequence.<br class="style-scope patent-text">   In general, the strategy the present inventors have taken is to choose from among the human germline variable region genes for the templates. <br class="style-scope patent-text">Alternatively, one can choose from rearranged variable region genes, both those which have and have not undergone somatic mutation. The rationale for the first strategy is that somatic mutations can introduce immunogenic epitopes, while germline genes would have less potential for doing so. The selection was further limited to germline genes which are known to be rearranged and expressed as functional proteins in humans.<br class="style-scope patent-text">     The choice of which germline gene to use as template is governed by the overall sequence similarity between the murine sequence and the human sequence;<br class="style-scope patent-text">the structural similarities between the two sequences (Chothia and Lesk, J. <br class="style-scope patent-text">Mol.<br class="style-scope patent-text">Biol. l96:901 ( 1987)); the anticipated ability of the chosen heavy chain template to pair with the chosen light chain template; and the presence of the germline gene in the majority of humans. The choice of which residues should be murine is governed by which residues are thought to come in contact with antigen and which are necessary to maintain the positioning and orientation of those residues which might contact antigen.<br class="style-scope patent-text">     Variable regions were assembled from oligonucleotides and inserted into expression vectors containing the human gamma 2 constant region (for the VH<br class="style-scope patent-text">region) and human kappa constant region (for the VL region). Heavy and light chain vectors were verified by nucleotide sequence and ability to direct the synthesis of antigen binding immunoglobulin (Ig) in COS cells (transient expression). Selected heavy and light chain vectors were then cotransfected into CHO cells to produce stable cell lines expressing the chimeric and humanized antibodies. Antibody was purified and tested for activity by antigen binding ELISA, ability to block the inhibitory activity of a2-AP in a plasmin assay, and ability to facilitate lysis of human clots by urokinase.<br class="style-scope patent-text">     A. Construction of Chimeric and Humanized Antibody Vectors A functional light chain variable region is formed by the rearrangement and juxtaposition of a V gene segment and J gene segment. Therefore, it was necessary to find the best match for each of these segments and combine them to form a human template. A FASTA search (using the Wisconsin Package Interface) of amino acids 1-95 (Kabat numbering system; V gene proper) of murine 77A3 (m77A3) light chain against a database of human Vk germline genes showed that m77A3 is clearly most similar to the human VkI subgroup (69.2%<br class="style-scope patent-text">- 71.6% identity vs less than 60% identity to sequences outside this subgroup).<br class="style-scope patent-text">   From among the Vk I sequences, the sequence with GenBank accession # X59312 (also known as the 02/012 gene) was chosen as a likely candidate because of the match with structurally important positions and because of its prevalent expression in humans. The human template for the light chain was completed by the addition of the human Jk2 sequence. This J region was chosen because of its high degree of similarity with the murine J region of 77A3.<br class="style-scope patent-text">     A functional heavy chain variable region is formed by the rearrangement and juxtaposition of a V gene segment, a D gene segment, and a J gene segment.<br class="style-scope patent-text">Therefore, it was necessary to find the best match for each of these segments and combine them to form a human template. A FASTA search (using the Wisconsin Package Interface) of amino acids 1-94 (Kabat numbering system; V gene proper) of murine 77A3 heavy chain against a database of human VH germline genes showed that m77A3 is clearly most similar to the human VH7 family (77 ~lo identity) with the human VH1 family having the next best match (about 60 identity). The human VH7 family is mostly composed of pseudogenes; the only active gene (7-04. l, Accession # X62110) is polymorphic in the human population (i.e. not all people have it) and therefore, in some people, this V gene could be more immunogenic than others. As an alternative human template for the heavy chain, the V gene with accession number Z 12316 ( 1-18 gene) was chosen. This sequence is very similar to 7-04.1 except for the H2 loop and FR3 region. A<br class="style-scope patent-text">human template for the D region was not considered because this region lies entirely within the H3 loop, the sequence of which is generally pivotal for antigen binding and therefore likely to entirely follow the murine sequence in a humanized antibody. The human template for the heavy chain was completed by the addition of the human JHS sequence. This J region was chosen because of its high degree of similarity with the murine J region of 77A3.<br class="style-scope patent-text">  Following the selection of human templates for the heavy and light chain variable regions, it was necessary to determine which positions should follow the murine sequence vs which positions should follow the human sequence. The following criteria were used in selecting positions to follow the murine sequence:<br class="style-scope patent-text">a11 positions falling within the CDR loops; all positions known to influence the conformation and/or spatial position of CDR loops (so called structural determinants; Chothia and Lesk, J. Mol. Biol. l96:901 ( 1987), Lesk and Tramontano, in: Antibody Engineering, W.H. Freeman and Co., pp.7-3 8 ( 1992));<br class="style-scope patent-text">residues which were close enough to interact with residues in the CDR loops; <br class="style-scope patent-text">and residues at or proximal to the VH-VL domain interface. All other residues followed the human sequence. These items are discussed in greater detail below.<br class="style-scope patent-text">     Positions falling within the CDR loops are shown enclosed within the boxes with solid borders and structural determinants are marked with an * in the row below the position number in Figures 17-19.<br class="style-scope patent-text">     In order to determine which residues were close enough to interact with the CDR loops, it was necessary to generate an approximate molecular model of the Fv region of murine 77A3. The molecular model was built based on the combined variable light chain of an anti-lysozyme mAb (D 1.3) and the variable heavy chain of an anti-neuraminidase mAb ( 1 ncca) as structural template. CDR<br class="style-scope patent-text">loop sequences were assigned to canonical loop conformations and a possible conformation for CDR H3 was extracted form the Protein Data Bank. The modeling building protocol followed procedures described by Bajorath &amp; Novotny (Therapeutic Immunol. 2:95-105 (1995)). Likewise, residues at or proximal to the VH-VL domain interface were identified and the murine residues were used for the humanized antibody. in all, for h77A3-1 heavy chain, h77A3-2 heavy chain, and for the common light chain there were 7, 18, and 11 murine residues, respectively, used outside of the CDR loops.<br class="style-scope patent-text">     In order to prepare vectors encoding these chains, the amino acid sequence must be back translated into nucleotide sequence. For the most part, this was done simply by using the nucleotide sequence from the human template in cases where the amino acid residue is derived specifically from the human template; otherwise, the nucleotides from the murine sequence were used. At a few positions, silent substitutions were made in order to eliminate restriction sites.<br class="style-scope patent-text">     Finally, signal peptides must be added to the sequence. For both the chimeric and humanized light chains, signal peptides corresponding to that of the murine 77A3 light chain were used. For the chimeric and humanized heavy chains, the same signal peptide as for the light chains was used. <br class="style-scope patent-text">Alternatively, signal peptides corresponding to that of murine 77A3 VH or any other signal peptide can be used in the chimeric and humanized heavy chains.<br class="style-scope patent-text">     Two humanized antibodies were created: h77A3-1 and h77A3-2. A third version of the humanized heavy chain was created by including an oligonucleotide designed for h77A3-1 in the construction of h77A3-2. This resulted in a hybrid molecule that was identical to h77A3-2 except for amino acids Ser and Leu at positions 9 and 11 of the heavy chain. One chimeric antibody, c77A3, was generated.<br class="style-scope patent-text">     Amino acid and nucleotide sequences of h77A3-1 and h77A3-2 heavy and light chains are shown in Figures 17-19 (SEQ &gt;D NOS:16-21). The common light chain is shown in Figure I7 (mature protein is amino acid residues 1 to 107 of SEQ m N0:17). The heavy chain of h77A3-1 is shown in Figure I8 (mature protein is amino acid residues I to 119 of SEQ ID N0:19). The heavy chain of h77A3-2 is shown in Figure 19 (mature protein is amino acid residues 1 to 123 of SEQ ID N0:21 ).<br class="style-scope patent-text">     Expression vectors for chimeric and humanized 77A3 light and heavy chains were prepared in three stages: ( 1 ) construction of cassettes containing human light or heavy chain constant region genes (pD 16-hCka and pD20-hy2a, respectively); (2) preparation of a PCR product containing the light or heavy chain variable region; and (3 ) insertion of the variable region into the appropriate expression cassette.<br class="style-scope patent-text">   Plasmid pDl3 was constructed and derived from the pcDNA3 plasmid (Invitrogen) in two steps. The SV40 promoter/enhancer and neomycin resistance genes were removed from pcDNA3 by digestion with NaeI and isolation of the 3.82 kb fragment. These genes were replaced by the SV40 promoterJenhancer and dhfr gene from pSV2-dhfr. The DNA containing the pSV2-dhfr sequence was isolated as a 1.93 kb fragment after digestion with PvuII and BamHI. The 3.82 and 1.93 kb fragments were ligated together and used to transform MC1061 bacteria following fclling in the protruding ends of the 1.93 kb fragment from pSV2-dhfr. The correct product (designated pDl2) was confirmed by the release of an 890 by fragment following HindIII digestion.<br class="style-scope patent-text">   The polylinker was replaced with alternative restriction sites by digesting the resultant vector above with Asp718 and Bsp120I. The following oligonucleotides were annealed to the vector and cloned by ExoIII cloning (I~.<br class="style-scope patent-text">    Hsiao, Nucl. Acid. Res. 21:5528-5529 (1993)) to complete the plasmid pDl3:<br class="style-scope patent-text">5' TAGGGAGACCCAAGCTTGGTACCAATTTAAATTGATATCTCCTT AG<br class="style-scope patent-text">     GTCTCGAGTCTCTAGATAACCGGTCAATCGATTGGGATTCTT 3' (SEQ<br class="style-scope patent-text">     ID N0:25) and S' GACACTATAGAATAGGGCCCTTCCGCGGTTGGATCCAACACGT<br class="style-scope patent-text">     GAAGCTAGCAAGCGGCCGCAAGAATTCCAATCGATTGACCGGTTA3' (SEQ ID N0:26). The resulting plasmid was used to transform competent E. coli DHS a and the correct product was confirmed by sequencing the polylinker region.<br class="style-scope patent-text">     Plasmid pD 16 was derived from the pcDNA3 plasmid (Invitrogen) in a series of steps which: add a polylinker sequence upstream of the CMV promoter for linearization; delete the SV40 promoter/enhancer and neomycin resistance gene and replace them with the histone H3 transcription termination sequence, the SV40 promoter (enhancer deleted) and DHFR gene; and insert the gastrin transcription termination sequence upstream of the CMV promoter.<br class="style-scope patent-text">pcDNA3 (Invitrogen) was digested with BgIII and annealed to the following oligonucleotides:<br class="style-scope patent-text">5' primer: 5'-GATCTGCTAGCCCGGGTGACCTGAGGCGCGCCTTTG<br class="style-scope patent-text">     GCGCC-3' (SEQ U~ N0:27);and 3' primer: 3'-ACGATCGGGCCCACTGGACGCCGCGCGGAAACCGCGG<br class="style-scope patent-text">     CTAG-5' (SEQ ID N0:28).<br class="style-scope patent-text">The plasmid was then ligated. After ligation, the resulting plasmid (pcDNA3-LSI) was used to transform competent E coli DHSa and the correct construct was confirmed by release of a Z30 by fragment following restriction enzyme digestion with Nhel and NruI, Plasmid pcDNA3-LSI was then digested with NgoMI, PvuI and BsmI.<br class="style-scope patent-text">  Following digestion, a 2.0 kb NgoMI-PwI fragment was isolated. Plasmid pD 12 (described above) was digested with Pvul and SphI to remove the S V40 enhancer and a 3.6 kb fragment was isolated. The following oligonucleotides, encoding the histone H3 transcription termination sequence were annealed and then ligated with the 2.0 kb NgoMI-PvuI fragment and 3.6 kb PvuI-Sphl fragment:<br class="style-scope patent-text">5' primer: 5'-CCGGGCCTCTCA~AAAAAGGGAAAAAAAGCATG-3' (SEQ 117 N0:29); and 3' primer: 3'-CGGAGAGTTTTTTCCCTTTTTTTC-5' (SEQ 117 N0:30). <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98/12329 PCT/ZJS97i16122 -SS-The resulting plasmid pcTwD-LS 1 was confirmed by the production of 3.3, 0.95, 0.82 and 0.63 kb fragments after digestion with NheI plus NciI and the production of 4.2, 1.0, 0.26 and 0.23 kb fragments after digestion with SphI plus BstEII.<br class="style-scope patent-text">   Insertion of the gastrin transcription termination sequence to form plasmid pD 16 was accomplished by digesting pcTwD-LS 1 with BssHII and NarI and isolating the 5.7 kb fragment and ligating with the following annealed oligonucleotides:<br class="style-scope patent-text">5' primer: 5'-CGCGCCGGCTTCGAATAGCCAGAGTAACCTTTTTTTTTAA<br class="style-scope patent-text">     TTTTATTTTATTTTATTTTTGAGATGGAGTTTGG-3' (SEQ ID N0:3 l ); and 3' primer: 3'-GGCCGAAGCTTATCGGTCTCATTGGAAAAAAAAATTAAAAT<br class="style-scope patent-text">     AAAAT AA.AATAAAAACTCTACCTCAAACCGC-S' (SEQ ID N0:32).<br class="style-scope patent-text">After ligation, the product was used to transform competent E. coli MC 1061 and the correct construction was confirmed by the production of 4.8, 0.66 and 0.31 kb fragments after digestion with NgoMI plus Spel and the production  of 3.3, 1.0, 0.82 and 0.67kb fragments following digestion with NgoMI plus Ncol, Plasmid pDl7 was derived from pDl6 by the removal of the NheI site from the linearization polylinker. This was accomplished by digestion of pDl6 with BstII<br class="style-scope patent-text">and NheI and filling the protruding ends using Klenow polymerase. The reaction mixture was self ligated and used to transform competent E. coli DHSa.<br class="style-scope patent-text">pD 17 was digested with Asp718I and Bsp 120I to remove a polylinker which was replaced by the 113 by Asp718I/Bsp 120I polylinker from pD 13 . After ligation, the resulting intermediate plasmid pD20 had the NheI site required for inserting heavy chain V genes. pD20 was distinguished from pD 17 by linearization with NheI, and distinguished from pD 13 by linearization with BssH II which cuts only once within the linearization site polylinkers of pD 16, pD 17 and pD20. <br class="style-scope patent-text">Finally, DNA sequencing was used to confirm the polylinker in pD20.<br class="style-scope patent-text">     A 2.9 kb EcoRI fragment was isolated from pGk.l 1 (Walls et al.) Nucl.<br class="style-scope patent-text">    Acid. Res. 2l:2921-2929 (l993)) and this was Iigated into the plasmid pDl3 (described above) previously digested with EcoRI. This construct (pDl3-hCka) containing the human CK exon and flanking intron sequences was used to transform WO 98/12329 PCTlUS97/16122 E. coli DHSa and the correct product was confirmed by restriction digestion.<br class="style-scope patent-text">Digestion with EcoRI resulted in fragments of 5.7, 2.8 and 0.3 kb and digestion with SacI resulted in fragments of 7. l, 1.1 and 0.5 kb.<br class="style-scope patent-text">     Construction of the light chain expression cassette was completed by removing the CK fragment along with the flanking polylinker sequences from pD <br class="style-scope patent-text"> <br class="style-scope patent-text">and inserting it into pD 16. Plasmid pD 13-hCka was digested with Asp7I 8I and Bsp 120I to release the CK fragment and polylinker sequences, The same enzymes were used to linearize pDl6 and the Crc containing fragment was legated into pDl6 to form pD 16-hCka. Following transformation of DHS a E. coli and amplification, the correct construct was confirmed by the release of 2.9 kb fragment following digestion with Asp718I and Bsp 120I and linearization following digestion with a restriction enzyme present in pD 16, but not pD 13 . The nucleotide sequence was also confirmed by sequencing various regions of the construct.<br class="style-scope patent-text">     A genomic DNA fragment encoding the human y2 gene was preassembled in pIC, and then transferred into pD20 as follows. Phage clone Phage SA <br class="style-scope patent-text">(Ellison and Hood, Proc. Natl. Acad Sci) 79: 1984-1988 ( 1982)), containing the human y2 gene was digested with HindIII and cloned into the HindIII site of pUC 18 to form the vector py2. In pY2, the 5' end of the y2 gene is adjacent to the polylinker region.<br class="style-scope patent-text">pG was derived from pSV2-gpt by digestion with Hind III and Bgl II, Klenow fill in, and relegation. This served to remove a 121 by Hind III-Bgl II<br class="style-scope patent-text">fragment. py2 was then digested with BamH I and inserted into the BamH I site of pG to form pGy2.2. pGy2.2 contains a BgIII site 3' of the coding region that would interfere with later cloning steps. To remove this restriction site, pGy2.2 was first digested with Bgl II , the sticky ends filled in by Klenow DNA <br class="style-scope patent-text">polymerase I, then the plasmid relegated, The resulting intermediate plasmid, pG~y2.3 was screened for lack of digestibility with Bgl II.<br class="style-scope patent-text">   For purposes of later cloning in variable region genes, it was important to provide a restriction site in the y2 containing cassette. This is conveniently done by mutating the nucleotides encoding the first two amino acids of the CHl exon to encode an Nhe I site (Coloma M.J. et al, J. Immunological Methods l52:89-104(1992)). Previously, an Nhe I to Bst E II fragment from the human y4 gene was cloned. In this region, human y2 and human y4 genes encode identical amino acids. Thus, the y4 containing vector (pIChy4.1 ) could serve as a source for the 5' end of the y2 gene. This vector was obtained as follows: The 8.6 kb BamH<br class="style-scope patent-text">I fragment from Phage SD (Ellison, J. et al DNA l :11-18 ( 1981 )), containing the human 'y4 gene, was subcloned into pUC, resulting in the plasmid pUChy4.<br class="style-scope patent-text">pUChy4 served as the template for a PCR reaction involving the following primers:<br class="style-scope patent-text">sense primer: 5'-ATCGAT .~,TAGCACCAAGGGCCCA-3' (SEQ ID N0:33); and antisense primer: S'-CTCGAGG~TCACCACGCTGCTGA-3' (SEQ m N0:34).<br class="style-scope patent-text">    The sense primer contained a Clal site for subcloning the PCR product into pIC20R (Marsh J.L., et al, Gene 32: 481-48S (l984)) adjacent to a synthetic Nhel site (underlined). Note that the bases for the Nhe 1 site can encode the first two amino acids (Alanine and Serine) for the human y 1, y2, y3 or y4 CH1 exon. The antisense primer has an Xho I site for subcloning into pIC20R, next to a BstE <br class="style-scope patent-text">II site (underlined) which is in the CH1 exon of the human 'y4 and 'y2 gene. The PCR<br class="style-scope patent-text">product formed was restricted with Cla I + Xho I then ligated into pIC20R <br class="style-scope patent-text">which had been digested by the same enzymes, to generate the intermediate pIChy4.1.<br class="style-scope patent-text">pGy2.3 was digested with BamH I and HinD III and a 6.1 Kb fragment including the human y2 gene locus was isolated from a 1.4% agarose gel for purification by the Qiaex~ gel extraction kit (Qiagen, Chatsworth, CA}. The 2.9 Kb pIChy4.1 plasmid was treated in a similar manner, and the two fragments were ligated together to form the intermediate vector pICh~y2.1. To screen, an EcoR <br class="style-scope patent-text">I<br class="style-scope patent-text">digest yielded appropriate fragment sizes of 6.3 Kb and 2.6 Kb.<br class="style-scope patent-text">pIChy2. l contained a duplication of the 5' portion of the human y2/y4 CH 1 exon. In order to remove the duplicated region, it was digested with BstE II <br class="style-scope patent-text">giving fragment sizes of 4.0 Kb, 1.8 Kb, 1.6 Kb, 1.1 Kb, and 0.4 Kb. The 4.0 Kb fragment was isolated from a 1.4% agarose gel, while the 1.6 Kb fragment was separated and isolated away from the 1.8 Kb fragment in 4% NuSieve~ GTG (FMC Bioproducts, Rockland, ME) agarose. Both fragments were purified by Qiagen gel extraction prior to ligating them together to prepare pIChy2.2. In order to confirm the proper orientation of the two fragments the following primers were used to determine that the 3' portion of the human y4 CHl exon's BstE II sticky end had joined with the 5' end of the human y2 CH1 exon (thus forming a contiguous human y2 locus in pIC20R):<br class="style-scope patent-text">sense primer: 5'-AACAGCTATGACCATGATTAC-3' (SEQ 117 N0:35); and antisense primer: 5'-CACCCAGCCTGTGCCTGCCTG-3' (SEQ ID N0:36).<br class="style-scope patent-text">The sense primer is homologous to sequence 5' of the pIC20R EcoR I site that is adjacent to the Cla I site. The antisense primer was chosen to be 500 by downstream of the sense strand primer, and is homologous to sequence within the human y2 CH1 to CHZ intron. Thus, visualization of a 500 by PCR product in a 1.4% agarose gel confirmed that the hybrid human y4- y2 CH1 exon formed and was oriented in a contiguous manner to the remainder of the locus. pIChy2.2 was digested with EcoR I to give the expected 2.6 Kb and 1.9 Kb fragments. The entire human y2 CHl exon was confirmed by DNA sequencing.<br class="style-scope patent-text">     The 1.8 Kb Nhe I + HinD III fragment containing the human y2 gene locus was removed from pIChy2.2 for ligation into plasmid pD20 opened by Nhe I +<br class="style-scope patent-text">     HinD III. The resulting vector is the expression cassette pD20-hy2a.<br class="style-scope patent-text">     The variable region (V) genes for both chimeric and humanized antibodies were synthesized by a modification of the non template specific PCR protocol (Prodromou C., and Pearl L. H., Protein Eng. S: 827 -829 (1992)). The PCR<br class="style-scope patent-text">products included DNA encoding both the signal peptide and variable region proper as well as flanking sequences to facilitate insertion into the vector as well as correct splicing (light chain only).<br class="style-scope patent-text">     The following primers were used:<br class="style-scope patent-text">LH1, sense chimeric 77A3 VH outer primer (30mer), 5'-CGATTGGAATTCTTG<br class="style-scope patent-text">     CGGCCGCTTGCTAGC-3' (SEQ ID N0:37); <br class="style-scope patent-text"> <br class="style-scope patent-text"> LH2, sense chimeric 77A3 VH primer 1 (80 mer), 5'-CTTGCGGCCGCTTGCTA<br class="style-scope patent-text">     GCATGGATTGGGTGTGGAACTTGCTATTCCTGATGGCAGCTGCCCAA<br class="style-scope patent-text">     AGTATCCAAGCACAGA-3' (SEQ )17 N0:38);<br class="style-scope patent-text">     LH3, anti-sense chimeric 77A3 VH primer 2 (80 mer}, 5'-CTTGACTGTTTC<br class="style-scope patent-text">     TCCAGGCTTCTTCAGCTCAGGTCCAGACTGCACCAACTGGATCTGTGC<br class="style-scope patent-text">    TTGGATACTTTGGGCAGCTG-3' (SEQ m N0:39);<br class="style-scope patent-text">     LH4, sense chimeric 77A3 VH primer 3 (80 mer), 5'-CTGAAGAAGCCT<br class="style-scope patent-text">     GGAGAAACAGTCAAGATCTCCTGCAAGGCTTCTGGGTATACCTTCAC<br class="style-scope patent-text">     AAACTATGGAATGAACTGGGT-3' (SEQ il? N0:40);<br class="style-scope patent-text">     LHS, anti-sense chimeric 77A3 VH primer 4 (80 mer), 5'-TCTTGGTGTTTAT<br class="style-scope patent-text">     CCAGCCCATCCACTTTAAACCCTTTCCTGGAGCCTGCTTCACCCAGTT<br class="style-scope patent-text">     CATTCCATAGTTTGTGAAG-3' (SEQ ID N0:41);<br class="style-scope patent-text">     LH6, sense chimeric 77A3 VH primer 5 (80 mer), 5'-AGTGGATGGGCT<br class="style-scope patent-text">     GGATAAACACCAAGAGTGGAGAGCCAACATATGCTGAAGAGTTCAA<br class="style-scope patent-text">     GGGACGGTTTGCCTTCTCTTTG-3' (SEQ B7 N0:42);<br class="style-scope patent-text">     LH7, anti-sense chimeric 7?A3 VH primer 6 (80 mer), 5'-TCCTCATTTTTGA<br class="style-scope patent-text">     GGTTCTTGATCTGCAAATTGGCAGTGCTGGCAGAGGTTTCCAAAGAG<br class="style-scope patent-text">     AAGGCAAACCGTCCCTTGAA-3' (SEQ &gt;D N0:43);<br class="style-scope patent-text">     LHB, sense chimeric 77A3 VH primer 7 (80 mer), 5'-GCAGATCAAGAACC<br class="style-scope patent-text">     TCAAAAATGAGGACACGGCTACATATTTCTGTGCAAGATGGGTACCT<br class="style-scope patent-text">     GGGACCTATGCCATGGACT-3' (SEQ n7 N0:44);<br class="style-scope patent-text">     LH9, anti-sense chimeric 77A3 VH primer 8 (80 mer}, 5'-TGGGCCCTTGGTGC<br class="style-scope patent-text">     TAGCTGAGGAGACGGTGACTGAGGTTCCTTGACCCCAGTAGTCCATG<br class="style-scope patent-text">     GCATAGGTCCCAGGTACCC-3' (SEQ ff~ N0:45);<br class="style-scope patent-text">     LH10, anti-sense murine 77A3 VH outer primer (29 mer), 5'-GGGAAGAGGGATG GGCCCTTGGTGCTAGC-3' (SEQ ID N0:46);<br class="style-scope patent-text">     LH11, sense chimeric 77A3 VL outer primer (30mer), 5'-ATTTAAATTGAT<br class="style-scope patent-text">     ATCTCCTTAGGTCTCGAG-3' (SEQ ID N0:47}; <br class="style-scope patent-text"> <br class="style-scope patent-text"> LH12, sense chimeric 77A3 VL primer 1 (79 mer), 5'-ATTTAAATTGATATCTCC<br class="style-scope patent-text">     TTAGGTCTCGAGATGAGTGTGCTCACTCAGGTCCTGGCGTTGCTGCT<br class="style-scope patent-text">     GCTGTGGCTTACAG-3' (SEQ m N0:48);<br class="style-scope patent-text">     LH13, anti-sense chimeric 77A3 VL primer 2 (78 mer), 5'-AGATGCAGATAGG<br class="style-scope patent-text">     GAGGCTGGAGACTGAGTCATCTGGATGTCACATCTGGCACCTGTAAG<br class="style-scope patent-text">     CCACAGCAGCAGCAACGC-3' (SEQ ID N0:49);<br class="style-scope patent-text">     LH14, sense chimeric 77A3 VL primer 3 (78 mer), 5'-GTCTCCAGCCTCCCTA<br class="style-scope patent-text">     TCTGCATCTGTGGGAGAAACTGTCACCATCACATGTCGAGCAAGTGG<br class="style-scope patent-text">     GAATATTCACAATTA-3' (SEQ m NO:50);<br class="style-scope patent-text">     LH15, anti-sense chimeric 77A3 VL primer 4 {78 mer), 5'-TATAGACCAG<br class="style-scope patent-text">     GAGCTGAGGAGATTTTCCCTGTTTCTGCTGATACCATGCTAAATAATT<br class="style-scope patent-text">     GTGAATATTCCCACTTGCTC-3' (SEQ ID NO:51);<br class="style-scope patent-text">     LH16, sense chimeric 77A3 VL primer 5 (78 mer), 5-AAATCTCCTCAGCT<br class="style-scope patent-text">     CCTGGTCTATAATGCAAAAACCTTAGCAGATGGTGTGCCATCAAGGT<br class="style-scope patent-text">     TCAGTGGCAGTGGATCA-3' (SEQ m N0:52);<br class="style-scope patent-text">     LH 17, anti-sense chimeric 77A3 VL primer 6 (78 mer); 5'-CTCCCAAAATCT<br class="style-scope patent-text">     TCAGGCTGCAGGCTGT~'GATCCTGAGAGAAAATTGTGTTCCTGATCC<br class="style-scope patent-text">     ACTGCCACTGAACCTTGAT-3' (SEQ B7 N0:53);<br class="style-scope patent-text">     LH18, sense chimeric 77A3 VL primer 7 (78 mer), 5'-GCCTGCAGCCTGAAGATTTTGGGAGTCATTACTGTCAACATTTTTG<br class="style-scope patent-text">   GACCACTCCGTGGACGTTCGGTGGAGGCACCA-3' (5EQ ID N0:54);<br class="style-scope patent-text">     LH19, anti-sense chimeric 77A3 VL primer 8 (81 mer), 5'-TTCCAATCGATTGA<br class="style-scope patent-text">     CCGGTTATCTAGAGACTCGAGACTTACGTTTGATTTCCAGCTTGGTGC<br class="style-scope patent-text">     CTCCACCGAACGTCCACGG-3' (SEQ m NO:55);<br class="style-scope patent-text">     LH20, anti-sense chimeric 77A3 VL outer primer (30mer), 5'-TCGATTGA<br class="style-scope patent-text">     CCGGTTATCTAGAGACTCGAGA-3' (SEQ ID N0:56);<br class="style-scope patent-text">     LH21, anti-sense humanized 77A3 VL primer 2 (78 mer), 5'-AGATGCAGATA<br class="style-scope patent-text">     GGGAGGATGGAGACTGAGTCATCTGGATGTCACATCTGGCACCTGTA<br class="style-scope patent-text">AGCCACAGCAGCAGCAACGC-3' (SEQ m N0:69) WO 98l12329 PCTiUS97i16122 LH22, sense humanized 77A3 VL primer 3 (78 mer), S'-GTCTCCATCCTCC<br class="style-scope patent-text">     CTATCTGCATCTGTGGGAGACAGAGTCACCATCACATGTCGAGCAAG<br class="style-scope patent-text"> TGGGAATATTCACAATTA -3' (SEQ )D N0:70) LH23, sense humanized 77A3 VL primer 5 (78 mer), 5'-AAATCTCCTCAA<br class="style-scope patent-text">     CTCCTGGTCTATAATGCAAAAACCTTAGCAAGTGGTGTGCCATCAAG<br class="style-scope patent-text">     GTTCAGTGGCAGTGGATCA -3' (SEQ ID N0:71}<br class="style-scope patent-text">     LH24, anit-sense humanized 77A3 VL primer 6 (78 mer), 5'-CTCCCAAAATC<br class="style-scope patent-text">     TTCAGGCTGCAGGCTGCTGATGGTGAGAGTAAAATCTGTTCCTGATC<br class="style-scope patent-text">     CACTGCCACTGAACCTTGAT -3' (SEQ &gt;17 N0:72) LH25, sense humanized 77A3 WH -I primer I (80 mer), S'-CTTGCGGCCGCTTG<br class="style-scope patent-text">     CTAGCATGAGTGTGCTCACTCAGGTCCTGGCGTTGCTGCTGCTGTGG<br class="style-scope patent-text">     CTTACAGGTGCCAGATGTC -3' (SEQ m N0:57);<br class="style-scope patent-text">     LH26, anti-sense humanized 77A3 VH -1 primer 2 (80 mer); 5'-GACTGAGGCT<br class="style-scope patent-text">     CCAGGCTTCTTCAGCTCAGATCCAGACTGCACCAACTGGATCTGACA<br class="style-scope patent-text">     IS TCTGGCACCTGTAAGCCACAGCA -3' (SEQ &gt;D NO: 58);<br class="style-scope patent-text">     LH27, sense humanized 77A3 VH -I primer 3 (80 mer), 5'-GAGCTGAAGAAGC<br class="style-scope patent-text">     CTGGAGCCTCAGTCAAGATCTCCTGCAAGGCTTCTGGGTATACCTTCA<br class="style-scope patent-text">     CAAACTATGGAATGAACTG -3' (SEQ m N0:59);<br class="style-scope patent-text">     LH28, anti-sense humanized 7?A3 VH -1 primer 4 (80 mer) 5'-TGGTGTTTATC<br class="style-scope patent-text">     CAGCCCATCCACTCTAAACCTTGTCCTGGAGCCTGTCGCACCCAGTTC<br class="style-scope patent-text">ATTCCATAGTTTGTGAAGGTA -3' (SEQ )D N0:60};<br class="style-scope patent-text">     LH29, sense humanized 77A3 VH -I primer 5 (80 mer), 5'-TAGAGTGGATGGG<br class="style-scope patent-text">     CTGGATAAACACCAAGAGTGGAGAGCCAACATATGCTGAAGAGTTCA<br class="style-scope patent-text">     AGGGACGGTTTGTCTTCTCT -3' (SEQ ID N0:61);<br class="style-scope patent-text">     LH30, anti-sense humanized 77A3 VH -1 primer 6 (80 mer), 5'-TCAGCTTTGAGG<br class="style-scope patent-text">     CTGCTGATCTGCAAATAGGCAGTGCTGACAGAGGTGTCCAAAGAGAA<br class="style-scope patent-text">     GACA AACCGTCCCTTGAACTC -3' (SEQ B7 N0:62);<br class="style-scope patent-text">     LH31, sense humanized 77A3 VH -1 primer 7 (80 mer), 5'-TTTGCAGATCAG<br class="style-scope patent-text">     CAGCCTCAAAGCTGAGGACACGGCTGTGTATTTCTGTGCAAGATGGG<br class="style-scope patent-text">     TACCTGGGACCTATGCCATGG -3' (SEQ m N0:63); <br class="style-scope patent-text"> <br class="style-scope patent-text"> LH32, anti-sense humanized 77A3 VH -1 primer 8 (80 mer), 5'-GCCCTTGGTG<br class="style-scope patent-text"> CTAGCTGAGGAGACGGTGACCGTGGTTCCTTGACCCCAGTAGTCCAT<br class="style-scope patent-text">     GGCATAGGTCCCAGGTACCCATC -3' (SEQ &gt;D N0:64);<br class="style-scope patent-text">     LH33, anti-sense humanized 77A3 VH -2 primer 2 (80 mer), 5'-TGCTGTGGCT<br class="style-scope patent-text">     TACAGGTGCCAGATGTCAGATCCAGTTGGTGCAGTCTGGAGCTGAGG<br class="style-scope patent-text">     TGAAGAAGCCTGGAGCCTCAGTC -3' (SEQ &gt;D N0:65);<br class="style-scope patent-text">     LH34, sense humanized 77A3 VH -2 primer 5 (80 mer), S'-TAGAGTGGATGGGC<br class="style-scope patent-text">     TGGATAAACACCAAGAGTGGAGAGCCAACATATGCTGAAGAGTTCAA<br class="style-scope patent-text">     GGGACGGTTTACCTTCACC -3' (SEQ m N0:66);<br class="style-scope patent-text">     LH35, anti-sense humanized 77A3 VH -2 primer 6 (80 mer), 5'-TCAGATCTGAG<br class="style-scope patent-text">     GCTCCTGATCTCCAAATAGGCAGTGCTCGTAGAGGTGTCCAAGGTGA<br class="style-scope patent-text">     AGGTAAACCGTCCCTTGAACTC -3' (SEQ m N0:67); and LH36, sense humanized 77A3 VH -2 primer 7 (80 mer, 5'-TTTGGAGATC<br class="style-scope patent-text">     AGGAGCCTCAGATCTGACGACACGGCTGTGTATTTCTGTGCAAGATG<br class="style-scope patent-text">     GGTACCTGGGACCTATGCCATGG -3' (SEQ B7 N0:68).<br class="style-scope patent-text">     Table 3 summarizes how the above primers were used in the non-template PCR protocol. <br class="style-scope patent-text"> <br class="style-scope patent-text"> slaurud apiloa~anuo~rlo g aqs ~(gA) aauanbas aua~ A arlT .ro (IA) apiidad I~u~rs aqT~o Iu S9-gb sd~hano pua '~ iraql alnlnn 'aauanbas lo~oan aqT~o Tu p~- SI <br class="style-scope patent-text">uI~<br class="style-scope patent-text">d~j.rano oI pau~rsap sr pua 'S .uaql '(~ alq~.L) 8A p~ IA s.ramr.id aplloalanuo~~o .rod ~~uT a~o~ yu LZ-bZ ~q .raulo ~a~a d~hano slau~ud ~~d asaqs ~q~ua~ m Iu I g-gL<br class="style-scope patent-text">3o sapiToalanuo~rlo pu~.c~s asuascTu~ ~mdd~Ltano tr q~cnn aT~uraTl~ <br class="style-scope patent-text">sap~Toa~anuo~rlo OZ<br class="style-scope patent-text">pu~ys asuas .rno3 '(~ alq~,I, ur 8A-iA) paztsaqTu~is aar; aua~ A uc~eqa ~Cnr,au .ro ~q~rl ayaq~u~s ~ ~uasaida.r qanlnn saptloa~anuo~clo Tuaa~fp~ g '~~aug (9S~OI~I (9S~OI~I(9b~0I~I  (9b~OH   (9b~Ol~I (asuaszlu~) QI       QI      QI        QI       QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> Z?~S)    b~S)    b~S) OiH'Ib3S) 0IH'Ib~S) OIH'Iia~ud.ta~no OZH'I    OZH'I                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> (SS~OI~I (SS~OI~I(b9~ON    (b9~0I~I (Sb~OI~I (asuas~Iu~)SI<br class="style-scope patent-text">     QI       QI      QI        QI       QI         <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) 6IH'Ib3S)    b3S) ZH'I b3S) ZH'Ib~S) 6H'ISA        <br class="style-scope patent-text">6IH'I                                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> (bS~OI~I (bS~OI~I(89~OI~I  (9~OIvI  (bb~OIvI           <br class="style-scope patent-text">     QI       QI      QI        QI       QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) 8IH'Ib~S)    b~S) 9H'I b~S) IH'Ib~S) 8H'I(asuas) 8IH~         LA         <br class="style-scope patent-text"> <br class="style-scope patent-text"> (ZL~OI~I (S~OI~I (L9~OI~I  (Z9~OI~I (b~OI~I  (asuasyu~) QI       QI      QI        QI       QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) bZH'Ib~S)    b~S) SH'I b~S) 0H'Ib~S) LHZ 9A        <br class="style-scope patent-text">     LIH'I          <br class="style-scope patent-text"> <br class="style-scope patent-text"> (iL~OI~I (ZS~OI~I(99~OI~I  (I9~OI~I (Zt~~ON.           <br class="style-scope patent-text">     QI  QI      QI        QI       QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) ZH'Ib~S)    b~S) bH'~ b~S) 6ZH'Ib~S) 9H'I(asuas)   OI<br class="style-scope patent-text">9IH'I                               SA         <br class="style-scope patent-text"> <br class="style-scope patent-text"> (I S~OI~I(I S~OIvI(09~OI~I  (09~OI~I (I b~OI~I(asuasiTu~e) QI       QI      QI        QI       QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) SLH'Ib~S)    b3S) 8ZH'Ib3S) 8ZH'Ib~S) SHZ bA        <br class="style-scope patent-text">     SIH'I                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> (OL~OI~I (OS~OI~I(65~01'~I (6S~OI~I (Ob~OI~I           <br class="style-scope patent-text">aI       QI      QI        QI     QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) ZZH'Ib~S)    b~S) LZH'Ib3S) LZH'Ib~S) bH'I(asuas) bIH'I                               A          <br class="style-scope patent-text"> <br class="style-scope patent-text"> (69_OI~I (6b~Ol~I(S9~OI~I (BS~OI~I (6~OI~I  (asuas~Iu~) QI       QI      QI        QI       QI            <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) IZH'Ib~S)    b~S) H'I  b~S) 9ZH'Ib~S) H'I ZA        S<br class="style-scope patent-text">     IH'I                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> (8b~0I~I (8b~0I~I(LS~OI~I  (LS~OI~I (8~OI~I            <br class="style-scope patent-text">     QI       QI      QI        QI       QI    <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) ZIH'~b~S)    b~S) SZH'Ib~S) SZH'Ib~S) ZH'I(asuas) ZIH'I                         IA         <br class="style-scope patent-text"> <br class="style-scope patent-text"> (Lb~OI~I (Lb~OI~I(L~OrI    (L~OI~I  (L~OI~I  (asuas) QI       QI                         QI                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> b~S) i   b~S)    QI b3S)   QI b~S)  b~S) IH'I-ray!-rd iH'I     t IH'I  IH'I      tH'I              .raTno pazm~utntl~uauya  Z-pazru~utn~I-paztu~wnuauau~nla sur~qa           sureqmCn~aH                            <br class="style-scope patent-text">     Iq~y gad a~gl         dwa~-uou ui saamaad ~o asn ' alq~,L                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> -~9-ZZI9i/G6Sfl/.l.Jd 6Z~ZIl8b OM<br class="style-scope patent-text">6l-~0-666l ib~99ZZ0 ~a WO 98/12329 PCTlU597/16122 are all included in the same first round PCR. Reaction conditions for this 1 st round PCR were 0.125 picomoles of each primer, 10 ~l of lOX Pfu buffer (Stratagene Inc., San Diego, CA), 10 nanomoles dNTP's (Boehringer Mannheim, Indianapolis, IN), 10% dimethylsulfoxide (DMSO), and 2.5 units cloned Pfu DNA polymerase I (Stratagene Inc., San Diego, CA) in a l00 ~cl reaction volume. Reactants were first denatured at 95~C for S min, annealed at 45 ~C for 5 min, and extended at 72 ~C for 1 min, followed by 25 cycles of denaturation at 94 ~C for 30 sec, annealing at 55 ~C<br class="style-scope patent-text">for 30 sec, and extension at 72 ~C for 30 sec. The 25 cycles were followed by a final extension at 72 ~C for 7 min in a Perkin-Elmer DNA Thermal Cycler (Norwalk, CT).<br class="style-scope patent-text">     The amplified PCR product was electrophoresed through a 1.4% agarose gel and the smear ofDNA running between approximately 350 by - 500 by was cut out prior to purification by the QiaexTN' II gel extraction kit (Qiagen, Chatsworth, CA). This purified non template specific PCR product served as the template for a IS 2nd round PCR. To complete the 2nd round PCR, two additional outer primers are utilized. These outer primers are homologous to 29 - 30 nt of the vector sequence that is either 5' (sense primer) or 3' (antisense primer) of the linearized cloning site within the mammalian expression cassette vector. This allowed for the amplified PCR product to be subcloned into the vector by bacterial homologous recombination (Jones, D.H. and Howard, B. H., BioTechniques I D: 62-66 (l991)).<br class="style-scope patent-text">Thus, the reaction conditions for the 2nd round PCR were 0.125 picomoles each of outer sense and antisense primers, 10 ~cl of 10X Pfu buffer, 10 nanomoles dNTP's, 10% DMSO, 2.5 units Pfu DNA polymerase I, and approximately 100 ng of 1 st round PCR template DNA. The reactants underwent the same thermocycle program described above. Subsequently, the amplicand from this reaction was removed from a 1.4% agarose gel and purified with the Qiagen~ II gel extraction kit.<br class="style-scope patent-text">200ng -1000ng of PCR product was mixed with an equal weight of linearized vector, and this mixture was used to transform 200 mI of competent E.<br class="style-scope patent-text">coli DHSa cells (GIBCO BRL/ Life Technologies, Gaithersburg, MD).<br class="style-scope patent-text">Transformed cells were selected by 100 ~eg/ml ampicillin in LB agarose. <br class="style-scope patent-text">Typically, pD 16-hCka digested with Xho I was used for subcloning light chain V genes.<br class="style-scope patent-text">pD20-hg2a digested with Nhe I served as the vehicle for heavy chain V gene constructs.<br class="style-scope patent-text">    In order to confirm that the V gene of interest had been inserted into the expression vector, two screens were performed. The primary screen was by PCR, while the secondary screen was by restriction digest. Each individual colony of bacteria was picked into 5 ml of T broth (GIBCO BRL/ Life Technologies, Gaithersburg, MD) containing 100 ~.g/ml ampicillin and grown 8 - 16 hr at 37 ~C<br class="style-scope patent-text">with shaking. The conditions for the PCR screen were 0.125 picomoles of both outer primers (Table 3), 2 ml 10X Mg+2 buffer (Boehringer Mannheim, Indianapolis, IN), 10 nanomoles dNTP's (Boehringer Mannheim, Indianapolis, IN), 1 unit Taq DNA polymerise I (Boehringer Mannheim, Indianapolis, IN), and 1 ,ul of the liquid culture growth (which served as the source of DNA template since the cells lysed at high temperature) in a 20 ,ul volume. Reactants first underwent denaturation at 94 ~C for 5 min, followed by 25 cycles of denaturation at 94 ~C for 25 sec, annealing at 45 ~C for 25 sec, and extension at 72 ~C for 12 sec. The cycles were followed by a final extension at 72 ~C for 7 min. Positives were determined by size comparison relative to a DNA standard marker after electrophoresis through a 1.4% agarose gel.<br class="style-scope patent-text">     For the secondary screen, midi DNA preparations (Qiagen, Chatsworth, CA) were made from bacterial pellets and a portion was digested with either Xho I (VL genes) or Nhe I (VH genes). Again, after electrophoresis through a 1.4%<br class="style-scope patent-text">agarose gel, size comparison of the fragment released due to enzyme digestion served to identify potentially positive clones.<br class="style-scope patent-text">     The above procedures were used to confirm the presence of a potentially correct insert. However, they were not specific enough to detect small errors in the sequence (insertions, deletions and substitutions). To determine which clones contained DNA encoding complete Ig genes, each potentially positive heavy chain clone was cotransfected into COS cells with each potentially positive light chain clone. Culture supernatants were screened by ELISA for the presence of human IgG, and then for the presence of IgG binding to a2-antiplasmin (see below).<br class="style-scope patent-text">     DNA for COS transfections was derived from midi DNA preparations described above. COS tranfections were performed in 60 mm dishes. Complete details of the DEAF - dextran technique employed have been described (Linsley P. S. et al, J. Exp. Med. I73: 721-73 0 ( 1991 )). Typically, 1. 5 ~cg - 6 ,ug of whole antibody is derived from small scale COS transfections As a final confirmation, the V region inserts from the above clones were sequenced by the dideoxy nucleotide procedure.<br class="style-scope patent-text">     B. Production of Humanized and Chimeric Antibodies Once heavy and light chain vectors encoding each of the desired antibodies were qualified, sufficient quantities of chimeric and humanized antibody for testing in functional assays were needed. This was first done as a scale-up of the COS<br class="style-scope patent-text">transfections using the selected vectors. Finally, stable cell lines were prepared by high copy number electroporation. The electroporation protocol of Barsoum (Barsoum, DNA and Cell Biology 9:293-300 (1990)) was followed with the exception that 100 ug each of the heavy and light chain vector were used (following restriction with BssHII) and the electroporation was performed in PFCHO media (PX-CELL PFCHO media, 3RH Biosciences, Lenexa, Kansas).<br class="style-scope patent-text">    Transfected cells were selected in media containing either 20 nM or 100 nM<br class="style-scope patent-text">methotrexate (MTX). Culture supernatants were assayed for the presence of whole antibody using the non-specific IgG ELISA. Cells from master wells containing the most antibody in the supernatant were expanded into larger volumes. In some cases, the methotrexate concentration was also increased in order to amplify the vector in the cell lines. The vector pairs in Table 4 were electroporated into CHO cells. <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98/12329 PCT/iJS97/16122 -67_ Table 4. Vector pairs for production of antibody Product                  Heavy Chain    Light Chain Vector         Vector c77A3 {chimeric 77A3)    pD20-cRI.HI    pDl6-cRl.Ll h77A3-1 {humanized 77A3) pD20-hRl.H1    pDl6-hRl.Ll h77A3-2 (humanized 77A3) pD20-hR2.Hl    pDl6-hRl.L1 h77A3-3 (humanized 77A3) pD20-hR3.H1    pDl6-hRI.LI <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. Purification of Humanized and Chimeric Antibodies The purification of the antibody was first performed using protein-A af~lnity chromatography. A Pharmacia column, sized so that 5 mg of antibody to be loaded per 1 ml of resin, was packed with Perseptive Biosystems Poros 50 A protein-A<br class="style-scope patent-text">resin. The column was then sanitized according to the methods recommended by the resin supplier. The column was equilibrated with pyrogen free 10 mM sodium phosphate, 150 mM sodium chloride pH 7.0 (PBS). The cell culture supernatant was adjusted to pH of 7.0-7.5 and loaded on the column at a flow rate equal to - 3 column volume/nun (CV/min). The column was then washed with 15 CV<br class="style-scope patent-text">pyrogen free PBS or until a stable base line has been achieved. The antibody was eluted with 20 mM glycine/HCl pH 3.0 elution buffer. The eluted peak was collected in a pyrogen free vessel that contained 1/20 CV of 1 M Tris base solution.<br class="style-scope patent-text">The pH of the eluted antibody solution was adjusted to pH 8.0 with IM Tris base immediately. The column was then cleaned with 5 CV I2 mM HCl solution. The column was stored in 20% ethanollwater at 4.0~C.<br class="style-scope patent-text">     The antibody was next purified using anion exchange chromatography. A<br class="style-scope patent-text">Pharmacia column, sized so that 5 - 10 mg of antibody to be loaded per 1 ml of resin, was packed with Perseptive Biosystems Poros HQ 50 anion exchange resin.<br class="style-scope patent-text">The column was then sanitized according to the methods recommended by the resin supplier. The column was equilibrated with pyrogen free 50 mM Tris/HCI, 50 mM<br class="style-scope patent-text">NaCI, pH 8 The protein-A purified antibody adjusted to pH of 8.0 was loaded on the column with flow rate equal to 1 CV/min. The column was then washed with 5 CV pyrogen free 50 mM Tris/HCI, 1M NaCI pH 8 The antibody does not bind to this column under the running conditions and was present in the flowthrough fraction. The column was stored in 20% ethanoUwater at 4.0~C. The antibody was then concentrated and diafiltered against PBS using a 30K cut off membrane.<br class="style-scope patent-text">     D. Non-specific IgG ELISA to detect presence of antibody This ELISA detects whole antibody (containing both heavy and light chain) and relies on a capture antibody specific for human IgG Fc region and a conjugate specific for human kappa chains. In this assay, Immunlon II flat bottom plates (Dynatech) were coated with goat anti-human IgG (Fc specific, adsorbed on mouse IgG) (Caltag, Inc. catalog #H10000) at 0.5 /,cg/ml in carb/bicarb buffer pH <br class="style-scope patent-text">9.6 and then blocked with PTB (PBS containing 0.05% Tween 20 and 1.0% BSA). Sample was added (either undiluted or diluted in PTB or Genetic Systems specimen diluent), the plates were incubated oin at 4~C or for a few hours at room temperature. After washing, conjugate (goat anti-human kappa conjugated with horseradish peroxidase from Southern Biotech) was added at 1:10000 in PTB.<br class="style-scope patent-text"> After approximately 1 hour incubation at room temperature, plates were washed and 100 ,ul chromagen/substrate was added (Genetic Systems chromagen diluted 1:100 into Genetic Systems substrate). After sufficient color development (usually 5 to 15 minutes) 100 ~1 1 N H2S04 was added to stop the reaction. Optical densities were determined using a Biotek plate reader set at 450 and 630 nm wavelengths.<br class="style-scope patent-text">     In the occasional case that none of the samples from small COS<br class="style-scope patent-text">transfections showed the presence of whole antibody, similar ELISAs were performed to determine whether any light chain was being secreted. In this case, WO 98l12329 PCTJUS97/16122 the plates were coated with a goat anti-human kappa chain at 1 ,ug/ml. The rest of the assay was done exactly as above.<br class="style-scope patent-text">     The assay was used for three purposes. First, to screen small COS<br class="style-scope patent-text">transfections that were set up to qualify various heavy and light chain vectors. In this case, the presence or absence of a signal was sufficient and it was not necessary to quantify the amount of antibody present. Second, to determine which of many master wells from CHO transfections were producing the most antibody. In this case, culture supernatants were diluted so that relative signals could be compared and the master wells containing the most antibody could be distinguished and thus selected for cloning and expansion. Thirdly, to determine amounts of antibody, either in culture supernatants or following purification. In this case, a standard consisting of either a chimeric or human IgGl or a human myeloma IgG2 were used. Both standard and sample were serially diluted (2x) across a plate and sample concentration relative to standard was determined by comparing position of the curves. The concentrations thus determined were used for following antibody production during the cloning and amplification process and for determining specific activity in the antigen binding ELISA and any of the functional assays.<br class="style-scope patent-text">     E. ELISAs to show that antibody is capable of binding to antigen This ELISA relies on an antigen capture and a human kappa chain specific conjugate. It was used for two purposes. Initially, to qualify a vector, supernatants from COS transfections were screened for the ability of antibody to hind to antigen.<br class="style-scope patent-text"> Vectors passing this test were then submitted to DNA sequencing. Secondly, to determine relative antigen binding ability of the various chimeric and humanized antibodies. This ELISA is very similar to the non-specific IgG ELISA described above except that the plates were coated with a2-antiplasmin (obtained from American Diagnostica) at 1 ~g/ml in PBS.<br class="style-scope patent-text">  To determine relative antigen binding ability of various antibodies, scatter plots were used with log antibody concentration along the X axis and optical density along the Y axis. Antigen concentration was determined either from the non-specific ELISA or based on optical density of purified preparations. All three forms of humanized antibody (h77A3-1, -2, and -3) show antigen binding similar to that of the chimeric antibody. Comparisons were not made with the murine antibody (m77A3) because the m77A3 cannot be detected in the assay as described (the antibody-conjugate used in the second step recognizes only human constant regions).<br class="style-scope patent-text">F. Functional Assays Two functional assays were performed. The first, known as the "plasmin assay with chromogenic substrate" is based on the ability of plasmin to convert Spectrozyme PL, H-D-Nle-HHT-Lys-pNA.2AcOH into pNA, which absorbs light at 405 nm. If unblocked a2-antiplasmin is present, little or no conversion occurs.<br class="style-scope patent-text">Active antibody is capable of blocking the inhibitory activity of a2-antiplasmin. The second assay, the clot lysis assay, is a measure of the ability of antibody along with urokinase to lyse preformed clots.<br class="style-scope patent-text"> The plasmin assay with chromogenic substrate is designed based on the action of plasmin on its chromogenic substrate according to the reaction:<br class="style-scope patent-text"> Plasmin H-D-Nle-HHT-Lys-pNA.2AcOH--~ H-D-Nle-HHT-Lys-OH + pNA<br class="style-scope patent-text">Plasmin Chromogenic Substrate The generation of pNA was monitored by the increase in absorption at 405 nm using a SpectraMax 250 spectrophotometer. The addition of a2-antiplasmin inhibits the plasmin activity and no increase in absorption at 405 nm will be observed. Premixing of a2-antiplasmin with functional antibody blocks the ability of a2-antiplasmin to inhibit the plasmin activity. Plasmin activity was measured as the initial rate of color development.<br class="style-scope patent-text">    Assays are performed in 96 well microtiter plates. The chromogenic substrate Spectrozyme PL, H-D-Nle-HHT-Lys-pNA.2AcOH, human plasmin, and human a2-antiplasmin were purchased from American Diagnostica. Stock and working solutions are prepared as follows: Spectrozyme PL stock solution - 10 mM in H20; Spectrozyme PL working solution - 1: l2.5 dilution of stock solution in H20; human plasmin stock solution - 0.2 mg/ml in 50% glycerol, 50% 2 mM<br class="style-scope patent-text">HCI; human plasmin working solution - 1 : 12. S dilution of stock solution in 0.11 mM HCI, which must be prepared immediately before use; human a2-antiplasmin stock solution - 0.2 mg/ml in PB S; and human a2-antiplasmin working solution -1:15 dilution of stock solution in PBS. Stock solutions were stored at -70 and should not be refrozen after thawing.<br class="style-scope patent-text">   Reagents are added in the following order, with mixing after each addition:<br class="style-scope patent-text">80 ul antibody or PBS, 40 ul a2-antiplasmin working solution, 40 ul plasmin working solution, and 40 ul Spectrazyme PL working solution. R is the rate of color development. Rp, which represents maximum plasmin activity, is determined in wells lacking both antibody and a2-antiplasmin. Ro, which represents minimal plasmin activity, is determined in wells lacking antibody. Rs is the rate of color IS development in the sample. Antibody activity is calculated as (Rs - Ro)/(Rp - Ro) * 100. Values should range between 0% and 100%. Antibody activity was plotted vs. amount antibody (on a dog scale). Curves generated by test antibody and standard (usually murine 77A3) were compared.<br class="style-scope patent-text">     The data for murine 77A.3, c7?A3, and h77A3-1 are shown in Figure 20.<br class="style-scope patent-text">    The curves for murine and chimeric 77A3 were superimposable. The curve for h77A.3-2 indicates a potential small loss in activity (20-3'0%).<br class="style-scope patent-text">The clot lysis assays were performed as follows. Test clots were formed in 96-well Corning #25805 microtiter plates by mixing 25 uL 16 mM CaCl2, 50 uL of pooled human plasma, and 25 uL of 4 NIH unitJml of human alpha-thrombin (Sigma) in 30mM Hepes buffer, pH 7.40. Plates were incubated overnight at room temperature to allow clots to achieve maximum clot turbidities. Clot lysis was initiated by adding 10 uL of antibody to give 5 or 10 ug/well and 100 uL of urokinase to give 1, 3 or 5 units of urokinase/well (Abbott Labs) at pH 7.40. <br class="style-scope patent-text">Plates were mixed on a table top nucroplate vortexer for 30 sec before the initial reading at 405 nm to get values corresponding to 0% lysis. Plates were sealed with Corning WO 98l12329 PCTlUS9'7116122 sealing tape #430454 and incubated at 37~C. During the course of 24 hrs, the decrease of turbidity was measured at 405 nm to quantify the progress of clot lysis.<br class="style-scope patent-text">     The results of a clot lysis experiment of humanized 77A3-1 indicate that h77A3-1 enhances clot lysis dramatically in comparison to buffer controls in each of the conditions tested. There was significant separation between the humanized and murine 77A3 in clots containing 5 ug antibody in the presence of 1 or 3 units of urokinase indicating that humanized 77A3 was somewhat less active than murine 77A3, even though the lysis profiles were similar at the remaining four conditions tested. It should be noted that murine RWR, a monoclonal antibody with a 10-fold lower affnity than murine 77A3, causes no lysis at 10 ug per clot in the presence of i unit of urokinase and would give a lysis profile like buffer control.<br class="style-scope patent-text">     Example S<br class="style-scope patent-text">     Preparation and Characterization of Single Chain Fv Fragments A. Design and expression of sFv form of 77A3 The sFv fragment of an antibody is most commonly obtained by the tandem expression of the variable region of the antibody heavy chain along with the variable region of the antibody light chain spaced by a linker of 1 S-20 amino acids. <br class="style-scope patent-text">sFv fragments are expected to have superior clot penetration to parent antibodies. <br class="style-scope patent-text">Two constructs, p53-6 and p52-12, were prepared using murine variable regions with a VH-(linker)-VL polarity using YPRSIYIRKRI-IPSPSLTT (SEQ ID N0:73) as linker 1 for sFv77A3-1 and GGSGSGGSGSGGSGS {SEQ ID N0:74) as linker 2 for sFv77A3-2. Both constructs were cloned into the pET-22b vector from Novagen and transformed into the BL21 (DE3 ) strain of E coli grown in minimal M9 media. Though the majority of the His-tagged product was found in inclusion bodies, supernatants of cell lysate contained sufficient quantities of soluble sFv fragments for nickel-column purification. <br class="style-scope patent-text"> <br class="style-scope patent-text"> sFv77A3-2 present in fractions 7-11 collected from a nickel-column gave a single Coomasie staining band with a MW about 30,000 agreeing well with the calculated MW of 29,986. A similar but more weakly staining gel was obtained for sFv77A3-1.<br class="style-scope patent-text">     B. Activity of sFv77A3-1 and sFv77A3-2 Preparations of both sFv77A3-1 and sFv77A3-2 were tested for alpha2-antiplasmin binding activity in a competition binding assay. Microplate wells coated with 77A3 were treated with mixtures of biotinylated-human aipha2-antiplasmin and either sFv77A3-1 or sFv77A3-2 along with positive control ?7A3 and negative control, mAb-59D8. Increasing quantities of 77A3 prevented binding of biotinylated-human alpha2-antiplasmin whereas negative control 59D8 had little effect as an competitive inhibitor. With concentrations of test samples estimated by intensity of Coomasie stained bands, both sFv77A3-1 and sFv77A3-2 completely inhibited the binding of biotinylated-human a2-antiplasmin with a profile of inhibition nearly superimposible to the parental 77A3 reference.<br class="style-scope patent-text">     Idiotypic markers present on 77A3 were probed with a sandwich ELISA<br class="style-scope patent-text">using a biotinylated polyclonal reagent rendered specific by multiple immunoadsorbtion steps through columns bearing immunoglobulins from man, mouse, baboon and cynomologous monkey (P Stenzel-Johnson &amp; D Yelton, Seattle). Microplate wells were coated with 77A3 and 59D8 as controls along with sFv77A3-l and sFv77A3-2. It is evident that 77A3 control and both sFv fragments bear idiotypic markers at each dose tested indicating that the sFv fragments "look"<br class="style-scope patent-text">like the parental ??A3.<br class="style-scope patent-text">     It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. <br class="style-scope patent-text"> <br class="style-scope patent-text"> -?4-Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.<br class="style-scope patent-text"> The disclosure of alI references, patent application, and patents referred to herein are hereby incorporated by reference. <br class="style-scope patent-text"> <br class="style-scope patent-text"> -74.1-Appliant'soragent'sGlc G609.432PC,01 - - ~Internatioa~lappliationNo.<br class="style-scope patent-text">reteratce number INDICATIONS RELATING TO A DEPOSITED MICROORGANISM<br class="style-scope patent-text">(PCT Rulc 136is) A. The indications made below relate to the microorganism tetctted to in the description on page 7 , line 12 B. IDENTIFICATION OF DEPOSIT    <br class="style-scope patent-text">     Further deposits are identiCted on an additional sheet Name of depository institution AMERICAN TYPE CULTURE COLLECTION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address of depository institution (including postal code and could ry) 12301 Parklawn Drive Ftockville, Maryland 20852 United States of America Date of deposit                 Accession Number 20 September 1996               I-Ig-l2192 C. ADDITIONAL INDICATIONS (!tour blank if not applicable) 'Ibis information is continued on an additional sheet Hybridtxna cell line, 77a3 D. DESIGNATED STATES FOR WI3ICIi INDICATIONS ARE MADE (ijlluindicationsarenot/orall designalrdSlatcs) E. SEPARATE FLIItIVISHING OF    <br class="style-scope patent-text">   INDICATIONS (lwcblankif not applicoblc) 'IlteindicationslistedbelowwiilbesubmittedtothelnternationalDureaulacct(sprcijy thegeneralnarurrojrhrindicauorerr.g., Accession Numbrr ojDrposil") - For receiving OfCrce use only For International Bureau use only This sheet was received with Ihc international application ~ llis sheet was received by the lnternalional Bureau on:<br class="style-scope patent-text">     Auth~ri-ccd oCCtccr ~~\~ Autivorv.cd c~lCiccr ~~t~~<br class="style-scope patent-text">     C~.,~ ~~S 3'1S<br class="style-scope patent-text">1~mrm 1'C.'C/Itt)/134 (July 1942) -74.2-Applinnt'soragent'sCtlc 09.432PC01 Internationalapplidtioti' reference number INDICATIONS RELATING TO A DEPOSITED MICROORGANISM<br class="style-scope patent-text">(PCT Rule 136is) A. The indications made below relate to the microorganism referred to in the description on page 18 , line B. IDENTIFICATION OF DEPOSIT    <br class="style-scope patent-text">     Further deposits are identified on an additional sheet Name of depositary institution AMERICAN TYPE CULTURE COLLECTION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address of depositary institution (including postal code and country) I2301 Parklawn Drive Rpckviller Marylaru3 20852 United States of America Date of deposit Accession Number 19 Se tember 1997               TBA <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. ADDTTIONAL INDICATIONS ((cave blank if not applicable) This information is continued on an additional sheet D. DESIGNATED STATES FOR WHICH  <br class="style-scope patent-text">     INDICATIONS ARE MADE (iftheindicationsarenot foratt dcrignatrdStates) E. SEPARATE FL1R1VISHING OF INDICATIONS<br class="style-scope patent-text">(Iwve blank if not appticablc) Theindicationslistedbelowwillbesubmittedtothelnternationalf3ureaulater(specifyt hegenoalnarureoftficindicatianse.g., itccession Number of Deposit') Accession number will be furnished at a later date.                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ivor reccimng OfC~ce use only F'or International Bureau use only ~ This sheet was received with the international applicaoon ~ This sheet was received by the International Bureau on:<br class="style-scope patent-text">     I~uthcuiicd officer /wtliormeJ mlliccr ~~ l ~L,.b-~-C'~..'~ %c~ ~ ~'a. 1 Form !'l 'I/IL()/I i.t (Julv 1')'~: ) WO 98j12329 PCT/US97J16122 -74:3 Applicant'soragent'stiic ~09.432PC01 Intcmationalapplicat~ion referutce number INDICATIONS RELATING TO A DEPOSITED MICROORGANISM<br class="style-scope patent-text">(PCT Rule l3bis) A. The indications made below relate to the microorganism referred to in the description on page 18 , fine 19 B. IDENTIFICATION OF DEPOSIT f urther deposits are identified on an additional sheet Name of depositary institution AMERICAN TYPE CULZTJRE COLLECTION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address of depositary institution (including postal code and country) 12301 Parklawn Drive Pvckville, Maryland 20852 United States of Amexica Date of deposit                  Accession Number 19 Se tember 1997                TBA <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. ADDTTIONAL INDICATIONS (!rout blank if not applicable) This intortnation is continued on an additional sheet D. DESIGNATED STATES FOR WIiICIi INDICATIONS ARE MADE (i jtht indications art not jar aJJ designated States) E. SEPARATE FURNISHING OF INDICATIONS<br class="style-scope patent-text">(lcaveblankiJnotapplicoblc) The indications listed belowwill be submitted to the lnternanonal Bureau later (specify the general natureojthcinditations e.g., Accession Number of Dtposit ") Accession number will be furnished at a later date.                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> lvor receiving Office use only For InternaVOnal Surcau use only ~ This sheet was received with the international application ~ 'This sheet was received by the international Bureau on:<br class="style-scope patent-text">/~ulhoriied officer /~mY~e~rmed mlJicer ~l .~}~~~,...<br class="style-scope patent-text">y:"r~f~ nc-fnctm smai~ n~&gt;&gt;i -74.4-Applicant's or agent's file 09. 432PC01 ~ internatiom~lapplication rcferrrtcx number -INDICATIONS RELATING TO A DGPOSITCD MICROORGANISM<br class="style-scope patent-text">(PCT Rule l3bis) A. The indications~ade below relate to the microorganism r~~rred to in the description on page 1t5 , lin Ce B. IDENTIFICATION OF DEPOSIT    <br class="style-scope patent-text">further deposits are identified on an additional sheet Name oC depositary institution AMERICAN TYPE CULZTJRE COLLECTION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockviller Maryland 20852 United States of America Date of deposit                 Accession Number 19 Se tember 1997      TBA <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. ADDITIONAL INDICATIONS (Iwvc blank ijnot applicable/ This information is continued on an additional sheet Q            <br class="style-scope patent-text"> <br class="style-scope patent-text"> D. DESIGNATED STATES FOR WHICFi INDICATIONS ARE MADE (if fhe indications are not for all designated Slatesj E. SEPARATE FIJItNISFIING OF    <br class="style-scope patent-text">     INDICATIONS It~veblankijnoe applicable) The indications listed below will be submitted to the Internet tuna I Burea a later (spedjy the general nature of the indications e.g., 'Accession Number of Deposit') Accession ntanber will be furnished at a later date.          <br class="style-scope patent-text"> <br class="style-scope patent-text"> For recervtng Ofl-tce use only hot International Bureau use only This sheet was recemed with the rnternanonal a~pllcaoon Q 'Ibis sheet was received by the Intemattonal Bureau on:<br class="style-scope patent-text">     /~uthorW cd offrcur ~t /',W Imrmvd mllm:or ~~~i.. , I~crrW I'l-I:IL()il S~7llulv pl'!;&gt;~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> -74.5-Applicant's or agent's file 09. 432PC01 ~ lntematio~ pplication t -reference number (PCT Rule 136is) A. The indications made below rciate to the microorganism referred to in the description on page ~~ , line B. IDENTIFICATION OF DEPOSTT    <br class="style-scope patent-text">     Further deposits arc identiCted on an additional sheet Name of depositary institution AMERICAN TYPE CULTURE COLLECTION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address of depositary institution (including poslol code and country) 12301 Parklawn Drive Rtxkville, Maryland 20B52 United States of America Date of deposit     Accession Number 19 Se tember 1997               TBA <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. ADDITIONAL INDICATIONS (leave blank if nor opplicoblc) 'Ibis information is continued on an additional sheet D. DESIGNATED STATES FOR WHICH  <br class="style-scope patent-text">     IND1CAT10NS ARE MADE (i f tlu indications are not for alf designated StatGr) E. SEPARATE FURIHISHING OF INDICATIONS<br class="style-scope patent-text">(tcaveblanki/not opplicoblc) The indications listed below will be submitted to the International bureau later (specify thegenoal natureoftiteindicationse.g., Accession Number of Deposit ") Accession number will be furnished at a later date.                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> For receiving Office use only For International Bureau use only -This sheet was received with the international application Q l~his sheet was received by the International Bureau on:<br class="style-scope patent-text">     Aulhori'ted officer /~utl~~rmd oflcer v C''tV"31 '.;: i'1 ~! ~ _ farm I'/'f/IR)/1.1.i IJulv I'1'tW <br class="style-scope patent-text"> <br class="style-scope patent-text"> Applicant'soragent'sGlc -09.432PC01 ~Intcmationalapplidtionv reference number INDICATIONS RELATING TO A DCPOSITED MICROORGANISM<br class="style-scope patent-text">(PCT Rule 136is) A. 'Ihe indications made below relate to the microorganism referred to in the description on page 18 , line 23 B. IDENTIFICATION OF DEPOSIT    <br class="style-scope patent-text">further deposits are identified on an additional sheet Name of depositary institution At~RICAN TYPE CULTURE COLLECI'ION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address oC depositary institution (including postal code and country) I2301 Parklawn Drive Rpckville, Maryland 20852 United States of I-unerica Date of deposit                 Accession Number 19 Se tember 1997               TBA <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. ADDITIONAL INDICATIONS (Icavr blank ijnd applicable) This information is continued on an additional sheet D. DESIGNATED STATES FOR WHICH  <br class="style-scope patent-text">     INDICATIONS ARE MADE (i f the indications are not for all drsignated States) E. SEPARATE FI)ItNISIiING OF    <br class="style-scope patent-text">     INDICATIONS (lcavrblanki/not applicable) The indications listed below will be submitted to thelnternaUOnalL~ureaulater(spccifythcgcnoalnaturcoftheindicationse.g., :4ccersion Numbrr of Deposit") Accession rnunber will be furnished at a later date.                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> For receiving Office use only For International Bureau use only This sheet was received with the international application a 'this sheet was received by the International Bureau on:<br class="style-scope patent-text">     Authe~rW ed officer AutImW mJ e~llicer ~ - ~~~,Y~~, Iwm I't'C/IL()/I l~t (lulu I'tu: I <br class="style-scope patent-text"> <br class="style-scope patent-text"> WO 98/12329 _ ~4 . ~ _ PCT/US97/16122 Applicant's or agent's file 0609 . 432PCOI ~ Intetnationalapplicatior ~ o -refe.rrttoe number ~1 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM<br class="style-scope patent-text">(PCT Rule l3bis) A. The indications made below relate to the microorganism referred to in the description on page 18 , line B. IDENTIFICATION OF DEP05TT    <br class="style-scope patent-text">     Durther deposiu are identified on an additional sheet Name of depository institution AMERICAN TYPE CULTZJRE COLLECTION <br class="style-scope patent-text"> <br class="style-scope patent-text"> Address of depository institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 UrLited States of America Date of deposit                 Accession Number 19 Se tember 1997               TBA <br class="style-scope patent-text"> <br class="style-scope patent-text"> C. ADDITIONAL INDICATIONS (leave blank if no( applicable) This information is continued on an additional sheet D. DESIGNATED STATES FOR WIiICFi INDICATIONS ARE MADE (i f tlu indications are not for all darignated States) E. SEPARATE FURNISHING OF INDICATIONS<br class="style-scope patent-text">(Ie;ave 6fank ijnoe applicable) TheindicauonsfistedbelowwillbesubmittedtotheinternattonallW<br class="style-scope patent-text">reaulater(specifythegenoalnatureoftheindicationse.g.,'Accession Number of Deposit ") Accession ntynber will be furnished at a later date.     <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ivor receiving Office use only For lnternaaonal Bureau use only ~ This sheet was received with the international application ~ 'IOis sheet was received by the International Bureau on:<br class="style-scope patent-text">     Aulitcttmcd officer /W tlmrm.eJ mlfi~cr y ~~~ ~ v~~ ~~ ~ t-iwnn I'C'/~/I(()/I S~I Ilulv I'~'i.'i , ; ;<br class="style-scope patent-text">~ ~ . . , " , . , ~ ,,, (,~<br class="style-scope patent-text">-~:~. s-SEQUENCE LISTIDIG<br class="style-scope patent-text">('_) GENERAL INFORMATION:<br class="style-scope patent-text">(i) APPLICANT/INVENTCR: ~~ED, GUY L.<br class="style-scope patent-text">(ii) TITLE CF INVENTT_ON: COMPOSITION AND METHOD FCR ENHANCING<br class="style-scope patent-text"> <br class="style-scope patent-text">(iii) NUMBER OF SEQUENCES: 81 (iv) CORRESPONDENCE ADDRESS:<br class="style-scope patent-text">(A) ADDRESSEE: STERNS, KESSLER, GOLDSTEIN &amp; FOX P.L.L.,..<br class="style-scope patent-text">(B) STREET: 110C NEW YORK AVENUE, N.'r1. SUITE o00 (C) CITY: WASHT_NG'_'CN<br class="style-scope patent-text">(D) STATE: D.C.<br class="style-scope patent-text">(E) COUNTRY: USA<br class="style-scope patent-text">=' ZIP: 20005 (~r) COMPUTER READABLE =CRM:<br class="style-scope patent-text">(A) MEDIUM TYPE: __oppy disc (3) COMPUTER: _3M PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS<br class="style-scope patent-text">(D) SOFTWARE: PatentT_n Release ,1.0, Version 1.3C<br class="style-scope patent-text">(vi) CURRENT APPLICATION DATA:<br class="style-scope patent-text">(A) APPLICATION N'uMHER: PCT/US97/16122 (B) FT_LI~IG DATE: "_9-SEP-i997 (C) CLASSIcICATION:<br class="style-scope patent-text">.;vii) PRIOR APPLICATION CATS:<br class="style-scope patent-text">(A) APPLICATION JItJ?~!BER: US o0/026, 356 (B) FILING DATE: ~,,-SEP-i996 (C) CLASSIFIC?.T_IO'I:<br class="style-scope patent-text">(Vii') ATTORNEY/AGENT TNFORMATION:<br class="style-scope patent-text">(A) NP.ME: GOLDSTEIN, JORGE A<br class="style-scope patent-text">(B) REGISTRATION :tUi~_HER: 29, 021 (C) REFERENCL/DOC:~E'" NUMBER: 0609.432PC01 (ix) TELECOMMUNICATION INFORMATION:<br class="style-scope patent-text">(A) TELEPHONE: (2~2', 371-2600 (B) T.ELEFP.X: (2C2', Q71-2540 (2) INFORMATION FOR SEQ ID _dC:l:<br class="style-scope patent-text">(i) SEQUENCE CHARACTEF.ISTICS:<br class="style-scope patent-text">(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDDIESS: sinCJle (D) TOPOLOGY: nct re~-evant (ii) MOLECULE TYPE: pepride (:&lt;i) SEQUENCE DESCRiPTT_ON: SEQ ID N0:1:<br class="style-scope patent-text">:Caa Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser 'lal AM~wIOtO ~N~~ i v , , ~ ~ . y -/'1.9-) INFORMATION ECR SEQ ID NC:2:<br class="style-scope patent-text">( i i SEQUE.ICE CaARAC"_'Et'ZISTICS<br class="style-scope patent-text">(A? LENGTH: 5 amine acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide SEQUENCE DESCRIPTIQN: SEQ ID NO:~:<br class="style-scope patent-text"> Asp_ T_ie Gln Met Thr l2) IDIFORMATiCN FOR SEQ ID N0:3:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LEDIGTH: 15 ami__~.c acids (B) TYPE: amine acid (C) STRPNDEDNESS: single (D) TOPOLOGY: net relevant ;ii) MOLECULE TYPE: peptide (:ti) SEQUENCE DESCRIPTION: SEQ ID DI0:3:<br class="style-scope patent-text">  Xaa Ile Gln Met Thr G1n Ser Pro Ala Ser Leu Ser Ala Ser Val (2) INFORMP.TION FOR SEQ ID t10:4:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">( i:t ) FEATURE<br class="style-scope patent-text">(A) NAME/KEY: CDS<br class="style-scope patent-text">(B) LOCATION: 1..381 ( i:t ) FEATURE<br class="style-scope patent-text">(A) NAME/KEY: sig peptide (B) LOCATION: 1..'o0 (:~ij SEQUED1CE DESCRIPTIOD1: SEQ ID N0:4:<br class="style-scope patent-text">.4TG AGT GTG CTC ACT CAG GTC CTG GSG TTG CTG CTG CTG TGG CTT ACF_ 48 Met Ser 'Ja1 Leu Thr G1n Val Leu Kaa Leu Leu Leu Leu Trp Lau Thr ~:~a_-~~'r~ '~i'L.~'I <br class="style-scope patent-text"> <br class="style-scope patent-text"> ;,, ; . , . ) , _ , ~ ", .<br class="style-scope patent-text">-7~.10-GlyAlaArg CysAspIle GlnMetThr GlnSerPro AlaSer LeuSer GCATCTGTG GGAGAAACT GTCACCATC RCATGTCGA GCRAGT GGGa.~T  1-14 AlaSerVa1 GlyGluThr VaiThrI1e ThrCysArg AlaSer GlyRsn 1tC111JllJnailiuG~ufSyc~ua.pi~ Vu.~VW L~=:,VlliV1yLyJ JCS.iiv i CAGCTCCTG GTCTATRAT GCA.~,AACC TTRGCAGAT GGTGTG CC:~TCR   2:10 GlnLeuLeu VaiTyrAsn AlaLysThr LeuAla.aspGlyVal PrcSer 45              50               55               c0 AGGTTCAGT GGCAGTGGA 'T_'CAGGARCA C.~TTTTCT CTCAGG ATC~=W.  2a9 ArgPheSer GlySerG1y SerGlyThr GlnPheSer LeuArg IleAsn SerLeuG1n PrcGluAsp PheGiySer HisT.yCys G1nHis PheTrp r RCCACTCCG TGGACGTTC GGTGGAGGC ACCAAGCTG GAARTC RP.A      39i ThrThrPro TrpThrPhe GlyrGlyGly ThrLysLeu G1uIle Lys (2) ID1FORMATION FOR SEQ ID N0:5:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 127 amino acids (B) T':PE: amine acid (D) TOPOLOGY: linear (i,~) MOLECULE TYPE: protein (ix) FEATURE:<br class="style-scope patent-text">(A) NRME/KEY: Modi~ied-site (B) LOCATION: 9 (D) OTHER INFORMATION: /note= "Can be either Gly or Ala"<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTICD1: SEQ ID PI0:5:<br class="style-scope patent-text"> Met Ser Val Leu Thr Gln Val Leu Kaa Leu Leu Leu Leu Trp Leu Thr Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val G1y Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp G1y Val Pro Ser - ~::1~NDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> . ., , -~~. 1 1-Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Asn 0'S 70 75 Ser Leu Gln Pro Glu Asp Phe G1y Ser His Tyr Cys Gln His Phe Trp Thr Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu I1e Lyrs (2) INFORMATION FOR SEQ ID NO: o':<br class="style-scope patent-text">( i ) S EQUENCE CHARA~:TEr'ci ~ T ~::~<br class="style-scope patent-text">(A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (Di TCPOLCGY: linear !ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(is) FEATURE:<br class="style-scope patent-text">(A)          CDS         <br class="style-scope patent-text">     NAME/KEY:                                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> (B)      1..39i LOCATION:                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> (   FEATURE      <br class="style-scope patent-text">.x ) (            sigpep tide A) NAMEi KE'f :                                <br class="style-scope patent-text"> <br class="style-scope patent-text"> (B)          1..0'0 LOO:-1TIGN:                                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> (xi)SEQUENCE                 SEQID                        <br class="style-scope patent-text">     DESCRIPTION:        NO:                       <br class="style-scope patent-text">o':                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> MetSer ValLeuThr G1nValLeu GlyLeuLeu LeuLeuTrp LeuThr _20              _15             _10  _5 GlyAla ArgCysasp IleGlnMet ThrGlnSer ProAlaSer LeuSer AlaSer ValGlyGlu ThrValThr ValThrCys RrgAlaSer GlyAsn IleHis AsnTyrLeu AlaTrpTyr GlnGlnLys GlnGlyLys SerPro GlnLeu LeuValTyr AsnAlaArg ThrLeuAla AspGlyVal ProSer 45               50              55             0'0 AGGTTC RGTGGCAGT GGATCAGGA ACACAATAT TOTOTCAAG ATCAAC  '288 ArgPhe SerGlySer GlySerGly ThrGlnTyr SerLeuLys IleAsn SerLeu GlnProGlu AspPheGly SerTyrTyr CysGlnHis PheTrp SerAsn ProTrpThr PheGlIG1y GlyThrLys LeuGluIle Lys .;~tEidDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ( CA 02266341 1999-03-19 ~~,, ,., -7.12_ (2) INFORMATION FOR SEQ ID NC:7:<br class="style-scope patent-text">(i) SEQUENCE CHARACT~R_TSTICS:<br class="style-scope patent-text">(A) LENGTH: i27 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:<br class="style-scope patent-text">:"ier ~~y ~'i3~_ _.c'~ _..- '.~;..~_ ~J.:- -~'s _-l _.~'.1 ........ :.e'.~ <br class="style-scope patent-text">:.c'.~ -_r .__- -..-G1y Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser -1 5 i0 Ala Ser Val Gly G1u Thr Val Thr 'lal Thr Cys Arg Ala Ser Gly Asn 15 ~0 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys G1n G1y Lys Ser Pro 30 35 ~0 Gln Leu Leu Val T_;r ?~sa A1 a Arg Thr Leu Ala Asp Gly 'Jal Pro Ser Ara Phe Ser Glv Ser Gin Ser Glvr Thr Gln Tvr Ser Leu Lv_s Ile Asn - 05 - ' 70 ' 75 Ser Leu Gin Pro Giu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp eo s5 90 Ser Asn Pro Trp Thr Phe G1_r Gly Gly Thr Lys Leu Glu Ile Lys (2) INFORMATION FOR SEQ ID :1G:3:<br class="style-scope patent-text">i.i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNP:<br class="style-scope patent-text">(ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: CDS<br class="style-scope patent-text">(B) LOCATION: 1..381 (ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: sig_peptide (B) LOCATION: 1..60 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:<br class="style-scope patent-text"> <br class="style-scope patent-text">Met Ser Val Leu Thr Gln Va1 Leu Ala Leu Leu Leu Leu Trp Leu Thr Gly Rla .erg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser ::i_'fQEu Si;EEi " . , , v1 1 v o 1.~ .1 11 -7~.1~-TCT    GGA    RCT    RTC       TGT  GCA                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> Rla SerVal GlyGluThr Val Thr   ThrCysArg AlaSerG1y Asn Ile ATT CRCAAT TRTTTAGCA TGG TAT   CAGAAACAG GGR~  TCT CCT 192 CAG                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ile HisRsn TyrLeuAla Trp Tyr  GlnLysGln GlyLysSer Pro Gln v.i -  ..  .1 -. .1"~.: \..    -  W....1.:l1~,.,,..v   ~ L,  L T 'v 1   ., .,  ~  .  ~   : . ..    ~     ~   v. ~  v.        <br class="style-scope patent-text">:   v  r   v  -      :: 1 .'1v..         ~  ..,v ..   .                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> G1n LeuLeu ValTyrAsn Ala Lys   LeuAlaAsp GlyValPro Ser Thr AGG TTCAGT GGCRGTGGR TCA GGR   CAATTTTCT CTCAAGATC AAC   2g8 ACA                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> Arg PheSer GlySerGiy Ser G1y   GlnPheSer LzuLysIle Asn Thr 65               70              , AGC CTGCAG CCTGAAGAT TTT GGG   CRTTACTGT CR.'SCATTTT TGG   336 AGT                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ser LeuGln ProG1uAsp Phe Gly   HisTyrCys GlnHisPhe Trp Ser ACC ACTCCG TGGACGTTC GGT GGR   ACCARGCTG GRRATCPAA       38i GGC                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> Thr ThrPro TrpT_hrPhe Gly Gly   ThrLysLeu GluI1eLys Gly (2) INFORMATION       FORSEQ ID .'1C:9:      <br class="style-scope patent-text"> <br class="style-scope patent-text"> (i)       CHARACTERISTICS:                                    <br class="style-scope patent-text">     SEQUENCE                                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> (A)LENGTH:    127 amino acids (B)TYPE:                               <br class="style-scope patent-text">amine acid (D)TOPOLOGY:                 <br class="style-scope patent-text">linear !ii) TYPE:                                    <br class="style-scope patent-text">     MOLECULE          p otein (xi)     DESCRIPTION:             N0:9:                    <br class="style-scope patent-text">     SEQUENCE          SEQ                                     <br class="style-scope patent-text">     ID      <br class="style-scope patent-text"> <br class="style-scope patent-text"> Met Ser'lalLeuThrGln Val Leu   LeuLeuLeu LeuTrpLeu Thr Ala Gly RlaRrg CysAspIle Gln Met   GlnSerPro.AlaSerLeu Ser Thr Ala SerVal GlyG1uThr 'lal Thr  ThrCysRrg AlaSerGly Asn Ile Ile HisAsn TyrLeuAla Trp Tyr   GlnI.ysGln GlyLysSer Pro Gln Gln LeuLeu ValTyrAsn Ala Lys   LeuAlaAsp GlyValPro Ser   ' Thr Arg PheSer GlySerGly Ser Gly   GlnPheSer LeuLysI1e Asn Thr Ser LeuGln ProGluAsp Phe Gly   HisTyrCys GlnHisPhe Trp Ser Thr ThrPro Trp   Phe           ThrLysLeu GluIleLys Thr   Giy Jly Gly A."~1ENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> , CA 02266341 1999-03-19 :, ~ ,&gt; , . _ , ~, ~ . , , , , '. , , . , ~ , ~, . : . . , , , . . ., -74.14-(2) INFORMATION FOR SEQ ID N0:1!' (i) .SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 414 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">  W x j FF.A'I'URE<br class="style-scope patent-text">(A) NAME/KEY: CDS<br class="style-scope patent-text">(B) LOCATION: 1..414 ( i:t ) FEATURE<br class="style-scope patent-text">(A) NAME/KEY: sig_oeptide_ (B) LOCATION: 1..57 (,:~i) SEQUENCE DESCRIPTION: SEQ ID N0:10:<br class="style-scope patent-text"> <br class="style-scope patent-text">     RGT       <br class="style-scope patent-text"> <br class="style-scope patent-text"> MetXaa TrpVal TrpXaaLeu LeuPheLeu MetAla AlaAlaGln Ser CTCCAA GCACRG ATCCAGTTG GTGCAGTCT GGACCT GAGCTGAAG ARG  90' LeuGln AlaGln IleGlnLeu ValGlnSer GlyPro GluLeuLys Lys CCTGGR GAAACA GTCAAGATC TCCTGCAAG GCCTCT GGGTATACC TTC  14=~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> ProGly GluThr ValLysIle SerCysLys AlaSer GlyTyrThr Phe ThrAsn TyrG1y MetAsnTrp ValLysGln RlaPro GlyLysGly Leu LysTrp MetGly TrpIleRsn ThrLysSer GlyGlu ProThrTyr Ala GluG1u PheLys GlyArgPhe ValPheSer LeuGlu ThrSerAla Ser ThrAla HisLeu GlnIleLys AsnPheArg AsnGlu AspThrAla Thr TyrPhe CysAla ArgTrpVal ProGlyThr TyrAla MetAspTyr Trp G1yGln GlyThr SerValThr !lalSerSer (2)INFORMATION FORSEQID  0:11:  <br class="style-scope patent-text">t1 (i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">a..:~;ENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> - . ' , ", . . , ,,;<br class="style-scope patent-text">_ ,) , . .... .. ., -7~.1 ~-(A) LENGTH: 138 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: modified-site (Bl LOCATION: 2 '~ ,r ,.'T::uR :.:i~si~:.i~t~:: , ..v.i.~= 'r.,..u:W... ..~.. ,..i ..':irn (ix) FEATURE:<br class="style-scope patent-text">(A) NP.ME/KEY: mcdified-site !B) LOCATION: o' (D) OTHER INFORMATICD1: /note= "Can be Asn or Thr"<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID D1C:11:<br class="style-scope patent-text">  Met Xaa Trp Va1 Trp Xaa Leu Leu Phe Leu Met Ala Ala Ala Gln Ser Leu G1n Ala Gln Ile Gln Leu Val Gln Ser Giy Prc Glu Leu Lys L_~s Pro G1y Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr G1_r Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Lys Ser Gly Glu Pro Thr T,,rr Ala Glu Glu Phe Lys Gly Arg Phe Va1 Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala His Leu G1n Ile Lys Asn Phe Arg Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Trp Val Pro Gly Thr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser (2) INFORMATIGN FOR SEQ ID N0:12:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 414 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: CDS<br class="style-scope patent-text">(B) LOCATION: 1..414 ''.:~w~'.;~J ~~EET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~, '_ . , . , -74.16-(ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: sig_peptide (B) LOCATION: 1..S7 (ai)                 SEQID                        <br class="style-scope patent-text">     SEQUENCE   N0:12:                      <br class="style-scope patent-text">     DESCRIPTION:                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> Met XaaTrpVal TrpXaaLeu LeuPheLeu MetAlaAla AlaG1n Ser ATC CAAGCACAG ATCCRGTTG GTGCAGTCT GGACCTGAG CTGAAG _~G  96 Ile GlnAlaGln IleGlnLeu 'Ja1GlnSer GlyProGlu LeuLys Lys CCT GGAGAGACA GTCAAGATC TCCTGC~G  GCTTCTGGG TATACC TTC  i-14 Pro GlyG1uThr ValLysIle Ser_  Lys RlaSerGly TyrThr Phe Cys 15              '~ 25 Thr LysTyrGly MetAsnTrp ~lalLysGln AlaProG1y LysGly Leu Lys TrpMetGly T.rpIleAsn ThrRsnSer GlyGluPro ThrTyr _~ia GAA GAGTTCAAG GGACGGTTT GCCTTCTCT TTGGARACC TCTGCC AGC  .88 Glu GluPheLys GlyRrgPhe AlaPheSer LeuGluThr SerAla Ser ACT GCCTATTTG CRGATCAAC ARCCTCAAA AATGAGGAC TCGGCT ACA  33o' Thr AlaTyrLeu GlnIleAsn AsnLeuLys AsnGluAsp SerR1a Thr Tyr PheCysRla ArgTrpVa1 PrcGlyThr TyrAlaMet AspTyr Trp Gly GlnGlyThr SerValThr ValSerSer (2) INFORMATION FOR SEQ ID N0:13:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 138 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATIOft: /note= "Can be Ala or Asp"<br class="style-scope patent-text">(ix) FEATURE:<br class="style-scope patent-text">(A) PIAME/KEY: Modified-site (B) LOCATION: 6 vra;l~_,. ;~; ~~r-y . CA 02266341 1999-03-19 ,. _ ' , ; , (C) OTHER INFORMATION: /note= "Can be Asn or Thr"<br class="style-scope patent-text">(ai) SEQUENCE DESCRIPTION: SEQ ID D10:13:<br class="style-scope patent-text">  Met :~aa Trp Val Trp Xaa Leu Leu Phe Leu Met Ala Ala Ala G1n Ser Ile Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro G1y Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Lys Tyr Gly Met Asn Trp Va1 Lys Gln Ala Pro Gly Lys Giy Leu Lys Trp Met Gly Trp Ile Asn Thr Asn Ser Gl y Glu Pro Thr T_: r a.'_a 50 55 0'0 Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 0'S 70 75 Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Ser Ala T':r Tyr Phe Cys Aia Arg Trp Val Pro Gly Thr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser (2) INFORMATION FOR SEQ ID t10:14:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 414 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">lix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: CDS<br class="style-scope patent-text">(B) LOCATION: 1..414 (ice) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: sig peptide (B) LOCATION: 1..57 (xi) SEQUENCE DESCRIPTLON: SEQ ID N0:14:<br class="style-scope patent-text"> <br class="style-scope patent-text">  Met Xaa Trp 'Jal Trp Xaa Leu Leu Phe Leu Met Ala Ala Ala Gln Ser -15 -10 ., Ile Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys ~.:~AENOEO SHE~~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> -~~. i s-ACA                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> ProGly GluThrVal LysIleSer CysLysAla SerGlyTyr ThrPhe ThrAsn TyrGlyMet AsnTrpVal LysGlnAla ProGlyLys GlyLeu 3                3               -10        -f RAGTGG ATGGGCTGG ATAAACACC AAG.SGTGGA GAGCCARCA TATGOT   240 LysTrp MetG1yTry IleAsnThr LysSerGly GiuProThr Tyr:-Q13 GluGlu PheLysGly ArkPheAla PheSerLeu G1uThrSer AlaSer ACT.GCC AATTTGCAG ATCAAGRAC OTCRAAAAT GAGGAOACG GOTACA   33o ThrAla AsnLeuG1n IleLysAsn LewLysAsn GluAspThr AlaThr T_rrPhe CysAlaArg TrpValPro GlyThrTyr AlaMetAsp TyrTrp GlyGln GlyThrSer ValThrVal SerSer (2) INFORMATION SCR SEQ ID ~IC:15:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 138 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE, TYPE: prctein ( i:~ ) FEATURE<br class="style-scope patent-text">(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /note= "Can be Ala or Asp"<br class="style-scope patent-text">( i:t ) FEATURE<br class="style-scope patent-text">(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFGRMATICN: /note= "Can be Asn or Thr"<br class="style-scope patent-text">(:ci) SEQUENCE DESCRIPTION: SEQ ID N0:15:<br class="style-scope patent-text">     Met Xaa Trp Val Trp Xaa Leu Leu Phe Leu Met Ala Ala Ala Gln Ser Ile Gln Ala Gln Ile Gln Leu 'lal G1n Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn Trp '~lal Lys Gln Ala Pro Gly Lys Gly Leu ~~ ~FNDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> CA 02266341 1999-03-19 , ~; ~ . ;,; , _ a ~ ..<br class="style-scope patent-text">_ , ,. .. . i -74.19-Lys Trp Met Gly Trp Ile Rsn Thr Lys Ser Gly Glu Pro Thr Tyr Ala 50 55 0'0 G1u Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Rla Ser a5 70 75 Thr Ala Asn Leu Gln Ile Lys Asn Leu Lys Asn Glu Asp Thr Rla Thr Tyr Phe Cys Aia Arg Trp Val Pro Gly Thr Tyr Ala Met asp Tyr Trp 95 l00 105 Gly Gln Gly Thr Ser Va1 Thr Val Ser Ser (2) INFORMATION FOR SEQ ID ~lC:lo':<br class="style-scope patent-text">(i) SEQUENCE CHRRACTERT_STT_CS:=<br class="style-scope patent-text">(A) LENGTH: 411 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNR<br class="style-scope patent-text">i i:t ) FEATURE<br class="style-scope patent-text">(R) NAME/:CEY: CDS<br class="style-scope patent-text">(B) LCCATICN: 31..411 (iYj FEATURE:<br class="style-scope patent-text">(A) NAME/:CEY: sig_peptide (B) LOCATION: 31. 90 (xi)                    SEQID                         <br class="style-scope patent-text">     SEQUENCE                       N0:16:                        <br class="style-scope patent-text">     DESCRIPTICD1:                                                <br class="style-scope patent-text"> <br class="style-scope patent-text"> ATTT.~r~.TTG      RTATCTCCTT                G                          54 AGGTCTCGAG                AGT                        <br class="style-scope patent-text">     RT                  GTG                        <br class="style-scope patent-text">  CTC                        <br class="style-scope patent-text">     ACT                        <br class="style-scope patent-text">     CAG                <br class="style-scope patent-text">     GTC                        <br class="style-scope patent-text">     CTG   <br class="style-scope patent-text"> <br class="style-scope patent-text"> Me t  r Se Val Leu Thr Gln 'Tal Leu Ala LeuLeuLeu LeuTrpLeu ThrGlyAlaArg CysAsp IleGlnMet ACT CAGTCTCCA TCCTCCCTA T.CTGCATCTGTG GGAGAC AGAGTCRCC    150 Thr G1nSerPro SerSerLeu SerAlaSerVal G1yAsp RrgValThr Ile ThrCysArg AlaSerGly AsnIleHisAsn TyrLeu AlaTrpTyr Gln GlnLysGln GlyLysSer ProG1nLeuLeu ValTyr AsnAlaLys Thr LeuAlaSer GlyValPro SerArgPheSer GlySer GlySerGll ~,~,E~IDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> .<br class="style-scope patent-text">  Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe G1~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ser His T,rr Cys Gln His Phe Trp Thr Thr Pro Trp Thr Phe G1y Gly 85 90 95 _~?0 GGC ACC AAG CTG GAA ATC AAA all Gly Thr Lys Leu Glu Ile Lys (2) INFORMATION FOR SEQ ID NG:17:<br class="style-scope patent-text">(i) SEQUENCE CHAR?.CTERIST_ICS:<br class="style-scope patent-text">(A) LENGTH: 127 amino acids (B) TYPE: amino acid (D) TOPOLOGY: 1i.~.ear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:<br class="style-scope patent-text">  Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr Gly Ala .-1rg Cys Asp I1e Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly As~:<br class="style-scope patent-text"> <br class="style-scope patent-text">  I1e His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu 'Jal Tyr Asn Ala Lys Thr Leu Ala Ser G1y Val Pro Ser 45 50 55 '00 Arg Phe Ser G1_r Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp Thr Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys (2) INFORMATION FOR SEQ ID N0:18:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 417 base pairs (B) TYPE: nucleic acid (C) STRADIDEDNESS: double (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE: cDDIA<br class="style-scope patent-text">(ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: CDS<br class="style-scope patent-text">(B) LOCATION: 1..417 rT<br class="style-scope patent-text">' -:'~~:;~~C., ':NEf r -~~.~ 1-(ix) FEATURE:<br class="style-scope patent-text">(A) NAME/KEY: sic peptide (B) LOCATION: 1..o'0 l:~i? SEQUED1CE DESCRIPTION: SEQ ID N0:'_9:<br class="style-scope patent-text">  ATG AGTGTGCTC ACTCAGGTC CTGGCGTTGCTG CTGCTG GG CTTACa   43 T                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> Met SerValLeu ThrGlnVal LauA1aLeuLau LeuLeu TrpLeuThr _  .._..':JT~..r..~..  _  '1T~..'... ~  _  _,._~~ .-__  _ _ Gly _  ArgCys G1n_  __  _  ValGl:~Ser ~.._   Glu_  Lys _            IleGln _            Gly_      Leu Ala                 Leu             Ser Lys ProGlyAla SerValLys IleSerCysLys RlaSer G1yTyrThr TTC ACARACTAT GGARTGRAC T~aGGTGCGACAG GCTCCR GGACAAGGT   192 Phe ThrRsnTyr GlyMetAsn TrpValArgGln RlaPro GlyGlnG1_;   <br class="style-scope patent-text"> <br class="style-scope patent-text"> Leu GluTrpMet ~:~ly:TrpIle RsnThrLysSer GlyG1u ProThrTyr =!5              50              55               60 Ala GluGluPhe LysGlyArg PheValPheSer Leu.aspThrSerVal 0'S             70               75 ACC ACTGCCTAT TTGCAGATC AGCRGCCTCAAA GCTGAG GACACGGCT   33a' Thr ThrAlaTyr LeuGlnIle SerSerLeuLys AlaGlu AspThrRla Val TyrPheCys AlaArgTrp ValProGlyThr TyrAla MetAspTyr TGG GGTC?.AGGA ACCACGGTC ACCGTCTCCTCA   417 Trp GlyGlnGly ThrThrVal ThrValSerSer (2) INFORMATION       FORSEQID  C:19:                            <br class="style-scope patent-text">     PI                                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> (i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 139 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (:~i) SEQUENCE DESCRIPTI01'I: SEQ ID D10:19:<br class="style-scope patent-text">  Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr G1y Ala Arg Cys Gln Ile Gln Leu Val G1n Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr ( CA 02266341 1999-03-19 ., -7~4.22-Phe Thr Asn T_Jr Gly Met Asn Trp Val Arg Gln Ala Pro G1y Gln Gly Leu G1u Trp Met Gly Trp Ile Asn Thr Lys Ser Gly Glu Pro Thr Tyr Ala Glu G1u Phe Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val 0'S 70 75 m~ r mv, ~ n_, , m.". r e,_ r=, ., r, o cc,- car r o,,_ r ..c a_, q r_1 ,y ~_~.. m~. ,. n,, , _ _ _.. _ _90 _ _. 85 _ : _ _ Val T_rr Phe Cys Ala Arg Trp 'Jal Pro Gly Thr T_rr Ala Met Ash Tyr Trp Gly Gln Giy Thr Thr Val Thr Va1 Ser Ser !2) INFORI~.ATIOD1 FOR SEQ ID V0:20:<br class="style-scope patent-text">!i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 447 base pairs (B) TYPE: nucleic acid (C) ST.R~~IDEDNESS: double (D) TOPOLCG'1: linear (ii; MOLECULE TYPE: cDNA<br class="style-scope patent-text">( i:~ ) FEATURE<br class="style-scope patent-text">(A) ~IAME/KEY : CDS<br class="style-scope patent-text">(B) LOCATION: 31..447 (ix) FEATURE:<br class="style-scope patent-text">(?.) NAME/KEY: sig_oeptide (B) LOCATION: 31. 90 (:~i)SEQUENCE                SEQ ID                       <br class="style-scope patent-text">     DESCRIPTIODf:                    N0:20:            <br class="style-scope patent-text"> <br class="style-scope patent-text"> GCTTGCTAGC                 AGT                       <br class="style-scope patent-text">     AT             GTG                       <br class="style-scope patent-text">     CTC                       <br class="style-scope patent-text">     ACT                       <br class="style-scope patent-text">     CAG                       <br class="style-scope patent-text">     GTC       <br class="style-scope patent-text">     CTG                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> Me  t      Leu Ser    Thr 'lal    Gln Val Leu CAG           <br class="style-scope patent-text"> <br class="style-scope patent-text"> AlaLeu LeuLeuLeu TrpLeuThrGly AlaArg CysGlnIle    Leu G1n AAG           <br class="style-scope patent-text"> <br class="style-scope patent-text"> ValGln SerG1yAla GluValLysLys ProGly AlaSerVal    I1e Lys TCCTGC AAGGCTTCT GGGTATACCTTC ACAP.ACTATGGAATG    TGG   198 AAC    <br class="style-scope patent-text"> <br class="style-scope patent-text"> SerCys LysAlaSer GlyTyrThrPhe ThrAsn TyrGlyMet    Trp Asn ATA           <br class="style-scope patent-text"> <br class="style-scope patent-text"> ValArg GlnAlaPro GlyGlnGlyLeu GluTrp MetGlyTrp    Asn Ile ( CA 02266341 1999-03-19 - ~ . ~, ., , , -"<br class="style-scope patent-text">- ,,. ,) ..<br class="style-scope patent-text">-74.23-ACCRAG RGTGGAGAG CCRACATAT GCTGAAGAG TTCRAGGGR CGGTTT   29~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> ThrLys SerGlyGlu ProThrTyr AlaG1uGlu PheLysGly ArgPhe 55              00               0'S              <br class="style-scope patent-text"> <br class="style-scope patent-text"> ThrPhe ThrLeuRsp ThrSerThr SerThrRla TyrLeuGiu IleRrg SerLeu RrgSerasp AspThrRla ValTyrPhe CysRlaRrg TrpVal CCTGGG ACCTATGCC ATGGRCTAC TGGGGTCAR GGAACCRCG GTCRC.C  -I38 ProGiy ThrTyrAla MetaspTyr TrpGlyGln G1_rThrThr ValThr 105              1l0              115 GTCTCC TC.a        -I.I7 ValSer Ser (2) INFORMATION FOR SEQ ID V0:21:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(R) LE:dGTH: 139 amino acids (B) TYPE: amine acid (D) TOPOLOGY: _inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTT_ON: SEQ ID N0:21:<br class="style-scope patent-text">  Met Szr Val Leu Thr Gln Vai ~au Rla Leu Leu Leu Leu Trp Leu Thr G1=J Ala Arg Cys Gln Ile Gln Leu Val Gln Ser Gly Rla Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Rla Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Arg Gln A13 Pro Glyr G1n Gly 30 35 ~IO<br class="style-scope patent-text">   Leu Glu Trp Met Gly Trp Ile Asn Thr Lys Ser Gly Glu Pro Thr Tyr Rla Glu Glu Phe Lys Gly Arg Phe Thr Phe Thr Leu Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu I1e Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Arg Trp 'Jal Pro Gly Thr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr 'Jal Thr Val Ser Ser I2) INFORMATION FOR SEQ ID M0:22:<br class="style-scope patent-text">  P~MEI~1DED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ ~ , "<br class="style-scope patent-text">,, . , ., ', , ,.. , ,~ ~ ,.,' ..<br class="style-scope patent-text">-74. 24-(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDN.a ..- ~ .. ~ ~. . . ~ _ .~.. ',_ ..- - - _ .,.. ~ . ... =. x _ ~ I _. _ _. .<br class="style-scope patent-text">     D1NNNNNGAP.T TCRCTGGATG GTGGGAAGAT GGA 33 (2) IRFORMATION FOR SEQ ID ~fC:23:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">lA) LENGTH: i2 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUErICE DESCRIPTION: SEQ ID N0:23:<br class="style-scope patent-text">     PfDINND1NGART TCAYCTCCAC ACACAGGRRC CRGTGGATAG AC<br class="style-scope patent-text">;2IDfFCRMATiON FOR SEQ iD '10:24:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STR.ANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE: cDDIA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTI~~N: SEQ ID N0:24:<br class="style-scope patent-text">     ACTAGTCGAC ATGRGTGTGC TCACTCAGGT CCTGGSGTTG 4p (2) INFORMATION FOR SEQ ID N0:25:<br class="style-scope patent-text">(i) SEQUENCE CHARACTEF.ISTICS:<br class="style-scope patent-text">(A) LENGTH: 88 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE T'!PE: cDDIA<br class="style-scope patent-text">n' y~! ~S~ SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ., ' .<br class="style-scope patent-text">~<br class="style-scope patent-text">..<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:25:<br class="style-scope patent-text">  TAGGGAGrICC CAAGCTTGGT .~CC.~1T.TTAA ATTGATATCT CCTT_AGGTCT CGr~GTCTCTA 60 GATaACCGGT CAATCGATTG GGATTCTT 88 (2) IDIFGR.'~IATIODI FOR SEQ ID NO:2'o:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 88 base pairs (B) TYPE: nucleic acid ,_~~..1~ -y,n :..W~.=u~.Jir... ~.:~J: 3~.:.yic (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:<br class="style-scope patent-text">  GACACTATAG AATAGGGCCC TTCCGC~GTT GGATCCAACA CGTGAAGCTA GCAAGCGGCC o0 GC.~IG~?~TTC C.~ATC:zATTG ACCGGTTA<br class="style-scope patent-text">ss 2) INcORM~T_ION FOR SEQ ID ?1C:27:<br class="style-scope patent-text">( i ; S EQUE:'ICE CHARACTERI STICS<br class="style-scope patent-text">(A) LENGTH: 41 base pairs (B) TYPE: nuclei= acid (C) sTRADIDEDNESS: single ,'D) TOPOLOGY: linear ( i i ) MOLECULE TYPE : cDDIA<br class="style-scope patent-text">  SEQUENCE DESCRIPTT_CN: SEQ ID N0:27:<br class="style-scope patent-text"> <br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID N0:28:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(:ti) SEQUENCE DESCRIPT.IOP1: SEQ ID N0:28:<br class="style-scope patent-text"> <br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID CI0:29:<br class="style-scope patent-text">(i) SEQUEDlCE CHARACTERISTICS:<br class="style-scope patent-text">  AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,. : :.. ' ' ~ , . , , ~~ , . . " ..<br class="style-scope patent-text">-74.26-(Aj LENGTH: 32 base aairs (B) TYPE: nucleic acid (C) STRANDEDNESS: si:.gle (D) TOPOLOGY: linear ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(:ti) SEQUENCE DESCRIPTT_ON: SEQ ID N0:29:<br class="style-scope patent-text">  CCGGGCCTCT CAAAAAAGGG AAA~rIAGCA TG 32 (2) INFORMATION FOR SEQ ID :10:30:<br class="style-scope patent-text">(i) SEQUENCE CH.~RACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">  SEQUENCE DESCRIPTION: SEQ ID N0:30:<br class="style-scope patent-text">  CTTTTTTTCC CTT_TTTTGAG AGGC 24 (=) INFORMATION FOR SEQ _TD A0:31:<br class="style-scope patent-text">) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 74 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(~i) SEQUENCE DESCRIPTT_ON: SEQ ID N0:31:<br class="style-scope patent-text"> <br class="style-scope patent-text">  GAGATGGAGT TTGG<br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID D10:32:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 72 base pairs (B) T'1PE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE: cD~IA<br class="style-scope patent-text">'."~aENDEO SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ' ., "<br class="style-scope patent-text">o , . . ' ' , ', ' ~' _ ' ~ ~ ~<br class="style-scope patent-text">~ ' w ~ ..<br class="style-scope patent-text">-74. 27-(:;i) SEQUENCE DESCRIPTION: SEQ ID N0:32:<br class="style-scope patent-text">C G C CAAAC T C CAT CT CAAAA ATAAAATAAA ATAAAAT TAA AP.AP.ARAG GT TAC T CT G G <br class="style-scope patent-text"> <br class="style-scope patent-text">  ATTCGAAGCC GG<br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID NO:33:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERT_STICS:<br class="style-scope patent-text">(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid '"=A~O_D.~C:_'_.. ___ , _ (D) TOPOLOGY: linear.<br class="style-scope patent-text">(ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(:;i~ SEQUENCE DESCRIPTION: SEQ ID N0:33:<br class="style-scope patent-text"> <br class="style-scope patent-text">(2) INFORMATION FCR SEQ ID NC:34:<br class="style-scope patent-text">. iii SEQUE~1CE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) 'TCPCLOGY: linear __, MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:34:<br class="style-scope patent-text">  CTCGAGGGGT CACCACGCTG CTGA 2~<br class="style-scope patent-text">(2) INIFORMATION FOR SEQ ID D10:35:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(~i) SEQUENCE DESCRIPTION: SEQ ID N0:35:<br class="style-scope patent-text"> <br class="style-scope patent-text">( 2 ) INJFORMATIODI FOR SEQ ID rf0: 36:<br class="style-scope patent-text">(i) SEQUEDICE CHARACTERISTICS:<br class="style-scope patent-text">(A) LET1GTH: 21 base pairs ~B) T'LPE: nucleic acid "';tE',lDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> CA 02266341 1999-03-19 _ t a n t ~ . w v v _ ~ n ~ w w ~ ~ ,t a t ~ 7 0 n w ' w - o ~ 1 t ~ ~ s ~ ~ 9 w a ~ 1 - w ._ ~ ~ v v ~ 1 . _ , . . ~ " ~ s v (C) STRA:'VDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECU~E TYPE: cDN.a ) SEQUENCE DESCRIPTION: SEQ ID N0:36:<br class="style-scope patent-text">  CACCCAGCCT GTGCCTGCCT G ?1 (2) INFORMATION FOR SEQ ID PIC:37:<br class="style-scope patent-text">(i) SEQUENCE CHtIRACTERTSTT_CS:<br class="style-scope patent-text">(A) LEDIGTH: 30 base pairs (B) TYPE: nucleic ac'_d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUE:1CE DESCRIPTION: SEQ ID N0:37:<br class="style-scope patent-text">  CGATTGGAAT TCT.TGCGGCC GCTTGCTAGC 30 (2) INFORMATION FOR SEQ ID NO:38:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(P.) LE:1GTH: 80 base pairs (g) TYPE; nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : cDDIA<br class="style-scope patent-text">(:~i) SEQUENCE DESCRIPTION: SEQ ID NC:38:<br class="style-scope patent-text">  CTTGCGGCCG CTTGCTAGCA TGGATTGGGT GTGGRACTTG CTATTCCTGA TGGCAGCTGC o0 CC.~AAGTATC CAAGCACAGA 80 (2) IDIFORMATIODI FOR SEQ ID DI0:39:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LEDtGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE T'CPE: cDNA<br class="style-scope patent-text">(xi) SEQUErICE DESCRIPTIOtt: SEQ ID P10:39:<br class="style-scope patent-text">n ;a r :4 ,. o~.~~:., .7('. ~!<br class="style-scope patent-text"> <br class="style-scope patent-text">  CA 02266341 1999-03-19 ..<br class="style-scope patent-text">y . . ., -74.29-CTTGACTGTT TCTCCAGGCT TCTTCAGCTC AGGTCCAGAC TGCACCAACT GGATCTGTGC n0 (2) INFORMATION FOR SEQ ID N0:40:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MULECULI'TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTT_ON: SEQ ID N0:40:<br class="style-scope patent-text"> <br class="style-scope patent-text">  AACTATGGAA TGAACTGGGT g0 (2) INFORMATION FOR SEQ ID N0:41:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDDIA<br class="style-scope patent-text">(~i) SEQUENCE DESCRIPTION: SEQ ID N0:41:<br class="style-scope patent-text"> <br class="style-scope patent-text">  TCATTCCATA GTTTGTGAAG g0 (2) INFORMATION FOR SEQ ID N0:42:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRADIDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(~i) SEQUEP1CE DESCRIPTIGPI: SEQ ID N0:42: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) IL~IFORMATION FOR SEQ ID b0:43:<br class="style-scope patent-text">  AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> . .<br class="style-scope patent-text">y -74.30-(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNR<br class="style-scope patent-text">(xi&gt; SEQUENCE nESCRIPTION: SF_O TD nln:a,3;<br class="style-scope patent-text">  TCCTCATTTT TGAGGTTCTT GATCTGCe~e~A TTGGCAGTGC TGGCAGAGGT TTCC.~IGaG 60 AAGGCAAACC GTCCCTTGAA g0 (2) INFORMATION FOR SEQ ID N0:44:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:44:<br class="style-scope patent-text"> <br class="style-scope patent-text">  TGGGRCCTAT GCCATGGACT g0 (2) INFORMATION FOR SEQ ID N0:45:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(R) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDDIA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:45: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID t10:46:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRAPIDEDNESS: single (D) TOPOLOGY: linear AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> -7~.31-(ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xil SEQUENCE DESCRIPTION: SEQ ID N0:46:<br class="style-scope patent-text">    GGGAAGACGG ATGGGCCCTT GGTGCTAGC ?9 (2) INFORMATION FOR SEQ ID N0:47:<br class="style-scope patent-text">i 1 SF~'.!,TF''~If'.R !'HARAC'TFRT PTT,~S<br class="style-scope patent-text">(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:47:<br class="style-scope patent-text"> <br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID N0:48:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 79 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:48: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:49:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUEDfCE DESCRIPTIOD1: SEQ ID N0:49:<br class="style-scope patent-text"> <br class="style-scope patent-text">' '-';,.~EJ SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> -74.3 ? _ (2) INFORMATION FOR SEQ ID N0:50:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:50: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:51:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLGGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:51:<br class="style-scope patent-text">  TATAGACCAG GAGCTGAGGA GATTT:'CCCT GTTTCTGCTG ATACCATGCT AAA'_'AATTGT 60 GAATATTCCC ACTTGCTC 7g (2) INFORMATION FOR SEQ ID N0:52:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (H) TYPE: nucleic acid (C) STRAD1DEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUED1CE DESCRIPTION: SEQ ID N0:52:<br class="style-scope patent-text">  AAATCTCCTC AGCTCCTGGT CTATAATGCA AAAACCTTAG CAGATGGTGT GCCATCAAGG FO<br class="style-scope patent-text"> <br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID t10:53:<br class="style-scope patent-text">(i) SEQUEPICE CHARACTERISTICS:<br class="style-scope patent-text">  SS,y~~.~t(1 !:~~:=f CA 02266341 1999-03-19 , ,.<br class="style-scope patent-text">-74.3 3-(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:53: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FCR SEQ ID N0:54:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:54: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:55:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 81 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTIOD1: SEQ ID N0:55: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:56:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRADiDEDNESS: single (D) TOPOLOGY: linear AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ( CA 02266341 1999-03-19 -74.34-(ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:56:<br class="style-scope patent-text"> <br class="style-scope patent-text">(2) INFORMATION FOR SEQ ID N0:57:<br class="style-scope patent-text">1 SEQUENCE CIiRRP.CTEFr_STICS:<br class="style-scope patent-text">(A) LENGTh: bU base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:57:<br class="style-scope patent-text"> CTTGCGGCCG CTTGCTAGCA TGAGTGTGCT CACTCAGGTC CTGGCGTTGC TGCTGCTGTG o'0 (2) ID1FORMATION FGR SEQ ID N0:58:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRAD1DEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:58: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:59:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRAtdDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : cDDIA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:59:<br class="style-scope patent-text"> A~'ENDED SHEET<br class="style-scope patent-text"> <br class="style-scope patent-text">. CA 02266341 1999-03-19 . . .. , -74.3 5-GAGCTGAAGA AGCCTGGAGC CTCAGTC.~-lG ATCTCCTGCA AGGCTTCTGG GTATaCCTTC 60 (2) INFORMATION FOR SEQ ID N0:60:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERT_STICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(Yi) SEQUENCE DESCRIPTION: SEQ ID N0:60:<br class="style-scope patent-text">  TGGTGTTTAT CCAGCCCATC CACTCT.~C CTTGTCCTGG AGCCTGTCGC ACCCAGTTCA 60 (2) INFORMATION FOR SEQ ID N0:61:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:61:<br class="style-scope patent-text">  TAGAGTGGAT GGGCTGGATA AACACC?AGA GTGGAGAGCC AACATATGCT GAAGAGTTCA 60 (2) INFORMATION FOR SEQ ID N0:62:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE: cDPIA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTIODi: SEQ ID N0:62: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) II'tFORMATIOD1 FOR. SEQ ID P10:63:<br class="style-scope patent-text">,~r,~E~.~ ~~~ sN~~r -7~.36-(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">  SECL'r"drc nce~~r~TDTT/1AT: SF~ T!-! rln.~~: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID NO: n4:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(:ti) SEQUENCE DESCRIPTION: SEQ ID N0:64:<br class="style-scope patent-text"> <br class="style-scope patent-text">  ATAGGTCCCA GGTACCCATC 8p (2) IDIFORMATION FOR SEQ ID N0:65:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (H) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:65: .<br class="style-scope patent-text"> <br class="style-scope patent-text">  AGAAGCCTGG AGCCTCAGTC g0 (2) IN FORMATIOD1 FOR SEQ ID P10:66:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRAP1DEDNESS: single (D) TOPOLOGY: linear AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> . CA 02266341 1999-03-19 -74. 3 7-(ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(:ti) SEQUENCE DESCRIPTION: SEQ ID N0:66:<br class="style-scope patent-text"> <br class="style-scope patent-text"> AGGGACGGTT TACCTTCACC g0 Q21 INFOR.M_ATION FOR. SEO _TD N0:67:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 80 base pairs !B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:67:<br class="style-scope patent-text"> TCAGATCTGA GGCTCCTGAT CTCCAAATAG GCAGTGCTCG TAGAGGTGTC C.~AGGTG?.AG 60 GTARACCGTC CCTTGr'~ACTC 90 2 ) IT1FORMATION FOR SEQ ID N0: 68 (i) SEQUEDJCE CHARACTERISTICS:<br class="style-scope patent-text">!A) LENGTH: 80 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ID) TOPOLOGY: linear (ii) MOLECULE TYPE: cDDIA<br class="style-scope patent-text">(:~i) SEQUEDJCE DESCRIPTION: SEQ ID N0:68: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:69:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE: cDDtA<br class="style-scope patent-text"> AMENDED SHEET<br class="style-scope patent-text"> <br class="style-scope patent-text">. CA 02266341 1999-03-19 -74.38-(xi) SEQUENCE DESCRIPTION: SEQ ID N0:69: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID N0:70:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid ,.~ , ~.. ~.,:-;~.r~~ . ~; ~,.. , (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:70:<br class="style-scope patent-text"> GTCTCCATCC TCCCTATCTG CATCTGTGGG AGACAGAGTC ACCATCACAT GTCGrIGCAAG 60 (2) INFORMATION FOR SEQ ID N0:71:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRADJDEDNESS: single (D) TOPOLOGY: linear (iij MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xij SEQUEDICE DESCRIPTION: SEQ ID N0:71: <br class="style-scope patent-text"> <br class="style-scope patent-text"> (2) INFORMATION FOR SEQ ID t10:72:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 78 base pairs (B) TYPE: nucleic acid , (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : cDDIA<br class="style-scope patent-text">(xi) SEQUEIICE DESCRIPTION: SEQ ID I10:72:<br class="style-scope patent-text"> <br class="style-scope patent-text"> CTGCCACTGA R.CCTT ~AT 78 ,~PJIF~~dGE~ JNc'~T <br class="style-scope patent-text"> <br class="style-scope patent-text"> . CA 02266341 1999-03-19 ' -s . : : , ,.<br class="style-scope patent-text">_ , , ...<br class="style-scope patent-text">-74.39-(2) INFORMATI~~N FOR SEQ ID A0:73:<br class="style-scope patent-text">iii SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRAD1DEDNESS: single D? TOPOLOGY: nct rele~Jant (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0:73:<br class="style-scope patent-text"> Tyr Pro Arg Ser Ile Tyr Ile Arg Arg Arg His Pro Ser Fro Ser Lau Thr Thr (2) INFORMATION FOR SEQ ID N0:7-J:<br class="style-scope patent-text">i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">~:A; LENGTH: 15 amino acids (B; TYP~: amino acid C) STRaNDEDNESS: s'_ngle :D) TOPOLOGY: not relevant ;ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTIOPJ: SEQ ID N0:74:<br class="style-scope patent-text"> G1y Gl,r Ser Gly Ser G1=a G1y Ser Gly Ser Gly Gly Ser Gly Ser ( 2 ) ID1FORMATIOD1 FOR SEQ ID N0: 75 ;i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 107 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide (:ti) SEQUENCE DESCRIPTT_ON: SEQ ID N0:75:<br class="style-scope patent-text"> Asp Ile Gln Met Thr Gin Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr ~Caa Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln G1y Lys Ser Pro Gln Leu Leu 'Jal AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,.<br class="style-scope patent-text">. .. ~.<br class="style-scope patent-text">~ - , f ' ~ f Tyr Asn Ala Xaa Thr Lau Ala Asp Gl.,r Val Pro Ser Arg Phe Ser G1_~<br class="style-scope patent-text"> <br class="style-scope patent-text">  Ser Gly Ser Gly Thr G1n Xaa Ser Leu Xaa Ile Asn Ser Lau Gln Pro G1u asp Phe :;ly Ser Xaa Tyr Cys Gln His Phe Trp Xaa Xaa =c ':rp Thr P.he G1_,r Gly G1y Thr Lys Leu Glu Ile Lys l00 105 (2) INFORMATION FOR SEQ ID N0:7o':<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 107 amizc acids (B) TYPE: amino acid (C) STRANDEDNESS: single ~,'D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide (~i) SEQUENCE DESCRIPTTON: SEQ ID N0:76:<br class="style-scope patent-text">  Asp Ile Gln Met Thr Gln Ser Pro Aia Ser Leu Ser Ala Ser 'lal G1~!<br class="style-scope patent-text"> <br class="style-scope patent-text">  Glu Thr Va1 Thr Ile Thr Cys Arg Ala Ser G1_! Asn Ile His Asn Tyr .0 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala L;ls Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Xaa Ile Asn Ser Leu Gln Pro '05 70 75 80 Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp Thr Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leti Glu Ile Lys (2) INFORMATION FOR SEQ ID N0:77:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 107 amino acids (B) TYPE: amino acid (C) STRAP1DEDNESS: single (D) TOPOLOGY: not relevant (ii) MOLECULE T'1PE: peptide (ai) SEQUEtICE DESCRIPTION: SEQ ID r~G:77:<br class="style-scope patent-text">  AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> CA 02266341 1999-03-19 ,. _, - , ,", ~ a a w n , ~ ~ . , ,e n n - . - . ., ~ s ~ a ~ ~ ~ a v " ' ', ee -74.41-Asp Ile Gln Met Thr Gln Ser Pro Xaa Ser Leu Ser Ala Ser Val Gly Xaa Xaa Val Thr Xaa Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Xaa Thr Leu Ala Xaa Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Xaa Xaa Xaa Leu Xaa Ile Xaa Ser Leu Gln Pro Glu .asp Phe Gly Ser Xaa Tyr Cys Gln His Phe Trp Xaa Xaa Pro Trp Thr Phe Gi_r Gly Gly Thr Lys Leu Glu Iie Lys (2) iNFORMATICN FGR SEQ ID N0:73:<br class="style-scope patent-text">(i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 119 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPGLOGY: linear (ii) MOLECULE TYPE: cDNA<br class="style-scope patent-text">(xi) SEQUENCE DESCRIPTION: SEQ ID N0:78:<br class="style-scope patent-text"> G1n Ile Gln Leu Val Gin Ser Gly Xaa Glu Xaa Lys Lys Pro Gly Ala Ser Val Lys I1e Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Lys Ser Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Xaa Phe Xaa Leu Asp 'rhr Ser Xaa Ser Thr Ala Tyr Leu Xaa Ile Xaa Ser Leu Xaa Xaa Xaa Asp Thr Ala Val Tyr Phe Cys Ala Arg Trp Val Pro Gly Thr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ( 2 ) INFORMATION FOR SEQ ID D10: 79:<br class="style-scope patent-text"> HMENDED SN'~~T <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ t a (i) SEQUENCE CHARACTERISTICS:<br class="style-scope patent-text">(A) LENGTH: 119 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide ._) ..E;~UE.;,::. LE::,.,.,____:'.:;: SEQ IL .;C:._.<br class="style-scope patent-text"> Gln I1e Gln Leu Val Gln Ser Gly Pro G1u Leu Lys Lys Pro Giy Glu Thr Val Lys Ile Ser C;rs Xaa Ala Ser Gly Tyr Thr Phe Thr Xaa Tyr Gly Met Asn Trp Val Lys Gln Ala Pro G1y Lys Gly Leu Lys Trp Met G1y Trp Ile Asn Thr :~aa Ser Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 .,., 0'0 Lys G1y Arg Phe Xaa Fhe Ser Leu Glu Thr Ser Ala Ser Thr Ala Xaa 05 ~0 75 80 Lau Gln Ile Xaa Asn Xaa '.~aa Asn Glu Asp Xaa Ala Thr Tyr Fhe Cys Ala Arg Trp Va1 Pro G1_r Thr Tyr Ala Met Asp Tyr Trp G1y Gin Gly 100 l05 110 Thr Ser Val Thr Val Ser Ser (2) INFORMATION FOR SEQ ID 10:80:<br class="style-scope patent-text">(il SEQUENCE CHARACTERT_STICS:<br class="style-scope patent-text">(A) LENGTH: 1l9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide (~i)SEQUENCE                 <br class="style-scope patent-text">    DESCRIPTION:                                           <br class="style-scope patent-text"> SEQ                                            <br class="style-scope patent-text">    ID                     <br class="style-scope patent-text">    N0:80:                                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> GlnI1e GlnLeuVal GlnSer    ProG1uLeu LysLy5 ProGlyGlu Gly ThrVal LysIleSer CysXaa    SerGlyTyr ThrPhe ThrAsnTyr Ala GlyMet AsnTrpVal LysGln    ProGlyLys GlyLeu LysTrpMet Ala GlyTrp IleAsnThr LysSer    GluProThr TyrAla GluG1uPhe Gly AMENDED SHEET <br class="style-scope patent-text"> <br class="style-scope patent-text"> ..,.<br class="style-scope patent-text">-74.43-L~_rs Gly Arg Phe Xaa Phz Ser Leu Glu Thr Ser Ala Ser Thr A'_a :{aa '05 70 75 90 Leu Gln I1 a Lys Asn Xaa Xaa Asn Glu Asp Thr Ala Thr T~:-r Phe Cy;s 95 90 a5 Ala Arg Trp Val Pro Gly Thr Tyr Ala Met Asp Tyr Trp G1_ Gln Gly 100 10S 1,~J<br class="style-scope patent-text">wu Jai ~J~31 wi ~~ul~. JC~i :JC~i (2) I:IFORMATT_ON FOR SEQ ID NC:31:<br class="style-scope patent-text">(i) SEQUENCE CHP_RACTERISTICS:<br class="style-scope patent-text">(A) LENGT~i: 119 amino acids (3) TYPE: amine acid (C) STRANDEDNESS: single (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide (xi) SEQUE.1CE DESCRIPTION: SEQ ID N0:81: , Gln Ile Gln Leu Val Gin Ser G1y Xaa Glu Xaa Lys Lys Pro Gly Xaa Xaa Val Lys Ile Ser Cys Xaa Ala Ser Gly Tyr Thr Phe Thr Xaa T_rr Gly Met Asn Trp Val Xaa Gln Ala Pro Gly Xaa Gly Leu Xaa Trp ?~.et Gly Trp Ile Asn Thr Xaa Ser Gly Glu Pro Thr Tyr Ala Give Glu ?'.:e Lys Gly Arg Phe Xaa Phe Xaa Leu Xaa Thr Ser Xaa Ser Thr Ala Xaa Leu Xaa Ile Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Ala Xaa Tyr Phe Cys Ala Arg Trp Val Pro Gly Thr Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 . 110 Thr Xaa Val Thr Val Ser Ser ~~~~1E~ IDE~ SHEST </div>
    </disclosure>
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(35)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM325314205" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <claim-statement class="style-scope patent-text"> What Is Claimed Is: </claim-statement>
    <div class="claim style-scope patent-text"> <div num="1" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. An immunologic molecule wherein said immunologic molecule is capable of binding to both (1) human and nonhuman circulating .alpha.2-antiplasmins and (2) human and nonhuman fibrin crosslinked .alpha.2-antiplasmins. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="2" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The immunologic molecule of claim 1, wherein said immunologic molecule is a chimeric antibody. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="3" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The immunologic molecule of claim 1, wherein said immunologic molecule is a humanized antibody. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="4" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The immunologic molecule of claim 1, wherein said immunologic molecule is an antibody fragment. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="5" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The immunologic molecule of claim 1, wherein said immunologic molecule is a monoclonal antibody. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="6" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The immunologic molecule of claim 1, wherein said immunologic molecule comprises amino acids 1 to 107 of SEQ ID NO:9 and amino acids 1 to 119 of SEQ ID NO:15. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="7" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The immunologic molecule of claim 1, wherein said immunologic molecule comprises amino acids 1 to 107 of SEQ ID NO:5 and amino acids 1 to 119 of SEQ ID NO:11. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="8" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The immunoiogic molecule of claim 1, wherein said immunologic molecule comprises amino acids 1 to 107 of SEQ ID NO:7 and amino acids 1 to 119 of SEQ ID NO:13. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="9" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. The immunologic molecule of claim 1, selected from the group consisting of (a) an immunologic molecule, wherein the CDR1 region of the light chain of said immunologic molecule comprises amino acids 26 to 32 of SEQ<br class="style-scope patent-text">     ID NO:75;<br class="style-scope patent-text">(b) an immunologic molecule, wherein the CDR2 region of the light chain of said immunologic molecule comprises amino acids 50 to 52 of SEQ<br class="style-scope patent-text">     ID NO:75;<br class="style-scope patent-text">(c) an immunologic molecule, wherein the CDR3 region of the light chain of said immunologic molecule comprises amino acids 91 to 96 of SEQ<br class="style-scope patent-text">     ID NO:75;<br class="style-scope patent-text">(d) an immunologic molecule, wherein the CDR1 region of the heavy chain of said immunologic molecule comprises amino acids 26 to 32 of SEQ<br class="style-scope patent-text">     ID NO:79;<br class="style-scope patent-text">(e) an immunologic molecule, wherein the CDR2 region of the heavy chain of said immunologic molecule comprises amino acids 53 to 56 of SEQ<br class="style-scope patent-text"> ID NO:79; and (f) an immunologic molecule, wherein the CDR3 region of the heavy chain of said immunologic molecule comprises amino acids 100 to 107 of SEQ ID NO:79. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="10" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The immunologic molecule of claim 1, selected from the group consisting of (a) an immunologic molecule, wherein the CDR1 region of the light chain of said immunologic molecule comprises amino acids 26 to 32 of SEQ<br class="style-scope patent-text">     ID NO: 76;<br class="style-scope patent-text">(b) an immunologic molecule, wherein the CDR2 region of the light chain of said immunologic molecule comprises amino acids 50 to 52 of SEQ<br class="style-scope patent-text">     ID NO:76; <br class="style-scope patent-text"> <br class="style-scope patent-text"> (c) an immunologic molecule, wherein the CDR3 region of the light chain of said immunologic molecule comprises amino acids 91 to 96 of SEQ<br class="style-scope patent-text">     ID NO:76;<br class="style-scope patent-text">(d) an immunologic molecule, wherein the CDR1 region of the heavy chain of said immunologic molecule comprises amino acids 26 to 32 of SEQ<br class="style-scope patent-text">     ID NO:80;<br class="style-scope patent-text">(e) an immunologic molecule, wherein the CDR2 region of the heavy chain of said immunologic molecule comprises amino acids 53 to 56 of SEQ<br class="style-scope patent-text">     ID NO:80; and (f) an immunologic molecule, wherein the CDR3 region of the heavy chain of said immunologic molecule comprises amino acids 100 to 107 of SEQ ID NO:80. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="11" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The monoclonal antibody of claim 5, wherein said monoclonal antibody is 77A3. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="12" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The monoclonal antibody of claim 5, wherein said monoclonal antibody is 49C9. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="13" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The monoclonal antibody of claim 5, wherein said monoclonal antibody is 70B11. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="14" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. A method of making the monoclonal antibody of claim 5 comprising:<br class="style-scope patent-text">(a) immunizing an animal with .alpha.2-antiplasmin or fragment thereof;<br class="style-scope patent-text">(b) fusing cells from the animal with tumor cells to make a hybridoma cell line;<br class="style-scope patent-text">(c) cloning the hybridoma cell line; <br class="style-scope patent-text"> <br class="style-scope patent-text"> (d) selecting for the monoclonal antibody capable of binding to both (1) human and nonhuman circulating .alpha.2-antiplasmins and (2) human and nonhuman fibrin crosslinked .alpha.2-antiplasmins; and (e) obtaining the monoclonal antibody. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="15" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. A hybridoma cell line which produces the monoclonal antibody of claim 5. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="16" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. The hybridoma cell line of claim 15, wherein said hybridoma cell line is ATCC Accession No. HB-12192. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="17" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. A method of making the hybridoma cell line of claim 15 comprising:<br class="style-scope patent-text"> <br class="style-scope patent-text">(a) immunizing an animal with .alpha.2-antiplasmin or fragment thereof;<br class="style-scope patent-text"> <br class="style-scope patent-text">(b) fusing the cells from the animal with tumor cells to make the hybridoma cell line; and (c) obtaining the hybridoma cell line which produces the monoclonal antibody capable of binding to both (1) human and nonhuman circulating .alpha.2-antiplasmins and (2) human and nonhuman fibrin crosslinked .alpha.2-antiplasmins. </div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div num="18" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. A nucleic acid molecule, selected from the group consisting of (a) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 107 of SEQ ID NO:5;<br class="style-scope patent-text">(b) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 107 of SEQ ID NO:7;<br class="style-scope patent-text">(c) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 107 of SEQ ID NO:9;<br class="style-scope patent-text">(d) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 107 of SEQ ID NO:75; <br class="style-scope patent-text"> <br class="style-scope patent-text"> (e) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 119 of SEQ ID NO:11;<br class="style-scope patent-text">(f) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 119 of SEQ ID NO:13;<br class="style-scope patent-text">(g) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 119 of SEQ ID NO:15; and (h) a nucleic acid molecule comprising a nucleotide sequence encoding for amino acids 1 to 119 of SEQ ID NO:79. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="19" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. A method for treating pulmonary embolism, myocardial infarction, or thrombosis in a patient comprising administering a therapeutically effective amount of an immunologic molecule of claim 1 to said patient. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="20" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">20. The method of claim 19, wherein said immunologic molecule is a monoclonal antibody. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="21" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">21. The method of claim 20, wherein said monoclonal antibody is 77A3. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="22" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">22. The method of claim 19, wherein said immunologic molecule is administered by continuous intravenous infusion or by bolus. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="23" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">23. A method of treatment for pulmonary embolism, myocardial infarction, or thrombosis in a patient which comprises co-administering to a patient in need of such treatment:<br class="style-scope patent-text"> <br class="style-scope patent-text">(a) a therapeutically effective amount of an immunologic molecule of claim 1; and (b) a therapeutically effective amount of a thrombolytic agent, wherein said immunologic molecule (a) is different from said thrombolytic agent (b), thereby treating said patient. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="24" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">24. The method of claim 23, wherein said immunologic molecule is a monoclonal antibody. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="25" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">25. The method of claim 24, wherein said monoclonal antibody is 77A3. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="26" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">26. The method of claim 23, wherein said thrombolytic agent is plasmin. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="27" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">27. The method of claim 23, wherein said thrombolytic agent is an anti-coagulant which inhibits fibrin. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="28" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">28. The method of claim 27, wherein said anti-coagulant is selected from the group consisting of heparin, hirudin and activated protein C. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="29" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">29. The method of claim 23, wherein said thrombolytic agent is an anti-coagulant which inhibits platelets. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="30" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">30. The method of claim 23, wherein said thrombolytic agent is a plasminogen activator. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="31" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">31. The method of claim 30, wherein said plasminogen activator is selected from the group consisting of streptokinase, prourokinase, urokinase, tissue-type plasminogen activator, staphylokinase, and vampire bat plasminogen activator. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="32" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">32. The method of claim 23, wherein both said immunologic molecule (a) and said thrombolytic agent (b) are provided to said patient by an intravenous infusion or by an intravenously injected bolus. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="33" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">33. The method of claim 23, wherein said patient is provided with a first bolus containing said immunologic molecule (a) and a subsequently administered second bolus containing said thrombolytic agent (b). </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="34" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">34. The method of claim 23, wherein:<br class="style-scope patent-text">(1) said immunologic molecule (a) is provided to said patient at a dose of between 3 to 600 nmole per kg of patient weight; and (2) said thrombolytic agent (b) is provided to said patient at a dose of between 0.01 to 3.0 mg per kg of patient weight. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="35" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">35. A kit useful for carrying out the method of claim 23, being compartmentalized in close confinement to receive two or more container means therein, which comprises:<br class="style-scope patent-text">(1) a first container containing a therapeutically effective amount of said immunologic molecule (a); and (2) a second container containing a therapeutically effective amount of said thrombolytic agent (b), wherein said immunologic molecule (a) is different from said thrombolytic agent (b). </div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (42)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE2532151C3/en"><a id="link" href="#" class="style-scope state-modifier">DE2532151C3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1975-07-18</span>
                    <span class="td style-scope patent-result">1979-06-13</span>
                    <span class="td style-scope patent-result">Biotest-Serum-Institut Gmbh, 6000 Frankfurt</span>
                    <span class="td style-scope patent-result">
  Antisenim for the quantitative determination of the breakdown products of fibrin and fibrinogen and process for its production
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NL7602846A/en"><a id="link" href="#" class="style-scope state-modifier">NL7602846A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1976-03-18</span>
                    <span class="td style-scope patent-result">1977-09-20</span>
                    <span class="td style-scope patent-result">Leuven Res &amp; Dev Vzw</span>
                    <span class="td style-scope patent-result">
  ANTIPLASMIN AND AN ANTI-SERUM AGAINST.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4273873A/en"><a id="link" href="#" class="style-scope state-modifier">US4273873A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1977-10-25</span>
                    <span class="td style-scope patent-result">1981-06-16</span>
                    <span class="td style-scope patent-result">Unitika Ltd.</span>
                    <span class="td style-scope patent-result">Preparation of antithrombogenic polymeric materials 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4245040A/en"><a id="link" href="#" class="style-scope state-modifier">US4245040A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1978-11-20</span>
                    <span class="td style-scope patent-result">1981-01-13</span>
                    <span class="td style-scope patent-result">Laurence Pilgeram</span>
                    <span class="td style-scope patent-result">Detection and measurement of circulating fibrin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4421735A/en"><a id="link" href="#" class="style-scope state-modifier">US4421735A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-04-17</span>
                    <span class="td style-scope patent-result">1983-12-20</span>
                    <span class="td style-scope patent-result">The Massachusetts General Hospital</span>
                    <span class="td style-scope patent-result">Radiolabeled diagnostic compositions and method for making the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPS57106626A/en"><a id="link" href="#" class="style-scope state-modifier">JPS57106626A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-12-22</span>
                    <span class="td style-scope patent-result">1982-07-02</span>
                    <span class="td style-scope patent-result">Teijin Ltd</span>
                    <span class="td style-scope patent-result">Cytotoxic protein complex and its preparation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4427646A/en"><a id="link" href="#" class="style-scope state-modifier">US4427646A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-04-02</span>
                    <span class="td style-scope patent-result">1984-01-24</span>
                    <span class="td style-scope patent-result">Research Corporation</span>
                    <span class="td style-scope patent-result">Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4455290A/en"><a id="link" href="#" class="style-scope state-modifier">US4455290A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-04-02</span>
                    <span class="td style-scope patent-result">1984-06-19</span>
                    <span class="td style-scope patent-result">Research Corporation</span>
                    <span class="td style-scope patent-result">Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2504010B1/en"><a id="link" href="#" class="style-scope state-modifier">FR2504010B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-04-15</span>
                    <span class="td style-scope patent-result">1985-10-25</span>
                    <span class="td style-scope patent-result">Sanofi Sa</span>
                    <span class="td style-scope patent-result">
  ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4474893A/en"><a id="link" href="#" class="style-scope state-modifier">US4474893A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-07-01</span>
                    <span class="td style-scope patent-result">1984-10-02</span>
                    <span class="td style-scope patent-result">The University of Texas System Cancer Center</span>
                    <span class="td style-scope patent-result">Recombinant monoclonal antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4671958A/en"><a id="link" href="#" class="style-scope state-modifier">US4671958A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-03-09</span>
                    <span class="td style-scope patent-result">1987-06-09</span>
                    <span class="td style-scope patent-result">Cytogen Corporation</span>
                    <span class="td style-scope patent-result">Antibody conjugates for the delivery of compounds to target sites 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0088994B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0088994B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-03-15</span>
                    <span class="td style-scope patent-result">1991-06-19</span>
                    <span class="td style-scope patent-result">Schering Corporation</span>
                    <span class="td style-scope patent-result">Hybrid dna, binding composition prepared thereby and processes therefor 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES521370A0/en"><a id="link" href="#" class="style-scope state-modifier">ES521370A0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-04-12</span>
                    <span class="td style-scope patent-result">1985-04-16</span>
                    <span class="td style-scope patent-result">Hybritech Inc</span>
                    <span class="td style-scope patent-result">
  A PROCEDURE FOR OBTAINING A POLYDOMA.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES521371A0/en"><a id="link" href="#" class="style-scope state-modifier">ES521371A0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-04-12</span>
                    <span class="td style-scope patent-result">1984-05-16</span>
                    <span class="td style-scope patent-result">Hybritech Inc</span>
                    <span class="td style-scope patent-result">
  A PROCEDURE FOR THE PURIFICATION OF AN ANTIBODY.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4470925A/en"><a id="link" href="#" class="style-scope state-modifier">US4470925A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-05-05</span>
                    <span class="td style-scope patent-result">1984-09-11</span>
                    <span class="td style-scope patent-result">E. I. Du Pont De Nemours And Company</span>
                    <span class="td style-scope patent-result">Immunoglobulin half-molecules and process for producing hybrid antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ATE25197T1/en"><a id="link" href="#" class="style-scope state-modifier">ATE25197T1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1982-05-12</span>
                    <span class="td style-scope patent-result">1987-02-15</span>
                    <span class="td style-scope patent-result">Harvard College</span>
                    <span class="td style-scope patent-result">
  FUSIONED GENES ENCODING HYBRID PROTEIN, CLONING VECTORS CONTAINING THEM AND THEIR USE.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU572125B2/en"><a id="link" href="#" class="style-scope state-modifier">AU572125B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-03-17</span>
                    <span class="td style-scope patent-result">1988-05-05</span>
                    <span class="td style-scope patent-result">Mabco Limited</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8308235D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8308235D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-03-25</span>
                    <span class="td style-scope patent-result">1983-05-05</span>
                    <span class="td style-scope patent-result">Celltech Ltd</span>
                    <span class="td style-scope patent-result">Polypeptides 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0142905A2/en"><a id="link" href="#" class="style-scope state-modifier">EP0142905A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-03-30</span>
                    <span class="td style-scope patent-result">1985-05-29</span>
                    <span class="td style-scope patent-result">Bio-Response Inc.</span>
                    <span class="td style-scope patent-result">Therapeutic substance for treating diseases such as cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4816567A/en"><a id="link" href="#" class="style-scope state-modifier">US4816567A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-04-08</span>
                    <span class="td style-scope patent-result">1989-03-28</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant immunoglobin preparations 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB2148299B/en"><a id="link" href="#" class="style-scope state-modifier">GB2148299B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-09-01</span>
                    <span class="td style-scope patent-result">1988-01-06</span>
                    <span class="td style-scope patent-result">Hybritech Inc</span>
                    <span class="td style-scope patent-result">Antibody compositions of therapeutic agents having an extended serum half-life 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4722903A/en"><a id="link" href="#" class="style-scope state-modifier">US4722903A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-11-14</span>
                    <span class="td style-scope patent-result">1988-02-02</span>
                    <span class="td style-scope patent-result">New York Blood Center, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE3482649D1/en"><a id="link" href="#" class="style-scope state-modifier">DE3482649D1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-12-16</span>
                    <span class="td style-scope patent-result">1990-08-09</span>
                    <span class="td style-scope patent-result">Denis M Callewaert</span>
                    <span class="td style-scope patent-result">
  JOB SELECTIVE PLASMINOGEN ACTIVATOR AND METHOD FOR THE PRODUCTION AND USE THEREOF.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPS60136520A/en"><a id="link" href="#" class="style-scope state-modifier">JPS60136520A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-12-23</span>
                    <span class="td style-scope patent-result">1985-07-20</span>
                    <span class="td style-scope patent-result">Otsuka Pharmaceut Co Ltd</span>
                    <span class="td style-scope patent-result">Fibrin-adsorbing urokinase complex 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8400653D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8400653D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1984-01-11</span>
                    <span class="td style-scope patent-result">1984-02-15</span>
                    <span class="td style-scope patent-result">Beecham Group Plc</span>
                    <span class="td style-scope patent-result">Conjugates 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DK166627B1/en"><a id="link" href="#" class="style-scope state-modifier">DK166627B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1984-04-17</span>
                    <span class="td style-scope patent-result">1993-06-21</span>
                    <span class="td style-scope patent-result">Teijin Ltd</span>
                    <span class="td style-scope patent-result">
  MONOCHLON ANTIBLE, ANTIBODY, SPECIFICALLY, HUMAN ALUMINUM, SPECIFIC WITH THE HUMAN-ALFA-2 PLASMININ INHIBITOR, human alpha-2-plasmin inhibitor
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4927916A/en"><a id="link" href="#" class="style-scope state-modifier">US4927916A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1984-04-23</span>
                    <span class="td style-scope patent-result">1990-05-22</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8422238D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8422238D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1984-09-03</span>
                    <span class="td style-scope patent-result">1984-10-10</span>
                    <span class="td style-scope patent-result">Neuberger M S</span>
                    <span class="td style-scope patent-result">Chimeric proteins 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU595173B2/en"><a id="link" href="#" class="style-scope state-modifier">AU595173B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-01-08</span>
                    <span class="td style-scope patent-result">1990-03-29</span>
                    <span class="td style-scope patent-result">General Hospital Corporation, The</span>
                    <span class="td style-scope patent-result">Method and use for site-specific activation of substances 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5116613A/en"><a id="link" href="#" class="style-scope state-modifier">US5116613A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-01-08</span>
                    <span class="td style-scope patent-result">1992-05-26</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Antibody-thrombolytic agent product and method of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH0735340B2/en"><a id="link" href="#" class="style-scope state-modifier">JPH0735340B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-05-23</span>
                    <span class="td style-scope patent-result">1995-04-19</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Thrombolysis promoter
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1987005934A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1987005934A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-03-28</span>
                    <span class="td style-scope patent-result">1987-10-08</span>
                    <span class="td style-scope patent-result">Roberto Crea</span>
                    <span class="td style-scope patent-result">Protein analogues of tissue plasminogen activator 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4916070A/en"><a id="link" href="#" class="style-scope state-modifier">US4916070A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-04-14</span>
                    <span class="td style-scope patent-result">1990-04-10</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Fibrin-specific antibodies and method of screening for the antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0266419B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0266419B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-05-15</span>
                    <span class="td style-scope patent-result">1994-03-02</span>
                    <span class="td style-scope patent-result">Emory University</span>
                    <span class="td style-scope patent-result">Fibrinolytic composition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4833085A/en"><a id="link" href="#" class="style-scope state-modifier">US4833085A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-08-13</span>
                    <span class="td style-scope patent-result">1989-05-23</span>
                    <span class="td style-scope patent-result">Monsanto Company</span>
                    <span class="td style-scope patent-result">Monoclonal antibody specific for human colon fibroblast-derived t-PA 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ATE87659T1/en"><a id="link" href="#" class="style-scope state-modifier">ATE87659T1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-09-02</span>
                    <span class="td style-scope patent-result">1993-04-15</span>
                    <span class="td style-scope patent-result">Enzon Lab Inc</span>
                    <span class="td style-scope patent-result">
  BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA1339445C/en"><a id="link" href="#" class="style-scope state-modifier">CA1339445C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-11-12</span>
                    <span class="td style-scope patent-result">1997-09-09</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Recombinant hybrid immunoglobulin molecules and method of use 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2871775B2/en"><a id="link" href="#" class="style-scope state-modifier">JP2871775B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-04-04</span>
                    <span class="td style-scope patent-result">1999-03-17</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Compositions and methods for promoting clot dissolution
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5582862A/en"><a id="link" href="#" class="style-scope state-modifier">US5582862A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-04-04</span>
                    <span class="td style-scope patent-result">1996-12-10</span>
                    <span class="td style-scope patent-result">General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Antibodies that bind to 2-antiplasmin crosslinked to fibrin which do not inhibit plasma 2-antiplasmin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5372812A/en"><a id="link" href="#" class="style-scope state-modifier">US5372812A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-04-04</span>
                    <span class="td style-scope patent-result">1994-12-13</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Composition and method for acceleration of clot lysis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5530101A/en"><a id="link" href="#" class="style-scope state-modifier">US5530101A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-12-28</span>
                    <span class="td style-scope patent-result">1996-06-25</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Humanized immunoglobulins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8928874D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8928874D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-12-21</span>
                    <span class="td style-scope patent-result">1990-02-28</span>
                    <span class="td style-scope patent-result">Celltech Ltd</span>
                    <span class="td style-scope patent-result">Humanised antibodies 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (14)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU6200599A/en"><a id="link" href="#" class="style-scope state-modifier">AU6200599A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-09-29</span>
                    <span class="td style-scope patent-result">2000-04-17</span>
                    <span class="td style-scope patent-result">Leuven Research &amp; Development Vzw</span>
                    <span class="td style-scope patent-result">Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of acomposition for the treatment of ischemic stroke 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1062953A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1062953A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-22</span>
                    <span class="td style-scope patent-result">2000-12-27</span>
                    <span class="td style-scope patent-result">Leuven Research &amp; Development vzw</span>
                    <span class="td style-scope patent-result">Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2813395B1/en"><a id="link" href="#" class="style-scope state-modifier">FR2813395B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-08-28</span>
                    <span class="td style-scope patent-result">2003-01-24</span>
                    <span class="td style-scope patent-result">Stago Diagnostica</span>
                    <span class="td style-scope patent-result">
  METHOD OF IN VITRO DETERMINATION OF SOLUBLE FIBRIN BY GENERATION OF SPECIFIC DEGRADATION PRODUCTS
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI323265B/en"><a id="link" href="#" class="style-scope state-modifier">TWI323265B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-06</span>
                    <span class="td style-scope patent-result">2010-04-11</span>
                    <span class="td style-scope patent-result">Glaxo Group Ltd</span>
                    <span class="td style-scope patent-result">Antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0304576D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0304576D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-02-28</span>
                    <span class="td style-scope patent-result">2003-04-02</span>
                    <span class="td style-scope patent-result">Lonza Biologics Plc</span>
                    <span class="td style-scope patent-result">Protein a chromatography 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0306309D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0306309D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-03-19</span>
                    <span class="td style-scope patent-result">2003-04-23</span>
                    <span class="td style-scope patent-result">Glaxo Group Ltd</span>
                    <span class="td style-scope patent-result">Method of treatment 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE10346751A1/en"><a id="link" href="#" class="style-scope state-modifier">DE10346751A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-10-06</span>
                    <span class="td style-scope patent-result">2005-04-21</span>
                    <span class="td style-scope patent-result">Transmit Technologietransfer</span>
                    <span class="td style-scope patent-result">
  Clot lysis assay
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008134577A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2008134577A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-04-25</span>
                    <span class="td style-scope patent-result">2008-11-06</span>
                    <span class="td style-scope patent-result">Reed Guy L</span>
                    <span class="td style-scope patent-result">Method of increasing plasmin activity through antiplasmin conversion 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009052367A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2009052367A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-10-17</span>
                    <span class="td style-scope patent-result">2009-04-23</span>
                    <span class="td style-scope patent-result">Clemson University</span>
                    <span class="td style-scope patent-result">Micro- and nanoscale devices for delivery of active fibronolytic agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2846667A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2846667A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-06</span>
                    <span class="td style-scope patent-result">2013-03-14</span>
                    <span class="td style-scope patent-result">Guy L. Reed</span>
                    <span class="td style-scope patent-result">Serpinf2-binding molecules and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2012327223A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2012327223A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-11-30</span>
                    <span class="td style-scope patent-result">2013-06-20</span>
                    <span class="td style-scope patent-result">Wellstat Diagnostics, Llc.</span>
                    <span class="td style-scope patent-result">Assays, antibodies, immunogens and compositions related to 5-FU 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10583104B2/en"><a id="link" href="#" class="style-scope state-modifier">US10583104B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-08-06</span>
                    <span class="td style-scope patent-result">2020-03-10</span>
                    <span class="td style-scope patent-result">Indiana University Research And Technology Corporation</span>
                    <span class="td style-scope patent-result">Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6826980B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6826980B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-12-22</span>
                    <span class="td style-scope patent-result">2021-02-10</span>
                    <span class="td style-scope patent-result">  </span>
                    <span class="td style-scope patent-result">
  How to prevent thrombosis
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20240010750A1/en"><a id="link" href="#" class="style-scope state-modifier">US20240010750A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-09-15</span>
                    <span class="td style-scope patent-result">2024-01-11</span>
                    <span class="td style-scope patent-result">Bayer Aktiengesellschaft</span>
                    <span class="td style-scope patent-result">Novel anti-a2ap antibodies and uses thereof 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3370324B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3370324B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-01-27</span>
                    <span class="td style-scope patent-result">
  Reshaped human antibodies to human interleukin-6 receptor
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7399837B2/en"><a id="link" href="#" class="style-scope state-modifier">US7399837B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-15</span>
                    <span class="td style-scope patent-result">Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4439914B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4439914B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-03-24</span>
                    <span class="td style-scope patent-result">
  Antibody inhibiting blood coagulation and method of use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NZ501215A/en"><a id="link" href="#" class="style-scope state-modifier">NZ501215A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-27</span>
                    <span class="td style-scope patent-result">Treatment of thrombosis using anti-Factor IX monoclonal antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5693323A/en"><a id="link" href="#" class="style-scope state-modifier">US5693323A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-12-02</span>
                    <span class="td style-scope patent-result">Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0800536B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0800536B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-11-29</span>
                    <span class="td style-scope patent-result">Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2006333870A/en"><a id="link" href="#" class="style-scope state-modifier">JP2006333870A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-12-14</span>
                    <span class="td style-scope patent-result">Recombinant il4 antibodies useful in treatment of il4 mediated disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2266341A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2266341A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-03-26</span>
                    <span class="td style-scope patent-result">Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5783184A/en"><a id="link" href="#" class="style-scope state-modifier">US5783184A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-07-21</span>
                    <span class="td style-scope patent-result">Method for treatment and diagnosis of IL-5 mediated disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998012334A9/en"><a id="link" href="#" class="style-scope state-modifier">WO1998012334A9</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2106719C/en"><a id="link" href="#" class="style-scope state-modifier">CA2106719C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-28</span>
                    <span class="td style-scope patent-result">Reshaped monoclonal antibodies against an immunoglobulin isotype 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040146511A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040146511A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-07-29</span>
                    <span class="td style-scope patent-result">Antithrombotic agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20070116192A/en"><a id="link" href="#" class="style-scope state-modifier">KR20070116192A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-06</span>
                    <span class="td style-scope patent-result">Antithrombotic agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4860877B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4860877B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-01-25</span>
                    <span class="td style-scope patent-result">
  Siaload Hezin Factor-2 antibody
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030235587A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030235587A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-25</span>
                    <span class="td style-scope patent-result">Anticoagulant agents useful in treatment of thrombosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU7737401A/en"><a id="link" href="#" class="style-scope state-modifier">AU7737401A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-07</span>
                    <span class="td style-scope patent-result">Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR100509993B1/en"><a id="link" href="#" class="style-scope state-modifier">KR100509993B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-02-28</span>
                    <span class="td style-scope patent-result">
  Recombinant IL-5 Antagonists Useful in the Treatment of IL-5 Mediated Diseases
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US2635696P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1996-09-20</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US60/026,356<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1996-09-20</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998012329A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US1997/016122</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1997-09-19</span>
                    <span class="td style-scope patent-result">Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2002-09-18</span>
                    <span class="td nowrap style-scope patent-result">EEER</span>
                    <span class="td nowrap style-scope patent-result">Examination request</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2005-09-19</span>
                    <span class="td nowrap style-scope patent-result">FZDE</span>
                    <span class="td nowrap style-scope patent-result">Discontinued</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.4100856596" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.4100856596" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=531395013" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>